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ABSTRACT 
Emily Jean Werder: Styrene exposure and neurologic effects in residents of the US Gulf 
States 
(Under the direction of Lawrence S. Engel) 
 
 
Styrene is an established neurotoxicant at occupational levels, but epidemiologic 
studies to date have focused on highly exposed workers. We examine whether 
neurologic effects are associated with styrene at environmental levels, and attempt to 
identify underlying sources of uniquely elevated exposure levels among Gulf coast 
residents. 
In Aims 1 and 2, we utilized data from the Gulf Long-term Follow-up Study and 
the nested Chemical Biomonitoring Study (CBS) to assess predictors of blood styrene 
levels (N = 667). In Aim 3, we estimated cross-sectional associations between ambient 
styrene exposure and neurologic symptoms (N = 21,962), as well as peripheral 
neurologic function (N = 2,956). Among CBS participants, we assessed blood styrene in 
relation to neurologic symptoms (N = 874) and peripheral neurologic function (N = 310). 
Ambient exposures were modeled as quartiles, and blood exposures were divided at 
the median or 90th percentile. We estimated prevalence ratios using log-binomial 
regression, and differences in continuous outcomes using linear regression.  
Blood styrene levels are 2-3 times higher in CBS compared to the U.S. general 
population. Smoking, housing characteristics, and recent behaviors were predictors of 
blood styrene levels. Neither ambient styrene concentrations nor industrial styrene 
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emissions were determinants of blood styrene levels. The highest quartile of ambient 
styrene was associated with increased central (PR = 1.20, 95% CI: 1.09, 1.32) and 
peripheral (PR = 1.12, 95% CI: 1.02, 1.23) nervous system symptoms, as well as 
impairments in vision (mean difference = -0.15, 95% CI: -0.25, -0.04), vestibular (β = -
4.65 mm/s, 95% CI: -8.20, -1.10), and sensory function (β = -0.12 log microns, 95% CI: 
-0.22, -0.01). We observed statistically significant monotonic exposure-response 
relationships between ambient styrene concentration and many neurologic endpoints. 
The relationship was less clear for blood styrene exposure, with some suggestive 
effects. 
Personal predictors of increasing blood styrene levels were largely consistent 
with previous literature. Our measures of increased regional exposure opportunity do 
not fully explain these elevated blood styrene levels. Increasing ambient styrene 
exposures elicited consistent neurotoxic effects, as well as some notable associations 
with measured blood styrene. Environmental styrene exposure levels may be sufficient 
to elicit subclinical neurotoxic effects. 
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CHAPTER I: INTRODUCTION & SPECIFIC AIMS 
 
A. Introduction 
Styrene is an industrial hydrocarbon used in plastics, fiberglass, rubber, and 
resins to manufacture consumer products and commercial and residential building 
materials. Manufactured styrene products include insulation, fiberglass boats, 
automotive parts, car tires, Styrofoam, and plastic drinking glasses [1]. Exposure to 
styrene in the general population occurs primarily through inhalation of tobacco smoke, 
off-gassing of building materials, and vehicle and industrial emissions [2, 3]. The Gulf 
States are home to many styrene emitting industries and over half of all U.S. styrene 
production [1, 4]. Styrene is an established neurotoxicant at occupational levels [1, 5, 6], 
but has not been studied at environmental levels experienced by the general population. 
Epidemiologic studies to date have focused on highly exposed workers, whose average 
blood levels were 25 times higher than those of the general population [7-14].  
We conducted a study of environmental styrene exposure and self-reported 
neurologic symptoms by taking advantage of data that were collected in the ongoing 
Gulf Long-Term Follow-up Study (GuLF STUDY). The study included individuals who 
participated in the 2010 Deepwater Horizon (DWH) oil spill response and cleanup and 
comparison subjects who did not. Neurologic symptoms were ascertained for the entire 
cohort (N=32,608) at the enrollment interview, which occurred between 2011 and 2013. 
Approximately two to three years after the oil spill (May 2012-July 2013), a subset of 
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participants (N=994) living in the Gulf region provided blood specimen for 
measurement of volatile organic compounds (VOCs), including styrene, as part of a 
Chemical Biomonitoring Study (CBS). Blood styrene levels collected from CBS 
participants are two to three times higher than those reported in the National Health and 
Nutrition Examination Survey (NHANES) [15], but considerably lower than levels 
typically observed among occupationally exposed populations. Because styrene is 
rapidly cleared from the body and blood measurements were obtained two to three 
years after the oil spill, these levels represent usual, ongoing exposures (i.e., they are 
not due to oil spill cleanup work). Although the sources for styrene levels of this 
magnitude are not well understood, increased exposure opportunity from industrial 
emissions in the Gulf region is plausible.  
In Specific Aim 1, we evaluate individual characteristics and estimate ambient 
styrene concentration as predictors of measured blood styrene levels among CBS 
participants. Individual covariate information is obtained from GuLF STUDY 
interview/questionnaire data. Ambient styrene estimates, from the 2011 National Air 
Toxics Assessment (NATA) [16], are used to evaluate the contribution of ambient 
styrene, in addition to exposure due to individual-level demographic, lifestyle, and 
housing characteristics, to variability in blood levels. 
In Specific Aim 2, we evaluate spatial patterns among point sources as predictors 
of blood styrene levels among CBS participants. Potential point sources of styrene 
emissions were identified using the United States Environmental Protection Agency’s 
(EPA) National Emissions Inventory (NEI) from 2011 [17]. Exposure is assigned based 
on proximity, density, and characteristics of NEI styrene point sources near the 
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participant’s residence. These distance-based metrics of exposure address diffusion of 
styrene emissions over space, allowing for exposure variability within and across 
census tract boundaries. 
In Specific Aim 3, we assess the exposure-outcome relationships between both 
metrics of styrene exposure (estimated ambient concentrations and measured blood 
levels) and indicators of neurologic function (self-reported symptoms and quantitative 
neurologic function tests) in the full cohort and the CBS. The 2011 NATA annual 
average ambient styrene concentration corresponding to an individual’s home census 
tract is applied as estimated styrene exposure for all cohort members residing in the 
Gulf region, and measured blood styrene are used for separate analyses among the 
CBS participants. We evaluate cross-sectional associations between ambient styrene 
exposure and self-reported neurologic symptoms among all study participants residing 
in the Gulf region (N=26,828), and also using blood styrene in the CBS subset. Among 
the 3,400 individuals who completed a follow-up clinical examination in 2014-2016, 
which included detailed neurological testing, we explore associations between styrene 
exposure and performance on neurologic tests.  
The purpose of this study is to examine whether neurologic effects are associated 
with styrene at levels relevant to the general population, accounting for other risk factors, 
and to identify underlying sources of these exposure levels. Specific Aims 1 and 2 
support the larger purpose of estimating health effects of styrene by evaluating different 
metrics of styrene exposure and elucidating potential confounding factors in the 
exposure-outcome relationship (Figure 1).  
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B. Specific Aims 
 
Specific Aim 1: Analyze individual covariate information, as well as modeled 
environmental styrene concentrations, as determinants of blood styrene levels. 
Candidate exposure opportunities were derived from questionnaires obtaining detailed 
exposure information about VOCs with emphasis on the previous 24 hours. Additionally, 
NATA 2011 estimated annual average ambient census tract styrene concentrations 
were applied as a surrogate of usual environmental styrene exposure. Linear regression 
models are used to evaluate predictors of blood levels.  
Hypothesis 1: Usual lifestyle factors and exposure opportunities account for more 
variability in measured blood styrene levels than do ambient styrene concentrations.  
Hypothesis 2: NATA 2011 annual styrene concentrations correlate with blood styrene.  
 
Specific Aim 2: Spatially evaluate point sources of styrene emissions as 
predictors of blood styrene levels.  
Facilities emitting airborne styrene are ascertained from the 2011 NEI. Proximity, 
density, and intensity of facilities are analyzed to quantify spatial gradients between 
ambient point source emissions and measured blood levels. This approach accounts for 
spatial variability that is smoothed over in NATA estimates. Point source characteristics 
are also evaluated as predictors of blood styrene. The variability in blood styrene levels 
explained by point sources is estimated using least squares linear regression.  
Hypothesis: Measured blood styrene levels vary as a function of residential proximity to 
and intensity of, point source styrene emissions.  
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Specific Aim 3: Estimate associations between measured and modeled styrene 
exposure and indicators of neurologic function.  
Associations with neurologic outcomes are estimated for ambient and blood styrene 
among CBS participants. Neurologic symptoms were ascertained at enrollment, and a 
subset of participants completed follow-up peripheral neurologic function testing 
between 2014 and 2016. Associations between styrene exposure and neurologic effects 
are estimated using multivariate linear and log-binomial regression. 
Hypothesis 1: Styrene exposure is associated with symptoms of neurologic impairment. 
Hypothesis 2: Peripheral neurologic function is inversely associated with styrene 
exposure. 
 
Figure 1. Organization of specific aims. 
Proximity to point 
sources 
Blood styrene  
 (N=667) AIM 2 
Individual predictors, 
NATA ambient styrene 
Blood styrene  
 (N=667) AIM 1 
Ambient styrene  Neurologic symptoms  (N=21,962) 
Peripheral neurologic function
 (N=2,956) Ambient styrene  
Blood styrene Neurologic symptoms  (N=874) 
Peripheral neurologic function
 (N=310) Blood styrene 
AIM 3 
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C. Innovation 
This study is the first to investigate the neurotoxicity of styrene at levels 
relevant to the general population. Previous studies have examined health effects of 
styrene in exposed worker populations whose average blood levels were 25 times 
higher than those of the general population, limiting extrapolation to the health effects 
from typical environmental exposures. Participants in the proposed study have average 
blood styrene levels two to three times higher than those reported in NHANES. These 
levels are considerably lower than occupational exposures, but higher than typical 
environmental exposures experienced in the U.S. population. This range provides an 
excellent opportunity to detect any exposure-response relationships at lower exposure 
ranges. Thus, the present study is the first to determine whether neurologic effects 
observed among highly exposed occupational populations are also observed for styrene 
exposure more typical of the general population. Moreover, blood styrene levels were 
measured two to three years after the oil spill and, therefore represent contemporary, 
not oil spill cleanup-related exposures. These measurements show virtually no 
correlation with cleanup worker status. The exposure profile of these study participants 
is ideally suited to investigate neurologic symptoms in relation to levels of styrene 
exposure relevant to the general population.  
This study investigates an understudied population. Few studies have 
investigated this socioeconomically disadvantaged, medically underserved, and racially 
diverse population. This study, together with the parent GuLF STUDY, can provide 
important insights into the general health issues faced by this population. 
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CHAPTER II: BACKGROUND AND SIGNIFICANCE 
 
A. Styrene exposure 
 
Sources of styrene 
Styrene, an industrial hydrocarbon derived from ethylbenzene, is widely used in 
plastics, fiberglass, rubber, and resins to manufacture consumer products and 
commercial and residential building materials. When styrene monomer, a colorless 
liquid, is synthesized into polystyrene polymer, it becomes a rigid plastic at room 
temperature [3]. After the manufacture, use, and disposal of styrene-based products, 
styrene is released primarily into air, though smaller amounts are detected in soil and 
water [18]. Ambient styrene, a volatile organic compound, breaks down in the 
atmosphere within 1 to 2 days [1]. 
Styrene production in the U.S. has been steadily increasing since its initiation in 
1938, and the U.S. now produces over 12 billion pounds of styrene annually, with 
atmospheric emissions of 28 million pounds per year [1, 19]. The main sources of 
styrene emissions to air include motor vehicle exhaust (approximately 30%), 
composites and boat building (approximately 40%), and all other sources 
(approximately 30%) [20].  
The largest U.S. styrene production facilities, accounting for more than half of all 
production, are located in Louisiana and eastern Texas [3].  In addition to a prolific 
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petrochemical industry, the Gulf region is home to many industrial and manufacturing 
facilities that use and emit styrene in the production of plastics, rubber, and fiberglass. 
Motivated by economic efficiency, this geographic clustering of industries relying on a 
common set of resources potentially exposes Gulf residents to a disproportionately high 
intensity of environmental styrene emissions from petrochemical, manufacturing, and 
coastal fishing and boating operations [21]. 
Styrene is used predominantly in the production of polystyrene plastics and 
resins, and to a lesser extent, as an intermediate in the copolymers styrene-acrylonitrile, 
acrylonitrile-butadiene-styrene, styrene-butadiene rubber, and styrene-butadiene latex 
[3]. These plastics, resins, and copolymers are commonly used in building materials and 
a variety of consumer products, including: fiberglass boat hulls, tubs, and shower stalls; 
packaging materials, paper coatings, food storage containers, and Styrofoam; industrial 
hoses, plastic piping, electrical insulation and wiring, building insulation, refrigerator 
liners, carpet backing, and latex paints; housewares and appliances; automotive parts, 
car tires, and car battery enclosures; toner found in photocopiers and printers [1, 4, 22]. 
These products mainly contain polystyrene chains, as well as a small amount of 
unlinked styrene. Smaller amounts of styrene are used for less common thermoplastics, 
laboratory and water purification uses (ion-exchange resins), and glues and adhesives 
[20]. 
Styrene is typically disposed of through absorption on vermiculite, incineration, or 
containment in EPA-permitted landfills [1]. Groundwater and soil styrene levels indicate 
leaching from landfills, and monitoring data document elevated ambient styrene closer 
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to landfills [6, 23]. Exposure to styrene from hazardous waste sites is potentially 
important, but the magnitude of the problem is unknown [6]. 
 
Routes of human exposure 
Human exposure to styrene can occur through inhalation, ingestion, or dermal 
contact. Inhalation of airborne styrene is the primary route of exposure, and the main 
source of concern for health effects due to styrene toxicity [24]. Ingestion and dermal 
exposure to styrene are possible, though inhalation accounts for over 90% of styrene 
exposure in the general population [6, 25].  
Air styrene is released from industries using or manufacturing styrene, 
automobile exhaust, cigarette smoke, and photocopiers and printers. Styrene is 
commonly detected in urban air, near industrial sites and landfills, and in high traffic 
areas, although typically at levels substantially lower than in occupational settings. Rural 
or suburban air generally contains lower concentrations of styrene than urban air [22]. 
National-scale ambient styrene monitoring is limited, with poor spatial and temporal 
coverage, but local-scale studies have demonstrated that residents living near high-
emitting styrene production or processing facilities frequently experience chronic 
elevated exposure from emissions [20, 26, 27] (i.e., 28 million pounds in 2013 [19]). 
While outdoor air styrene concentrations are driven by industrial and mobile emissions, 
indoor air styrene levels primarily result from tobacco smoke, off-gassing of building 
materials and consumer products, and emissions from photocopiers and laser printers 
[1].  
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Very low levels of styrene occur naturally in strawberries, coffee, cinnamon, oats, 
wheat, peanuts, wine, beef, eggs, cheese, beer, and some legumes [1, 20]. Styrene 
detected in other prepared foods is attributed to migration from polystyrene packaging 
and containers [28]. The amount of styrene migration to food and drink is variable, but 
migration is consistently dependent upon the fat content and storage temperature [29, 
30]. Higher fat content and temperature are associated with increased migration. In an 
experimental study of polystyrene containers and solvents, foods, and beverages, 
maximum observed migration for beverages and foods was 0.025% of the container’s 
total styrene [30]. Detected concentrations vary widely, with higher levels resulting from 
packaging than those due to naturally occurring styrene [31]. Styrene levels in bottled 
water increase over time, suggesting leaching from the containers [32].  
Due to styrene’s rapid biodegradation and volatility, surface and groundwater 
levels are generally below 1 µg/L [22]. Exposure levels observed in municipal drinking 
water supplies are considered negligible [18]. However, styrene has been detected at 
significant levels in the groundwater of hazardous waste sites [33, 34]. If used as a local 
water supply, this water would confer significant, potentially hazardous exposure to 
styrene. The magnitude of styrene exposure due to oral consumption, whether due to 
natural dietary sources or leaching from food packaging, is much lower than that of 
inhalation exposure. While ingested styrene is detectable, these trace levels are 
generally considered too low for toxicity [1, 2, 6, 25, 31]. 
A very small amount of styrene may enter the body when skin comes into contact 
with liquids containing styrene. Oxidative stress is involved in skin damage due to liquid 
styrene exposure[1]. The potential for exposure to liquid styrene through skin contact is 
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likely limited to occupational opportunities, but because of very low percutaneous 
absorption in humans, this exposure route does not contribute significantly to the body 
burden of styrene-exposed plastics workers [6, 35].  
 
Occupational exposure 
The highest styrene exposures generally occur in the workplace, where styrene-
exposed workers have blood levels that are 25 times higher on average than those in 
the general population [5, 7, 36]. Approximately 330,000 U.S. workers are 
occupationally exposed to styrene [37]. Occupational styrene exposure has been 
assessed extensively in blood, urine, personal air, ambient air, and using occupational 
histories and job exposure matrices. Measured biomarker levels consistently predict 
exposure classification according to job title and occupational styrene-related activities 
[7, 10, 38-47]. 
Occupational exposure to airborne styrene, resulting from industrial production 
and use of styrene and styrene-based polymers and copolymers, vehicle emissions, 
and combustion processes[4, 22], has been well-characterized among workers in boat 
building, plastics, rubber, and polystyrene manufacturing [10, 13, 14, 25, 48-50]. The 
highest potential exposure occurs in the reinforced-plastics industry, where workers 
may be exposed to high air concentrations and potentially have dermal exposure to 
liquid styrene or resins. Workers involved in styrene polymerization, rubber 
manufacturing, and styrene-polyester resin facilities and workers at photocopy centers 
may also be exposed to styrene. In typical work environments, air concentrations are 
currently below 10 ppm except in portions of the reinforced plastics industry, where 
levels of 20 ppm or more are common [20].  
12 
 
Environmental exposure 
In the U.S. general population, daily exposure to styrene in air is estimated to be 
18–54 μg/person, compared to  0.2–1.2 μg attributable to styrene in food [1]. Smoking 
a single cigarette delivers as much as 6 µg styrene [51]. Indoor air usually contains 
higher levels (0.07–11.5 ppb) of styrene than outdoor air (0.06–4.6 ppb), and inhalation 
of contaminated indoor air is considered the principal route of styrene exposure for the 
general population.  
 
Outdoor air 
Emissions from industrial activities and motor vehicle exhaust are the primary 
sources of styrene in outdoor air. Ambient measurements of styrene typically show 
airborne concentrations less than 1 part per billion by volume (ppb), although 
concentrations exceeding 5 ppb have been detected in urban areas [20, 22]. The 
commonly observed urban-rural styrene concentration gradient is attributed to 
increased motor vehicle emissions [52].  
The EPA compiled passively monitored ambient concentration data from three 
study areas throughout the United States from 1989-91 and reported an overall mean 
concentration of 0.13 ppb (0.55 µg/m3) [53]. More recent ambient styrene levels, 
measured at 74 different EPA monitoring sites across the five Gulf States in 2011, 
returned an observed mean styrene concentration of 0.04 ppb (SD, 0.3 ppb) (mean, 
0.15 µg/m3; SD, 1.3 µg/m3). Among the 2011 Gulf monitors, the maximum observed 
styrene concentration was 20.9 ppb. Concentrations exceeding 1 ppb were detected at 
12 different monitoring locations in the Gulf region during this time. Across the Gulf 
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States, average EPA estimated annual styrene concentrations partitioned by source 
were: 0.018 µg/m3 for point sources, 0.008 µg/m3 for mobile sources, and 0.004 µg/m3 
for all other sources [16]. 
Individuals living near domestic manufacturing or processing facilities may 
experience increased styrene exposure from point source emissions, totaling 47.3 
million pounds annually in the U.S. [1]. Elevated ambient styrene concentrations are 
observed near styrene emitting industries, with clear dose-response relationships 
among distance, emissions volume, and ambient concentration. The reinforced plastic 
industry emits the largest quantities of styrene to the ambient air due to the nature of 
the production process.  
In 2011, point source industrial styrene emissions in the Gulf region totaled 3,275 
tons, compared to 671 tons of mobile styrene emissions, and 223 tons due to other 
sources [54]. Atmospheric dispersion simulations indicate that residential proximity to 
styrene emitting industrial facilities confers up to 15 ppb of annual average styrene 
exposure [26]. The effective exposure distance depends on emissions volume, stack 
height, and meteorology characteristics, but elevated concentrations were detected up 
to 10 kilometers away [55]. This exposure estimate takes into account average styrene 
concentrations, residential occupancy period, daily hours spent in the home, daily 
hours spent outdoors at home, indoor air levels, and residence air exchange rate.  
Ambient monitoring of VOCs in New Jersey detected comparable mean and 
maximum styrene levels (mean, 0.16 µg/m3; maximum, 0.60 µg/m3) at mobile and 
industrial source-dominated sites [56]. Observed styrene levels were significantly 
higher (mean, 0.60 µg/m3; maximum, 0.98 µg/m3) at the commercial source-dominated 
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site [56]. This finding may reflect the combined effects of mobile and commercial 
sources because the commercial site was located in a high-traffic area. 
 
Indoor air  
Inhalation of contaminated air is the principal route of styrene exposure for the 
general population [1]. Typically, indoor air contains higher styrene levels than outdoor 
air [51].  Mean indoor air levels of styrene have been reported in the range of 0.1–50.0 
μg/m3 (0.02-11.7 ppb), and are attributed to emissions from building materials, 
consumer products, and tobacco smoke [24]. Specific materials off-gassing styrene 
include carpets, floor tiles, insulation, office copiers, laser printers, disinfectants, 
plastics and fiberglass, paints, varnishes, cleaning products, floor waxes and polishes, 
adhesives, and metal cleaners.  
Based on two studies [52, 57], passively monitored average styrene 
concentrations ranged from 0.05-0.58 µg/m3 at home, 0.08-0.48 µg/m3 in workplaces 
and schools, 0.28-0.56 µg/m3 in restaurants and bars, 0.46 µg/m3 in commercial 
shopping areas, 0.11 µg/m3 outdoors along streets, 0.18-0.33 µg/m3 in public 
transportation stations, and 0.43-0.45 µg/m3 in vehicles (private and public). These, 
and other, results suggest that both indoor and outdoor microenvironments are 
important determinants of actual styrene exposure [58]. 
People usually encounter substantially higher VOC concentrations during their 
normal daily activities compared to the ambient VOC levels recorded at central 
monitoring sites [58]. A VOC monitoring study in the U.K. examining percentage 
contribution of microenvironments to personal exposure, reported that home styrene 
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exposure accounted for 64%, work for 14.1%, and transportation combined accounted 
for approximately 5.5% of personal exposure [52]. Outdoor microenvironments had 
negligible contributions. 
Styrene exposure due to cigarette smoking is estimated to be 6 ppb annually, 
with an estimated delivery of 6 µg of styrene per cigarette [59]. Several studies suggest 
that exposure to styrene is approximately fourfold higher for smokers than for 
nonsmokers [1, 51, 59-65]. Among smokers, cigarettes are considered the dominant 
source of styrene exposure. Indoor air styrene concentrations are significantly higher in 
the homes of smokers than in those homes without smokers [1]. While tobacco smoke 
is a major source of styrene exposure among smokers, environmental tobacco smoke 
contributes only about 8% of nonsmokers’ exposure [20]. Most styrene exposure 
derived from environmental tobacco smoke occurs to individuals living with smokers, or 
those who stay overnight in the presence of smoking. Individuals who spend significant 
amounts of time (e.g., working) in spaces that formerly allowed smoking, may now 
experience meaningfully reduced exposure opportunity due to smoking bans [61].  
In recent years, indoor styrene concentrations have fallen in many buildings, as a 
result of reduced or eliminated tobacco smoke, use of low-VOC paints, and other 
indoor air quality improvements. Analyses of long-term ambient styrene trends indicate 
that year-to-year regional variation in concentration is not substantial, suggesting that 
lifetime average estimates are appropriate assessments of exposure [20]. These 
findings are corroborated by stable measured blood styrene levels in independent U.S. 
population samples, measured cross-sectionally, over a 20-year period [25, 60, 66].  
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Biological monitoring 
In addition to ambient air monitoring, styrene exposure is measured in blood, 
exhaled personal air, and as urinary metabolites [25]. In general, these biomarkers 
correlate well within indoor air styrene levels, but the relationship does not persist for 
outdoor air styrene concentrations. Observed correlations between environmental and 
personal measures were higher for biomarkers obtained in occupational settings, which 
are 25 times higher than average levels in the general population [5, 24]. 
Styrene is measured in blood in its unmetabolized form (blood styrene), as 
styrene-7,8-oxide, and by quantifying the formation of DNA and protein adducts [67-70]. 
Despite the extensive use of adducts as markers of styrene exposure in animal studies, 
they are less common in human studies. This is, in part, because the capacity of 
humans to form styrene oxide is much lower than rats or mice, resulting in very low 
levels of styrene adducts in human blood [71].  
For the proposed research, I will use unmetabolized styrene in blood measured 
using mass spectrometry as a biomarker of personal styrene exposure. The half-life of 
styrene in blood is approximately 13 hours [5], so blood styrene levels reflect recent 
exposure. In occupational studies, the correlation between styrene in blood and indoor 
air ranged from 0.62 to 0.94 [14, 46, 72]. In a study of low occupational styrene levels 
measured in air, blood, and urine, the best correlations with ambient levels were 
observed for blood styrene [45]. Between-worker variability is consistently higher than 
within-worker variability of blood styrene [6, 73]. 
 Recent NHANES data indicate that approximately 40% of the U.S. adult 
population has measurable levels of styrene in their blood [24, 62]. Samples from 
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NHANES and other small studies in the U.S. reported similar blood styrene levels that 
have remained fairly stable over the last 20 years [60, 66, 74]. In RIOPA, blood styrene 
demonstrated stronger correlation with indoor than outdoor air concentrations, but 
outdoor sources explained more variability in levels than did indoor sources [61, 75]. 
The median blood styrene exposure source fractions were 0.58 and <0.01 for outdoor 
and indoor sources, respectively [75]. In a study of adults in three U.S. urban areas with 
unique VOC source regimes, personal air samples explained less than 10% of the 
variance in corresponding styrene blood levels [58]. In a non-occupational setting, 
pronounced differences in blood styrene levels were seen between smokers and non-
smokers (mean, 0.12 vs 0.02 ng/mL, respectively), but no such differences were 
observed for the presence and absence of environmental tobacco smoke at home 
among non-smokers [62]. Further, outdoor exposure to environmental tobacco smoke 
or vehicle exhaust in urban areas has not been associated with increased blood styrene 
levels [62, 76]. 
Air styrene exposure levels monitored in environmental studies were highly 
variable, though determinants of relative exposure remained consistent [58, 59, 62, 75, 
77]. Exhaled styrene correlates significantly with indoor air styrene, but not with outdoor 
styrene levels. The ratio of exhaled to indoor styrene concentrations was close to 1 [58, 
75]. The ratio of indoor to outdoor air styrene levels ranged from 3.0 to 5.0, and 
increased with higher exposure [58, 59, 75]. Higher overnight personal air styrene levels 
implicate sources or activities within the home as the principal predictors of styrene 
exposure. In contrast to styrene measured in blood, personal air styrene levels do vary 
significantly with exposure to environmental tobacco smoke. 
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Glycol derivatives (mandelic acid (MA), phenylglyoxylic acid (PGA), and hippuric 
acid (HA)) account for over 95% of the styrene urinary metabolites excreted by humans 
[1].  The application of these urinary metabolites as styrene biomarkers tends to be 
more widespread in occupational studies. This may be because they are also used to 
quantify toluene, ethylbenzene, and other VOC exposure [78-80]. As such, the urinary 
metabolites MA, PGA, and HA are more appropriate for occupational settings with 
known co-exposures. Their utility in environmental styrene studies would be potentially 
limited by exposure misclassification due to co-exposure with other pollutants.  
 
Table 1. Blood styrene levels (ng/mL) in the United States, 1988-2008. 
Cohort Location Year N % Detect Geo. Arith. Med. P95 
NHANES III [60, 
66] 
United 
States 
1988-
1994 657 87.9 
 0.08 0.04 0.18 
LRGVES [81] Texas 1993 16 50.0  0.07 0.02 0.18 
NHEXAS [62] Midwest states 
1995-
1997 151 53.0 
 0.05 0.02  
NHANES United States 
1999-
2000 276 94.2 0.04 0.10 0.04 0.20 
DREAMS [82] Minnesota 2000-2002 48 76.2 
 0.07 0.07 0.11 
NHANES United States 
2001-
2002 922 54.5 0.04 0.23 0.02 0.20 
ATSDR [83] Louisiana 2002 111 39.0 0.03  0.02 0.06 
NHANES United States 
2003-
2004 1,213 41.6 0.03 0.04 0.02 0.11 
NHANES [15] United States 
2005-
2006 1,939 41.5 0.03 0.05 0.02 0.14 
NHANES United States 
2007-
2008 2,231 37.3 0.03 0.05 0.02 0.14 
% Detect, Percent of samples above limit of detection; Geo., geometric mean; Arith., arithmetic mean; Med., 
median; P95, 95th percentile 
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Determinants and predictors of exposure 
Several different environmental, behavioral, and social factors have been 
identified as determinants of styrene exposure. It is worth noting that, even in 
combination, these factors typically explain less than 25% of the variance in measured 
styrene exposure [52, 59]. This may be due to the fact that styrene is cleared from the 
body rapidly, and ascertainment of these determinants does not necessarily correspond 
to the relevant exposure time period. Exposure variation appears to be driven largely by 
house-level characteristics, rather than seasonal, neighborhood, or measurement 
variability [61]. Relative importance of different predictors varies depending on the 
exposure matrix (air, blood, etc.). 
Smoking is the single most important individual predictor of human exposure to 
styrene [1, 20, 51, 59, 60, 64, 84, 85]. The intake of styrene due to smoking 20 
cigarettes outweighs the total daily intake from food and air [23]. Exposure to 
environmental tobacco smoke is also associated with higher styrene exposure, 
particularly for non-smokers living with a smoker [59, 85]. Working in an environment 
with environmental tobacco smoke less consistently predicts styrene exposure. Among 
NHANES III participants, consuming more than one alcoholic beverage a day, on 
average, was also associated with increased blood styrene exposure [66]. 
Housing materials and characteristics are strongly predictive of VOCs, and 
styrene in particular. The size of the house (number of rooms) and number of windows 
are inversely associated with styrene exposure [75]. The house air exchange rate is 
negatively associated with styrene levels [86]. Likewise, opening windows and doors is 
predictive of lower styrene exposure. Conversely, air fresheners, excessive dust, 
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majority of floors carpeted, fireplaces, gas heating source, and attached garages are all 
associated with increased styrene exposure [51, 52, 59, 75]. Parking and storing motor 
vehicles and gas-powered equipment in the garage are also associated with increased 
styrene exposure [75]. Time spent at home is inversely associated with styrene 
exposure, suggesting that activities and sources outside the home could be driving 
higher exposures in non-smokers [75].  
Ambient relative humidity and wind speed are inversely associated with indoor 
styrene levels [87]. That is, dry, still conditions predict higher indoor air styrene. Wind 
speed dilutes outdoor concentrations from local sources and increases household air 
exchange rate, which effectively reduce indoor and outdoor air styrene exposure. 
Outdoor relative humidity may be a surrogate for precipitation, possibly representing the 
effects of low pressure systems with good dispersion or effective cleansing [75]. 
Blood styrene levels are fairly consistent within season, though monitoring 
suggests significantly lower styrene levels in the spring compared to all other seasons 
[56]. This is consistent with meteorological conditions (wind speed and humidity) that 
favor lower ambient concentrations.  Warmer months are characterized by increased 
seasonal emissions, more active atmospheric oxidation chemistry, and elevated outdoor 
styrene concentrations [87]. Relatively higher winter and autumn levels are likely 
attributable to increased rates of combustion for heating, lower photochemical 
degradation, and low mixing heights in cold seasons. Seasonal variability in personal 
styrene exposure may be difficult to predict because of the interaction between 
meteorological conditions and behavioral response. In the Gulf region, where hot 
summer temperatures potentially cause elevated outdoor concentrations, personal 
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exposures are influenced by the amount of time spent inside, and the use of air 
conditioning or windows.  
Regional variability of styrene levels between urban and rural areas suggests 
that differing outdoor source regimes and traffic emissions impact individual exposure 
[66, 75]. Other factors that might influence this relationship include weather and climate 
conditions, proximity to roadways, regional patterns in housing construction, and time 
spent in motor vehicles. Source apportionment factor analyses of the RIOPA data show 
that styrene, toluene, ethylbenzene, and xylenes form a common exposure mixture that 
accounts for 20% of total VOC exposure, and is attributed to motor vehicle exhaust [87].  
In population-based studies, reported occupational exposure to paint, cleaning 
products, and degreasers were associated with elevated styrene exposure [51, 59, 75]. 
Working in plastics, chemical, paint, or dye plants, as well as metal working, increased 
odds of high styrene exposure [51, 59]. These exposures encountered in presumably 
lower frequency or duration, through being in a paint store, or building scale models, 
painting, and doing metalwork as hobbies similarly predicted elevated styrene exposure. 
Spending time near vehicles or engines, in any capacity, was associated with higher 
breath styrene levels among non-smokers [75]. 
Demographic predictors of increased styrene exposure include race, ethnicity, 
and male gender. Non-Hispanic white people were significantly more likely than 
Mexican Americans to experience elevated styrene exposure, though no differences 
were seen for comparisons of white and black people in NHANES III [66]. A previous 
study demonstrated higher styrene levels among non-white participants than white 
participants [51]. I hypothesize that these characteristics indirectly determine styrene 
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exposure through the previously discussed occupational exposure opportunities, 
housing characteristics, behavioral determinants, and proximity to outdoor sources. 
Though ingestion of styrene is a possible exposure route, examinations of diet, 
weight, and body mass index as determinants of styrene exposure remain absent from 
the literature. Because increased styrene migration is associated with higher fat content 
[30], it is possible that a high-fat diet or elevated BMI would be predictive of styrene 
exposure. However, the trace amounts of styrene in food appear to be swamped by 
inhalation exposure, so the proportion of exposure due to ingested styrene is likely 
difficult to quantify [24]. 
 Although a candidate set of predictors for styrene exposure exists (smoking, 
environmental tobacco smoke, housing characteristics, and occupational exposures), 
the estimated relative contributions of these predictors, and others, are inconsistent. 
Further, the impact of outdoor sources and styrene concentrations on personal 
exposure levels remains unclear. Despite higher indoor concentrations, outdoor sources 
explained more variability in personal exposure measurements (median outdoor 
exposure source fraction, 0.58) than indoor sources (median indoor exposure source 
fraction, <0.01) in the Relationship of Indoor Outdoor and Personal Air (RIOPA) study 
[61, 75, 77].  Additionally, the presence or absence of a styrene source was a stronger 
determinant of indoor air concentration than the air exchange rate in one study [59]. The 
lack of consensus may be partly due to incomplete source ascertainment in many 
studies, which typically prioritize either indoor or outdoor styrene sources, but don’t 
comprehensively assess both. The proposed study includes detailed indoor exposure 
information, as well as two different assessments of outdoor styrene levels and sources.   
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B. Potential health effects of styrene exposure 
 
Toxicity 
In humans, approximately 70% of inhaled styrene is absorbed [6]. Styrene is 
distributed throughout the body, with the highest concentration generally found in 
adipose tissue [1]. Metabolism of styrene occurs primarily in the liver via the styrene 
7,8-oxide pathway. It is then excreted in the urine as mandelic and phenylglyoxylic acids 
[88]. After inhalation exposure, styrene can be metabolized in the lungs and nose, 
resulting in toxicity and, less commonly, carcinogenicity [89]. Styrene metabolism is 
concentration-dependent, with metabolic saturation occurring at 140–280 ppm in 
humans [90]. 
The health effects of styrene have been studied primarily in experimental animal 
studies and occupational human studies. Occupational exposure to styrene has been 
associated, albeit inconsistently, with a variety of acute health effects. Irritation of the 
eyes, throat, and respiratory tract, and contact dermatitis [91] have been reported, but 
not replicated [1]. Respiratory conditions, including chronic bronchitis [92] and asthma 
[93, 94], and hematological changes [95] have been demonstrated in highly exposed 
styrene workers. Occupational styrene exposure is inconsistently associated with 
altered liver function and elevated serum bile concentrations [6, 96, 97]. In animal 
studies, styrene exposure causes liver and lung toxicity in mice and nasal toxicity in rats 
and mice [71].  
Based on limited evidence in humans and experimental animals for the 
carcinogenity of styrene, the International Agency for Research on Cancer (IARC) 
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classifies it as possibly carcinogenic to humans (Group 2B) [6]. Data from both 
laboratory and human occupational studies demonstrate that styrene exposure leads to 
formation of DNA adducts, DNA damage, and cytogenic effects [68, 70, 71, 98]. In 
styrene-exposed workers, levels of DNA adducts are up to five times higher than those 
in non-exposed controls [98].  
Though styrene’s carcinogenic and genotoxic properties have been well 
characterized [6], the Agency for Toxic Substances and Disease Registry (ATSDR) has 
identified the central nervous system as the primary target for styrene toxicity, with less 
marked effects in the peripheral nervous system [2, 99]. 
 
Neurotoxicity 
Styrene monomer functions like many other VOCs, depressing the central 
nervous system and exhibiting anesthesia-like properties [6, 100]. Solvent-induced 
neurotoxicity, including that caused by styrene, produces symptoms of acute 
intoxication, commonly described as a feeling of drunkenness. Short-term acute 
intoxication is reversible, ceasing when styrene is cleared from the body. More 
concerning for overall health are the potential chronic, subtle but demonstrative, and 
irreversible effects that persist after styrene is cleared from the body [101]. It is not clear 
whether irreversible neurotoxic effects of styrene occur, and at what exposure levels.  
Occupational studies demonstrate styrene-induced neurotoxicity, evident as 
central and peripheral nervous system effects, from both acute and chronic inhaled 
exposure among highly-exposed workers. Symptoms of neurotoxicity, including feeling 
“drunk” and tiredness [41], impaired vision [99, 102], vestibular dysfunction [12], 
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headaches [103], delayed reaction time [104, 105], impaired attention and memory [9], 
hearing deficits [106], diminished nerve conduction velocity [9, 107-110], and abnormal 
EEG results [110, 111]. Dopaminergic [41, 112-114], functional [115, 116], and 
psychiatric anomalies [103, 117] have also been associated with high occupational 
exposure (approximately 100 ppm) to styrene. Similar effects have been observed at 
lower occupational exposure levels, ranging from 10-30 ppm, in most [10, 99, 103-105, 
114, 117-119], though not all [13, 120], studies. Increased mortality from diseases of the 
central nervous system, especially epilepsy, was associated with styrene exposure in a 
cohort study of reinforced-plastics industry workers [121]. 
Recent environmental studies evaluating effects of simultaneous exposure to 
multiple hazardous air pollutants have documented associations between environmental 
styrene and neurologic outcomes. When evaluating modeled ambient exposure 
estimates for a variety of HAPs, styrene was associated with increased risk of autism 
spectrum disorder [122, 123] and amyotrophic lateral sclerosis [124]. A cross-sectional 
analysis of blood VOCs and neurobehavioral testing in NHANES III found a general lack 
of significant adverse effects, with the exception that a mixture of BTEX and styrene 
was modestly associated with slower reaction time [125]. These results suggest that 
styrene may impact neurologic function at environmental levels relevant to the general 
population, implicating low-level, chronic styrene exposure as a possible public health 
problem. The human health effects due to chronic styrene exposure at typical 
environmental levels among the general population remain largely unknown – due in 
part to uncertainty regarding the magnitude of these levels and their underlying sources 
across populations [20]. Examining neurologic symptoms can reveal subclinical 
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impairments in neurologic function that appear earlier in the progression of disease. 
While less severe, these symptoms may be more sensitive to lower exposure levels, 
more prevalent in the general population, and possibly persist after exposure recedes.  
 
Mechanism 
Studies in humans and experimental in vitro and in vivo animal models have 
attempted to determine the mode of action for styrene neurotoxicity, with a 
dopaminergic mechanism gaining traction [71], but explanations remain speculative. 
Several studies suggest that styrene exposure alters dopamine metabolism, marked by 
decreased dopamine levels and increased dopamine receptors in rodents and humans 
[126-128]. The styrene metabolites phenylglyoxylic acid and mandelic acid were shown 
to deplete dopamine [129]. This mechanism is corroborated in blood samples of 
styrene-exposed plastics workers for whom prolactin levels are elevated, as prolactin 
release from the anterior pituitary gland is chronically inhibited by dopamine [130]. The 
change in prolactin may signal diminished inhibition of prolactin release by dopamine, 
whether through lower dopamine levels or weakened inhibitory action [127]. A dose-
dependent decrease in monoamine oxidase B was also observed in rats and workers 
exposed to styrene [41, 112]. 
Consistent with disturbance of the dopaminergic functions of the brain, styrene 
exposure potentiates a dose-dependent decrease in brain dopamine and an increase in 
homovanillic acid in male rats [128]. A decrease in dopamine and its metabolites in the 
corpus striatum, hypothalamus, and the lateral olfactory tract regions of the brain was 
observed in rats that were highly exposed to styrene [131]. Loss of motor function, 
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lasting for approximately a month, accompanied these changes in dopamine. This 
physiological manifestation supports the hypothesis that dopamine mediates styrene 
exposure to impact neurologic function. Styrene also caused cell loss and dopamine 
depletion in retinas isolated from female rats [132], which supports the established 
association between occupational styrene exposure and impaired color vision [133]. 
 
C. Summary of Background and Significance  
The blood styrene levels observed in the GuLF STUDY are much lower than 
occupational levels, but two to three times higher than those observed in the general 
U.S. population. This difference persists regardless of cigarette smoking, suggesting 
meaningfully increased exposure opportunity in the region. Identifying sources of 
uniquely elevated styrene exposure has implications for exposure mitigation policy.  
Given that styrene use is widespread, it is a critical public health priority to 
evaluate whether adverse health effects result from chronic exposure at environmental 
levels. Quantifying the association between environmental styrene exposure and highly 
sensitive, but non-specific, neurologic symptoms may lend insight into early 
manifestations of environmentally induced neurotoxicity. This research provides insight 
into the underlying sources responsible for styrene exposure in this population, as well 
as being the first to examine neurologic effects of styrene exposure of this magnitude.  
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CHAPTER III: METHODS 
 
A. Study Design and Population 
 
GuLF STUDY 
This research builds upon the GuLF STUDY, a prospective cohort study of 
community members who participated in the cleanup of the Deepwater Horizon oil spill 
in 2010 and comparison subjects who did not, for which extensive data and banked 
biospecimens have already been collected. Of the 32,608 people who enrolled in the 
GuLF STUDY between March 2011 and June 2013, 26,828 (90% of those contacted 
and eligible) resided in one of the five Gulf States (Alabama, Florida, Louisiana, 
Mississippi, and Texas). For reasons of exposure opportunity and data collection 
logistics, the proposed dissertation research is restricted to these 26,828 participants 
living in the Gulf States.  
 All English- and Spanish-speaking cleanup workers and a random sample of 
non-cleanup workers residing in one of the Gulf States were additionally invited to 
participate in a home visit, which included extensive interviewing on lifestyle, 
occupational, and health factors, collection of anthropometric measures, and blood 
collection. Over 11,000 participants (66% of those invited) completed a home visit. A 
stratified random sample of 1,055 home visit participants, oversampled for women and 
non-smokers, was recruited for a Chemical Biomonitoring Study (CBS) (94% 
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participation) at the time of their home visit two to three years after the oil spill. These 
CBS participants provided an additional 10 mL tube of whole blood for measurement of 
VOCs, including styrene. The whole blood specimens were shipped overnight at 4ºC to 
the Centers for Disease Control and Prevention (CDC) for analysis. GuLF STUDY 
personnel recorded the latitude and longitude of the home visit location using a handheld 
Global Positioning System (GPS) device. Home visits among CBS took place in 2012 
and 2013, a median of 105 days after enrollment, with 26% of exposure biomonitoring 
visits completed within 1 month of enrollment and 47% completed within 3 months of 
enrollment. Ultimately, after removal of samples due to insufficient quantity (N=13) and 
assay failure (N=47), 994 participants provided blood samples sufficient for 
quantification of styrene levels. 
Approximately 3,400 home visit participants living within 60 miles of New Orleans, 
LA or Mobile, AL completed a clinical examination between August 2014 and July 2016. 
Examinations took place in two clinical settings (one in New Orleans, LA and one in 
Mobile, AL) and included anthropometric measurements, biological sample collection, 
standardized computer-assisted neurocognitive testing, peripheral neurologic function 
evaluations, pulmonary function testing, and mental health questionnaires. 
Analyses rely on data collected at enrollment from 26,828 participants in the Gulf 
States, during the CBS home visit from 994 participants, and at the follow-up clinical 
exam from approximately 3,400 participants. Both the CBS and the clinical exam sub-
populations are nested within the Gulf States portion of the parent GuLF STUDY 
population.  
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Human Subjects 
The GuLF STUDY received approval from the Institutional Review Board of the 
National Institute of Environmental Health Sciences. This dissertation utilizes previously 
collected, de-identified data and no study participants were contacted for additional 
information. The project was approved by the Institutional Review Board of the University 
of North Carolina at Chapel Hill. 
 
Eligibility and sampling for Specific Aims 1 and 2 
 Analyses for Specific Aims 1 and 2 employ data collected at enrollment and the 
CBS home visit, as well as spatially referenced exposure assignment. As such, these 
analyses are restricted to those 994 GuLF STUDY participants who provided blood 
specimen for styrene measurements during participation in CBS. Because exposure 
assessment for these analyses is location-based, any members without a plausible 
geocoded location are excluded. Eligible participants in these analyses meet the 
following criteria: 
 Residence in one of the five Gulf States  
 Completion of home visit and provision of blood styrene specimen  
 English- or Spanish-speaking 
 Plausible geocoded home location 
 Quantifiable blood styrene and 2,5-dimethylfuran samples 
 Complete covariate information   
 Of the 994 participants with measurable blood styrene levels, 935 also have 
measured blood 2,5-dimethylfuran (2,5-DMF) levels. 2,5-DMF is a VOC and validated 
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blood biomarker for smoking [64]. Those 935 CBS participants with blood styrene and 
2,5-DMF information comprise the sample for comparisons to NHANES.  
 For regression analyses predicting blood styrene levels, we further restrict to 
participants who completed the recent exposure questionnaire (n=810) and have 
complete demographic and covariate information, yielding a final analytic sample of 667 
participants. 
 
Eligibility and sampling for Aim 3 
Aim 3 analyses examine associations between environmental styrene exposure 
and neurologic effects. Ambient styrene exposure is characterized using NATA 
concentrations, and blood styrene exposure is measured from samples provided in 
CBS. Neurologic outcomes include self-reported symptoms collected at enrollment and 
peripheral neurologic function testing conducted at follow-up. We exclude participants 
reporting physician diagnosis of diabetes from all neurologic analyses because 
peripheral neuropathy is a known complication of diabetes. 
Eligible participants for the analyses of ambient styrene exposure and neurologic 
outcomes meet the following criteria: 
 Residence in one of the five Gulf States  
 English- or Spanish-speaking 
 Plausible census-based home location 
 Complete outcome ascertainment 
 Complete covariate information 
 No self-reported physician diagnosis of diabetes 
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Of the 26,828 English- or Spanish-speaking GuLF STUDY participants residing 
in the Gulf states, 25,844 reported addresses which returned plausible census locations 
for ambient exposure assignment. We exclude any participants missing any symptom 
(n=1,245), demographic (n=573), or covariate (n=201) information, as well as anyone 
with known or missing diabetes diagnosis. Ultimately, this analysis of ambient styrene in 
relation to neurologic symptoms includes 21,962 non-diabetics with complete exposure, 
outcome, and covariate information.  
The association between ambient styrene and peripheral neurologic function 
includes 2,956 participants out of 3,403 who completed the follow-up clinical exam. 
Eligibility for participation in the follow-up clinical exam was restricted to GuLF STUDY 
participants living within 60 miles of New Orleans, LA or Mobile, AL. We made exclusions 
for implausible census location (n=74), missing all neurologic function testing 
information (n=8), missing covariate information (n=58), and possible diabetes 
diagnosis (n=305).  
Eligibility requirements for analysis of associations between measured blood 
styrene levels and neurologic outcomes (both symptoms and test performance) are as 
follows: 
 Participation in CBS and provision of blood styrene specimen 
 English- or Spanish-speaking 
 Plausible census-based home location 
 Successful lab measurement of blood styrene 
 Complete covariate information 
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 Out of 994 CBS participants providing adequate blood samples for styrene 
measurement, 974 had complete neurologic symptom ascertainment. We excluded 13 
participants with missing covariate information and 87 known or possible diabetics, 
arriving at a final analytic sample of 874 participants. 
 The intersection of CBS and the follow-up clinical exam include 343 eligible 
participants with blood styrene measurements and peripheral neurologic function 
testing, all of whom had complete demographic and covariate information. We exclude 
33 known diabetics, yielding a final sample size of 310 participants for the analysis of 
blood styrene and peripheral neurologic function. 
 
B. Data Collection and Measurement of Variables 
 
Exposure assessment 
Styrene exposure was ascertained 4 ways:  
Blood styrene levels 
NATA ambient concentrations 
NEI point source proximity 
Self-reported behavior and lifestyle indicators 
 
 For location-based exposure assessment (NATA ambient concentrations and 
NEI point source proximity), each participant’s home residence was geocoded and 
associated with the corresponding 2010 U.S. census tract within which it is located. 
Participant residence was ascertained at enrollment via self-reported address and at the 
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home visit via hand-held GPS device. Reported addresses were geocoded by GuLF 
STUDY personnel using ArcGIS and the Google maps application program interface. 
 Approximately 85% of home visits were successfully geocoded using the GPS 
device, and the remaining 15% were preliminarily geocoded to the corresponding 
census tract centroid. We preferentially use GPS-generated geocodes in analyses 
where available. Participants with implausible or missing GPS-generated geocodes 
were assigned address-based geocodes. Participants for whom no geocode location 
(GPS or address-based) was successfully determined were assigned to the nearest 
census tract centroid.  
 
Blood styrene levels 
 Participants provided a single 10 mL tube of whole blood at the home visit for 
measurement of VOCs. Measured pollutants included styrene, benzene, toluene, ethyl 
benzene, and xylenes (BTEX) and others. The whole blood specimens were shipped 
overnight at 4ºC to the Centers for Disease Control and Prevention (CDC) for analysis.  
 Blood levels of styrene and other chemicals were measured at the CDC 
laboratory using the standard methods used in NHANES. Measurement was by 
equilibrium headspace solid-phase microextraction/gas chromatography/mass 
spectrometry of hermetically collected blood specimens [134, 135]. Of the 1,055 
recruited CBS participants who provided blood specimen for any blood VOC 
measurements, 13 were eliminated because the quantity of sample was insufficient to 
measure styrene, 47 were removed due to quality control failure, and one outlying value 
(15.3 ng/mL) was eliminated. The remaining 994 samples, including those below the 
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limit of detection, make up the sample size for analyses examining blood styrene levels. 
Approximately 80% of samples had measurable styrene levels above the limit of 
detection. The laboratory provided all measured values, including those below the limit of 
detection (0.03 ng/mL). 
 
Figure 2. CBS blood VOC study sample. 
 
 
National Air Toxics Assessment 2011 
The EPA’s 2011 National-scale Air Toxics Assessment (NATA) evaluates 180 air 
toxics across the United States using emissions inventories, dispersion modeling, 
photochemical modeling, exposure modeling, and toxicity analyses. In this most recent 
Chemical Biomonitoring Study 
(N=1,075) 
Provided blood sample  
(N=1,055) 
Quantity not 
sufficient 
(N=13) 
Quality 
control 
(N=47) 
Detectable styrene level 
(N=767) 
Styrene < LOD 
(N=228) 
Analytic sample for blood styrene 
(N=994) 
Outlier 
(N=1) 
Blood sample analyzed for styrene 
(N=1,008) 
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NATA release, styrene is modeled using the dispersion component of the Human 
Exposure Model, version 3 (HEM-3). HEM-3 is a computer model designed to conduct 
inhalation risk assessments for sources emitting air toxics to ambient air. HEM-3 
contains the American Meteorological Society (AMS) and EPA Regulatory Model 
(AERMOD) dispersion model for air-transport simulations and U.S. Census data for 
identifying population receptors. AERMOD contains emissions and meteorological data, 
which is combined with HEM-3 census data to generate annual average ambient air 
toxic concentrations for each U.S. census tract. 
Emissions inputs to AERMOD come from the 2011 National Emissions Inventory. 
AERMOD predicts annual census tract concentrations for each major source type 
(point, nonpoint, on-road, non-road), which are then summed to a total concentration 
value for all source types combined.  
 NATA has been widely evaluated against observed air monitoring data in many 
sites across the country, both externally [136-143] and by the EPA [144]. AERMOD 
performance varies by pollutant, and styrene demonstrates strong agreement with 
monitored data in the Gulf region for 2011, based on a correlation of 0.73 and a model 
to monitor concentration ratio of 1.1. Assuming observed monitor values represent true 
ground-level exposure, AERMOD appears to characterize ambient styrene sufficiently 
well for use as an indicator of human exposure. 
Air toxics monitoring lacks the spatial and temporal coverage to estimate or 
interpolate exposures with any reasonable degree of certainty, particularly when 
compared to the residential locations of GuLF STUDY participants (Appendix 1). The 
average distance to the nearest styrene monitor among CBS participants is 114 miles, 
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and only 31 CBS participants within 10 miles of a monitor. The contribution of monitored 
styrene via kriging or otherwise combining with NATA would be negligible [145].  
We use NATA styrene estimates as indicators of typical, long-term environmental 
exposure. Although the assumptions inherent to an annual average estimate of air 
pollution potentially limit interpretation for acute exposure scenarios, NATA data are a 
valid estimation of usual exposure levels experienced in the Gulf. Despite the loss of 
spatial resolution within census tracts, dispersion modeling is considered superior to 
distance-based exposure metrics because it integrates meteorology, comprehensive 
ascertainment of all source types, and weighting by emissions quantities [146, 147]. 
 
Spatially estimated styrene exposure: National Emissions Inventory 2011 
 Point sources of styrene emissions were identified using the 2011 National 
Emissions Inventory Version 2 (NEI), the EPA’s latest comprehensive database of 
annual criteria (CAP), precursor, and hazardous air pollutant (HAP) emissions. The Air 
Emissions Reporting Rule (AERR) requires jurisdictions to report all sources of CAP 
and precursor emissions, including total VOCs, and sets forth guidelines for voluntary 
reporting of HAPs. Sources are collected from state, local and tribal air agencies, and 
augmented with information from the Toxics Release Inventory (TRI), the Acid Rain 
Program, and EPA’s regulatory air toxics data. The NEI is compiled and released every 
three years.  
 NEI sources are broadly categorized as stationary or mobile emitters. Stationary 
emissions sources, which are further designated as point or nonpoint, include large 
industrial sources (power plants and refineries), smaller industrial and commercial 
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sources (dry cleaners and commercial cooking), and residential sources (residential 
wood combustion and consumer products usage). The point and nonpoint designations 
reflect the way each source is modeled – point sources are associated with a latitude-
longitude geographic coordinate location, whereas all other sources are aggregated to 
county totals. The emissions potential of each stationary facility determines its 
designation as a point or nonpoint source, according to emissions thresholds set in the 
AERR. For the majority of the five-state GuLF STUDY region, the point source 
emissions threshold is 100 potential tons of ozone per year. The remaining study area 
includes two ozone non-attainment areas, where point source designation is attributed 
to facilities with the potential to emit at least 50 tons of ozone annually.  
 Nonpoint (stationary facilities emitting below the AERR threshold), on-road (cars 
and trucks driven on roads), non-road (locomotives, aircraft, marine, construction 
vehicles, off-road vehicles, and lawn and garden equipment), and event (wildfires, 
prescribed burning) sources are reported as aggregated county totals for each source.  
 In Specific Aim 2, we focus exclusively on point sources. Styrene emissions are 
estimated directly if a facility voluntarily reported HAPs, or indirectly for those facilities 
and jurisdictions that do not report HAP emissions. Indirectly reported styrene emissions 
are calculated by multiplying the appropriate surrogate CAP emissions volume by an 
emissions factor associated with the industrial process of interest. For all styrene 
emissions, the CAP surrogate is total VOCs. The emissions factors vary depending on 
the Source Classification Code (SCC) of each process. We abstracted styrene point 
source locations by identifying all records of reported styrene emissions from the 2011 
NEI point source database.  
39 
 
Self-reported styrene exposure 
 GuLF STUDY participants provided self-reported information that is potentially 
predictive of styrene exposure a minimum of one time (baseline telephone 
questionnaire at enrollment), and a maximum of three times (in-person home visit 
questionnaire, in-person exposure biomonitoring questionnaire at home visit). 
Extensive, thorough, detailed information about exposure to cigarette smoke (both 
active and passive) was obtained at enrollment and the home visit. 
All GuLF STUDY participants in the five-state Gulf region (N=26,828) completed 
the enrollment Computer Assisted Telephone Interview (CATI). Information obtained 
here is applied to all three Specific Aims.  
All CBS participants also completed the home visit questionnaire at the time of 
their blood draw. Information obtained here is applied in Specific Aims 1 and 2. This 
instrument is used primarily to characterize residential and recreational styrene 
exposure opportunities. A complete residential history was compiled including all places 
the participant lived for at least 3 months during their life. Residential characteristics 
included: 
 Live within ½ mile of a major highway, boatyard, docks, oil refinery, 
petroleum storage or transfer facility, gas stations, factory, power plant, 
hazardous waste site or Superfund site, landfill 
 Years lived at residence 
 Usual water supply at residence 
 Residential proximity to center or margin of town (urban/rural) 
 Residence classified as farm 
40 
 
Non-occupational exposure opportunities were assessed by asking, Do you have 
any of the following hobbies? 
 Woodworking or cabinetry, Boat repair, Car, motorcycle, or other vehicle 
repair, Gardening, Fishing, Pottery, Painting as art work, Sculpture, Home 
repairs or handyman work, Raising farm animals 
 All CBS participants completed the corresponding recent exposure questionnaire 
at the time of the blood draw. This instrument was developed to obtain detailed 
information about relevant predictors of VOC and metal exposure, though styrene was 
not specifically prioritized. Information obtained here is used in Specific Aims 1 and 2. 
This instrument is used primarily to characterize residential and non-occupational 
styrene exposure opportunities in the immediate vicinity and time of the blood collection. 
The following information pertains to housing and microenvironmental exposures: 
 Year built, housing type, number of rooms, exterior wall construction, 
attached garage, garage vehicle and equipment inventory 
 Home renovations in the past 6 months 
 New furniture in the past month 
 Anyone painted in or around the home in the past 6 months 
Activities performed by anyone in or around the home: 
 In the past 24 hours: cook, clean, burn candles or incense, open windows, 
open exterior doors, burn fuel  
 In the past week: painting, using chemical paint strippers, adhesives, or 
home maintenance products (caulk, grout), doing metalwork 
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 Did you smell smoke or any unusual chemical smells in or around your 
home within the last 24 hours? 
Products and materials used in or around the home in the past 24 hours: 
 Cleaning products, aerosol spray products, air fresheners, petroleum-
based solvents, paints or glues, household pesticides or lawn chemicals, 
air purifier, air filter, heater/heating devices, air conditioner, window fan 
 Use and repair of lawn mowers, small engines, equipment, and machinery 
Vehicle use in the past 24 hours): 
 Time driving, riding in, and refueling gas-powered and diesel vehicles 
Time spent away from home in the past 24 hours: 
 Hours away from home, hours outside, hours exercising outside 
The following information about current occupation at the time of the home visit 
was obtained: 
 Do you usually work a total of 35 hours or more per week? 
 Did you work yesterday or today before this visit? 
 Hours worked, commute type, and commute time in the past 24 hours 
 Materials worked with or near in the past 24 hours: insulation, brake 
shoes, paints, varnishes, stains, or strippers, other chemical used to clean 
floors, walls and other surfaces, diesel engine exhaust, gasoline engine 
exhaust, pesticides 
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Outcome assessment 
Neurologic outcomes were ascertained two ways: 
Self-reported neurologic symptoms 
Peripheral neurologic function testing 
  
Self-reported neurologic symptoms 
 Detailed health outcome ascertainment, including questions about neurologic 
symptoms, was completed at enrollment via CATI during the baseline interview. 
Symptoms of neurologic function were reported with respect to the previous 30 days. 
Participants were asked to report how often they experienced dizziness, 
lightheadedness, vision impairment, numbness, tingling, loss of balance or stumbling, 
headaches, and fatigue during this time period. Three additional outcomes, insomnia, 
vomiting, and seizures, were added to the questionnaire after data collection was 
underway. These outcomes are combined with other symptoms analytically only in 
appropriate population subsets because their enumeration in the study population is 
incomplete (i.e., those people who completed the enrollment interview prior to the 
inclusion of seizures and insomnia did not have the opportunity to report them).  
 Questionnaire items were developed using previous literature describing 
symptoms of petroleum/VOC-based neurotoxicity. All symptoms in question have been 
investigated with occupational styrene exposure and demonstrated significant 
associations, with varying degrees of consistency [1, 6, 24]. Symptoms of neurologic 
function were ascertained as follows: 
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In the past 30 days, how often: 
 have you had a severe headache or migraine? 
 have you felt dizzy or lightheaded? 
 have you been nauseated? 
 have you experienced vomiting? 
 have you had blurred or distorted vision? 
 did you have tingling or a “pins and needles” feeling in your hands, arms, 
feet, or legs? 
 you have numbness (parts of your body “go to sleep” for no apparent 
reason) in your hands, arms, feet, or legs? 
 did you stumble while walking? 
 had excessive fatigue or extreme tiredness? 
 have you experienced seizures? 
 did you have insomnia? 
 Frequency of symptom occurrence was reported as: all of the time, most of the 
time, sometimes, rarely, never. Symptoms are analyzed as a binary indicator of the 
presence (all or most of the time) or absence (sometimes, rarely, or never) of 
occurrence. A lower threshold is applied to the episodic symptoms because the relative 
frequency of their occurrence is expected to be lower, as compared with potentially 
ongoing symptoms. Accordingly, the presence of vomiting includes responses of 
sometimes, most, or all of the time, and the presence of seizures includes reporting a 
seizure at any point during the 30 days (rarely, sometimes, most of the time, all of the 
time). Adjusting thresholds in this manner is meant to facilitate interpretation of results. 
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Peripheral neurologic function testing 
Follow-up clinical examinations included anthropometric measurements, 
biological sample collection, peripheral neurologic function testing, neurobehavioral 
evaluations, pulmonary function testing, and mental health questionnaires. The 
neurologic function testing battery, which has been implemented in a previous study of 
chronic, low-level neurotoxicants [148], included the following seven tests: visual acuity, 
visual contrast sensitivity, handgrip strength, vibrotactile threshold testing, postural 
stability, single leg stance, and long-distance corridor walk. This study will focus on a 
subset of the neurologic function tests, selected to correspond with effects of solvent-
induced neurotoxicity in the occupational literature [149, 150].   
 Visual contrast sensitivity was evaluated with the Functional Assessment of 
Contrast Sensitivity test using a standard testing instrument, the Optec 1000 (Optec, 
Inc. U.S.A). Circular stimuli consisting of alternating light and dark bars were presented. 
Nine stimuli of decreasing contrast were presented at each of 5 spatial frequencies, i.e., 
1.5, 3, 6, 12, and 18 cycles per degree. The index of the weakest contrast correctly 
identified (i.e., threshold) was recorded for each spatial frequency.  
Postural stability was evaluated using the Advanced Mechanical Technology, Inc. 
(AMTI) force platform by measuring the forces applied to the platform through the 
participant’s feet. The device uses strain gauges in the metal platform and a computer 
interface to record the forces applied to it. The signals from these strain gauges are 
amplified, digitized, and stored in the computer. From these forces, a times series of 
locations of the participant’s center of pressure can be collected. The path of these 
center of pressure locations is plotted on the computer screen and the length and 
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velocity of the sway path over a standard time period (e.g., 60 seconds) is recorded. 
Summary measures such as the average deviation in the lateral and anterior-posterior 
directions will also be calculated. The test was repeated two times with the participant’s 
eyes open and two times with eyes closed.  
Single leg stance was evaluated by asking the participant to stand on one leg 
and maintain balance for 30 seconds. If the participant was unable to maintain their 
balance for the entire 30 seconds, the procedure was repeated up to two additional 
times. 
Vibrotactile threshold was evaluated using a portable Vibratron II 
electromechanical vibrometer consisting of a controller unit and two identical transducer 
units that cause plastic posts protruding from their housings to vibrate at a frequency of 
120 Hz. The amplitude of the vibration is controlled manually by the examiner and 
displayed digitally on the face of the controller. We obtained five threshold values (three 
descending and two ascending values) for each great toe, requiring a total of about 10 
minutes. The final vibration threshold for each toe is the median value obtained from 
values 2-5 (value 1 is discarded). Examiners entered data manually into the data 
system. 
Handgrip strength was assessed with a self-contained mechanical/hydraulic 
device that records on a dial the maximum force exerted by the participant’s "power" or 
whole-hand grip. It is equipped with a "tell-tale" that retains the maximum excursion of 
the force indicator needle. We performed one set of three grip strength measures of the 
dominant hand followed by one set of three grip strength measures of the non-dominant 
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hand. The bilateral mean of the six measures is the summary metric for the handgrip 
measure. 
  
Covariate assessment 
Covariates were obtained from the enrollment, home visit, and CBS 
questionnaires. For the predictive modeling in Specific Aims 1 and 2, covariates were 
selected on the basis of their theoretical association with styrene exposure. For the 
exposure-outcome modeling in Specific Aim 3, covariates were selected according to 
their theorized relationships with both the exposure and the outcome. Aim 3 analyses 
rely on covariates ascertained exclusively from the enrollment questionnaire. 
 Cigarette smoking is a primary source of population styrene exposure, with 
reported VOC levels in the blood of smokers mimicking levels found in mainstream 
cigarette smoke [64]. As such, determining smoking status and factors affecting dose of 
cigarette smoke received is essential in analyses of styrene as both an exposure 
(Specific Aim 3) and outcome (Specific Aims 1 and 2). Detailed reported smoking 
information was collected at each phase of study. Additionally, 2,5-DMF, a biomarker of 
smoking was measured in blood among all CBS participants. Because mainstream and 
sidestream cigarette smoke are strong predictors of styrene exposure, we assessed 
cigarette smoke multiple ways.  
 Alcohol consumption is associated with personal styrene exposure [66], and 
acute alcohol intoxication presents as many of the self-reported outcome measures in 
this study [151]. As such, alcohol consumption is a predictor of both the primary 
exposure and outcome, and will be treated as a potential confounder. Drinking habits 
47 
 
were ascertained with respect to lifetime habits, the past 12 months, and the past 30 
days. Alcohol consumption is considered in all three Specific Aims. 
 Demographic and social characteristics, including age, sex, marital status, race, 
and ethnicity were ascertained at enrollment using standard questions. Body mass 
index was calculated based on reported height and weight at enrollment, and measured 
height and weight at the home visit. These variables are applied in all three Specific 
Aims. 
Socioeconomic status is potentially associated with many predictors of styrene 
exposure, as well as health status and likelihood of symptom reporting. Indicators of 
socioeconomic status were collected at enrollment and the home visit. Highest grade 
level completed, household income, and current work status were all collected at 
enrollment.  
 
 
C. Data Analysis Methods 
Specific Aim 1: predict blood styrene levels using GuLF STUDY and NATA data 
Specific Aim 2: predict blood styrene levels using NEI data 
Specific Aim 3: examine associations between styrene exposure and neurologic 
outcomes  
 
Specific Aim 1 
Because these specimens were collected two to three years after the oil spill and 
styrene’s biological half-life in blood is 13 hours, these measurements reflect 
contemporary, ongoing exposures. Indeed, we observe virtually no correlation between 
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individual-level blood styrene levels and working on oil spill cleanup (Table 2). Any 
variability in styrene exposure according to oil spill cleanup experience is likely an 
artifact of other lifestyle factors associated with individual styrene exposure. Styrene is 
derived from, but not an important constituent of, petroleum [1, 78]; therefore, we do not 
estimate or account for cleanup-related styrene exposure in Specific Aim 1. 
 
Table 2. Bivariate distribution of blood styrene levels stratified by participation in DWH 
oil spill cleanup work. 
  Workers Non-workers 
N 844 150 
Mean (SD) 0.31 (2.1) 0.31 (2.1) 
Geometric mean (SD) 0.10 (4.0) 0.08 (4.2) 
Minimum 0.02 0.02 
25th percentile 0.03 0.02 
Median 0.07 0.05 
75th percentile 0.19 0.16 
95th percentile 1.62 2.00 
T statistic (p-value) 0.09 (p=0.90) 
R2 0.00001 
Characterize the distribution of blood styrene with respect to NHANES  
 To contextualize the observed blood styrene concentrations in CBS, we compare 
them to the levels observed in NHANES, examining differences in central tendency and 
interquartile range of blood styrene levels between the two study cohorts. The 
presence of outliers, skew, and other deviations from normal distribution is noted. 
These comparisons are evaluated jointly with cigarette smoking status.  
 In addition to comparing the continuous distribution of exposures, blood styrene 
in CBS is categorized with respect to the 95th percentile of NHANES blood styrene 
levels. In lieu of a clinical cutpoint, we designate these participants as elevated styrene 
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cases and compare age- and sex-standardized rates of elevated styrene arising from 
CBS and NHANES. This analysis is summarized with a rate ratio.  
 
Predict measured blood styrene levels using NATA and GuLF STUDY data 
We explored associations between identified predictors and blood styrene levels 
using correlations to inform regression-based methods for predicting blood styrene 
levels. The reduction in residual variance (R2) is reported for predictive associations. 
Because NATA estimates are averages, instead of analyzing ambient styrene 
concentrations as continuous measures, we designated rank-based exposure 
assignment using quantiles based on the distribution of NATA estimates across the five-
state Gulf region. NATA estimates are added to predictive models to capture the excess 
contribution of ambient styrene concentration to blood levels, above and beyond the 
variability explained by individual level predictors collected from questionnaire data. 
Reported information from the enrollment, home visit, and biomonitoring 
questionnaires includes a broad range of potential predictors of styrene exposure. 
Relationships with continuous styrene exposure are explored using correlation 
coefficients for continuous covariates, two-sample t-tests for binary covariates, and one-
way analysis of variance for categorical covariates.  
We use linear least squares regression to predict continuous blood styrene 
levels. Blood styrene was evaluated for potential log-transformation, and we also used 
the binary designation relative to the smoking-specific NHANES 95th percentile.  
A purely predictive approach to model specification is applied to meet the 
objective of predicting blood styrene levels in Specific Aim 1 [152].  A literature review of 
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occupational and environmental styrene exposure was conducted to identify potential 
determinants of styrene blood levels. The joint distribution of each potential predictor 
with blood styrene is examined to explore potential associations and determine which 
measure of a given predictor type demonstrates the strongest relationship with the 
outcome. 
We use stepwise regression to select predictors for the final model. First, each of 
the candidate predictor variables is evaluated in a univariate regression model with 
measured blood styrene as the dependent variable. Next, variables that achieve 
statistical significance (p<0.05) will be retained for consideration in multivariate models. 
We use backward elimination with a retention criteria of p<0.10 for model specification.  
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Specific Aim 2 
To extend the predictive modeling in Specific Aim 1, we predict measured blood 
styrene levels using NEI point source data and spatial indicators in Specific Aim 3. 
Proximity to and density of point source locations (PSLs) relative to a participant’s 
geocoded home residence were applied for location-based exposure estimates. 
Distance to sources, density of sources, and source emissions volume within a given 
circular buffer was used to capture the exposure frequency and intensity. The spatial 
radius of the buffer was determined based on pollutant dispersion ranges [56] and 
spatial distribution of participants and PSLs in the study region [153]. As such, multiple 
buffers are evaluated (0.5 miles, 1 mile, 2 miles, 5 miles, and 10 miles).  
 Proximity measures using distance as a proxy for exposure to industrial 
emissions have been used for a wide variety of pollutants at a broad range of spatial 
and temporal scales [154-161]. Though these measures are often criticized for making 
crude assumptions about pollutant dispersion behavior and volume [162], their use is 
recommended in conjunction with an additional marker of exposure, such as NATA 
estimates [163]. The following distance based measures of exposure are considered: 
 Euclidean distance to nearest PSL 
 Number of PSLs within a given radius 
 Inverse distance weighted (IDW) count of point source locations within a 
given radius of geocoded residence, a continuous exposure metric:  
𝐼𝐼𝐼𝐼𝐼𝐼 𝑃𝑃𝑃𝑃𝑃𝑃 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =  ∑ 1
𝑑𝑑𝑖𝑖
,𝑛𝑛𝑖𝑖=1  where di = distance of the ith individual PSL 
from residence; n = number of existing PSLs within given radius [164].  
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Emissions weighted proximity measures (EWPMs) have been used extensively 
in air pollution epidemiology, particularly for HAPs. Evaluations of spatially based 
exposure estimation in Texas indicate that EWPM estimation quantifies exposure more 
accurately than traditional proximity measures, and is a valid alternative to NATA [165, 
166].  The following emissions based measures of exposure are considered: 
 Annual styrene emissions volume within a given radius 
 Emissions volume weighted distance to nearest PSL 
 Emissions volume weighted IDW PSL count 
 In addition to distance and emissions based exposure assessments, facility 
characteristics were evaluated. Facilities were categorized according to SCC and 
NAICS codes to determine whether specific industries, activities, or source regime 
combinations are associated with increased emissions or blood styrene levels.  
We use a similar modeling approach to that described in Specific Aim 1 to predict 
continuous (natural log-transformed) blood styrene levels, now selecting predictors from 
the range of variables describing proximity to point source emissions. Log binomial 
regression models are used to estimate associations between PSL styrene exposure 
and prevalence of elevated styrene. We ultimately combine the results of Specific Aims 
1 and 2 to assess the combined predictive ability of both exposure approaches. We use 
backward elimination with a retention criteria of p<0.10 for model specification, building 
a combined model from predictors identified in Specific Aims 1 and 2. 
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Specific Aim 3 
For Specific Aim 3, we evaluate the association between environmental styrene 
exposure and neurologic outcomes:  
Estimate associations between ambient styrene and neurologic symptoms 
Estimate associations between blood styrene and neurologic symptoms 
Estimate associations between styrene exposure and peripheral neurologic function 
 
Estimate associations between ambient styrene and neurologic symptoms 
The principal analysis estimates associations between ambient styrene exposure 
metrics (NATA estimated concentrations) and self-reported symptoms of neurologic 
function with respect to the preceding 30 days.  
 We use log-binomial regression to estimate associations (prevalence ratios, PR, 
and 95% Confidence Intervals, 95% CI) between ambient styrene and self-reported 
neurologic symptoms (N=21,962). Outcomes are dichotomized as presence or absence 
of a given symptom. Separate multivariate regression models are implemented for each 
symptom.  
 Due to the likelihood of co-occurring symptoms, we explored the use of latent 
class analysis to analyze grouped neurologic symptoms. As previously mentioned, 
seizures, vomiting, and insomnia are excluded from latent class analyses (due to 
incomplete enumeration). Two neurologic symptom clusters were identified: a central 
nervous system (CNS) cluster, including dizziness, headache, nausea, sweating, and 
palpitations; and a peripheral nervous system (PNS) cluster, including tingling and 
numbness in extremities, blurred vision, and stumbling. In addition to specific individual 
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neurologic symptom analyses, we estimate associations between ambient styrene 
exposure and grouped outcomes: CNS, PNS, and any neurologic symptoms. 
Potential confounders were identified based on the existing literature, and a 
minimally sufficient adjustment set was selected using directed acyclic graph (DAG) 
analysis of the theoretical relationship between styrene exposure and neurologic 
impairment (Figure 3).  The following covariates are prioritized for inclusion in the causal 
diagram: 
 Demographics: age, sex, race, ethnicity, education, and income 
 Lifestyle: smoking, alcohol consumption, BMI, occupation 
 Environment: urban residence, population density, BTEX exposure, 
environmental tobacco smoke 
The minimally sufficient set identified using DAG analysis includes: {age, sex, 
race/ethnicity, season, occupation, alcohol consumption, cigarette smoking, and BTEX 
coexposure}. Age, sex, and race/ethnicity were all reported at enrollment via CATI. 
Season refers to season of study enrollment. Occupation is modeled as employment 
status (employed vs unemployed), due to limitations in available self-reported 
occupational data. Alcohol consumption and cigarette smoking are modeled as current 
users compared to all others, based on self-reported information at enrollment. Due to 
the correlation between BTEX and styrene exposure, as well as potential for adjusting 
away main exposure effects, BTEX co-exposure adjustment is relegated to sensitivity 
analyses only. In the analysis of ambient styrene exposure, NATA estimates are used 
as measures of BTEX co-exposures.  
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Figure 3. Directed acyclic graph for the relationship between styrene exposure and 
neurologic symptoms.  
 
Covariates included in the proposed regression model are shown in bold face type 
(exposure, outcome, and minimally sufficient adjustment set).  
 
Estimate associations between blood styrene and neurologic symptoms 
We evaluate the association between styrene and neurologic function among 
CBS participants (N=874) using measured blood styrene as the exposure of interest. 
These analyses are run in parallel with ambient exposure analyses, using the same 
statistical approach. Because the theoretical basis for the relationship is constant 
between the two models, the DAG, and minimally sufficient covariate set are the same. 
Further, to facilitate comparisons between the NATA estimated associations and the 
blood styrene associations, the models are run with identical adjustment covariates, 
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with one exception. Blood exposure analyses are additionally adjusted for the duration 
of time (days) between enrollment, when symptoms were ascertained, and the CBS 
home visit, when blood styrene was measured. Appropriately, blood BTEX levels are 
used as co-exposure adjustment factors in these models.  
Because outcome ascertainment occurred during the baseline telephone 
interview, and exposure assessment was subsequently completed at the home visit, we 
examine the distribution of elapsed time between enrollment and the home visit. The 
exposure-outcome analysis remains conceptually cross-sectional because styrene 
exposures are assumed to be typical, low- or medium-level, long-term exposures 
contributing to neurological effects assessed in the last month. We conduct sensitivity 
analyses restricting to participants with baseline and home visit dates that are closer in 
time. 70% of the study population has a lag of six months or less. 
 
Estimate associations between styrene exposure and neurologic tests 
We use multivariate linear regression to estimate styrene-associated continuous 
differences in peripheral neurologic function. Higher values indicate better performance 
for all continuous outcomes. To achieve this internal consistency, we report the opposite 
of the raw values for vibrotactile threshold and postural sway speed. For visual contrast 
sensitivity, we restrict to participants with better than 20/50 visual acuity (assessed 
during the clinical examination) and adjust for vision correction, comparing styrene-
exposed to unexposed participants and evaluating differences in adjusted mean scores 
at each spatial frequency.  
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We use log binomial regression to estimate prevalence ratios and corresponding 
95% confidence intervals (PR, 95% CI) for single leg stance. Single leg stance is 
modeled as inability to maintain balance for 30 seconds to preserve a large enough 
referent group to maintain reasonable precision. 
We analyze each exposure type separately, using identical statistical methods. 
For associations with ambient styrene (N=2,956), exposure is modeled as quartiles, with 
the lowest quartile designated as the referent group. For analyses of measured blood 
styrene (n=310), exposure is dichotomized at the 90th percentile of the distribution, 
defining the top 10% of blood measurements as exposed.  
Adjustment factors are identical to those reported for symptoms analyses, though 
we additionally adjust for height when assessing vibrotactile threshold and handgrip 
strength. 
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CHAPTER IV: DETERMINANTS OF STYRENE EXPOSURE (SPECIFIC AIMS 1 & 2) 
 
A. Introduction 
To address community concerns about exposure to potentially harmful oil spill-
related chemicals among Gulf coast residents, we measured blood volatile organic 
compound (VOC) levels in a subset of Gulf Long-Term Follow-up Study (GuLF STUDY) 
participants 2-3 years after the Deepwater Horizon (DWH) oil spill. We previously 
reported that blood levels of specific oil-related VOCs such as benzene, toluene, 
ethylbenzene and xylenes were similar to those found in the National Health and 
Nutrition Examination Survey (NHANES) (Werder EJ, in press).  Among other VOCs 
included in the CDC-based test panel, only styrene was substantially elevated. We 
further investigated styrene levels due to increased exposure opportunity in the region.  
Styrene, an industrial hydrocarbon and hazardous air pollutant, is an established 
neurotoxicant at occupational levels [1, 5, 6], that has not been studied at environmental 
levels experienced by the general population. Styrene is used in plastics, fiberglass, 
rubber, and resins to manufacture consumer products and commercial and residential 
building materials. Manufactured styrene products include insulation, fiberglass boats, 
automotive parts, car tires, Styrofoam, and plastic drinking glasses [1]. The U.S. 
produces over 12 billion pounds of styrene annually, with atmospheric emissions of 28 
million pounds per year [1, 19]. Environmental release of styrene from the manufacture, 
use, and disposal of styrene-based products occurs primarily through the air [18]. 
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Emissions from industrial activities and motor vehicle exhaust are the primary 
sources of styrene in outdoor air. Ambient measurements of styrene typically show 
airborne concentrations less than 1 part per billion by volume (ppb). Rural or suburban 
air generally contains lower concentrations of styrene than urban air [22], which is 
attributed to increased motor vehicle emissions in urban areas [52]. Elevated ambient 
styrene concentrations are observed near styrene emitting industries, suggesting that 
individuals living near manufacturing or processing facilities may experience increased 
styrene exposure [1]. Ambient styrene, breaks down in the atmosphere within 1 to 2 
days [1] and the half-life of styrene in blood is approximately 13 hours [5].  
Indoor air styrene levels result primarily from tobacco smoke, off-gassing of 
building materials and consumer products, and emissions from photocopiers and laser 
printers [1]. Smoking is the single most important individual predictor of human 
exposure to styrene [1, 20, 51, 59, 60, 64, 84, 85]. Exposure to environmental tobacco 
smoke is also associated with higher styrene exposure, particularly for non-smokers 
living with a smoker [59, 85]. Typically, indoor air contains higher styrene levels than 
outdoor air [51].   
Inhalation of contaminated air is the principal route of styrene exposure for the 
general population [1], and the main source of concern for health effects due to styrene 
toxicity [24]. Although ingestion and dermal exposure to styrene can occur in 
occupational settings, inhalation accounts for over 90% of styrene exposure in the 
general population [6, 25]. The highest styrene exposures generally occur in the work-
place, where styrene-exposed workers have blood levels that are 25 times higher on 
average than those in the general population [5, 7, 36]. Occupational exposure to 
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airborne styrene has been well-characterized among workers in boat building and 
reinforced plastics manufacturing [10, 13, 14, 25, 48-50]. 
The Gulf States are home to many styrene-emitting industries and over half of all 
U.S. styrene production [1, 4]. In addition to a prolific petrochemical industry, the Gulf 
region is home to many industrial and manufacturing facilities that use and emit styrene 
in the production of plastics, rubber, and fiberglass. This geographic clustering of 
industries potentially exposes Gulf residents to a disproportionately high intensity of 
environmental styrene emissions.  
 
B. Methods 
Study Design and Participants 
Approximately 2-3 years after the April 2010 Deepwater Horizon (DWH) disaster 
and oil spill, we took advantage of the ongoing enrollment of participants in the GuLF 
STUDY to recruit individuals living in the Gulf region for a study of current blood levels 
of VOCs. Because styrene is rapidly cleared from the body and blood measurements 
were obtained 2-3 years after the oil spill, these levels represent exposures occurring 
around the time of sample collection (i.e., they are not due to oil spill cleanup work). A 
total of 994 individuals provided blood specimen sufficient for quantification of styrene 
levels as part of their participation in the Chemical Biomonitoring Study (CBS) to 
measure current blood VOC chemical levels.  
In concert with ongoing home visits for the GuLF STUDY we enrolled participants 
for the CBS between September 2012 and March 2013. The GuLF STUDY is a 
prospective cohort of adults (ages 21 and older) who participated in oil spill response 
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activities and others who received safety training, but were not hired following the DWH 
disaster. A detailed description of this study is available elsewhere [167].  Eligible 
participants were 11 193 English- or Spanish-speaking individuals who lived in Florida, 
Alabama, Mississippi, Louisiana, or eastern Texas and participated in a home visit 
examination. CBS participants were selected from among GuLF STUDY participants 
whose home exams were scheduled in the later months of study enrollment and 
participation involved providing an extra blood sample for measuring styrene and other 
compounds and completing a questionnaire about usual and past 24-hour exposure 
opportunities. Study personnel geocoded participants’ residential locations using 
handheld global positioning system devices. We initially oversampled nonsmokers and 
women, but because of timing of the parent study, we ultimately invited all remaining 
eligible participants to participate. Of the 994 individuals who provided blood samples of 
sufficient quantity and quality to measure styrene levels [168-170], 935 also had both a 
measurement for the tobacco smoking biomarker 2,5-dimethylfuran (2,5-DMF) and 
provided self-reported smoking information. These 935 participants were included in 
analyses comparing blood VOC levels between the CBS and the NHANES 2005-2008 
[171, 172].  
We restricted the remaining analyses to participants who had complete 
information on all modeled predictors (n=667). We excluded participants who did not 
complete the questionnaire on recent exposure opportunities (n=125) or were missing 
data on demographic factors (n=142).  
 Participants provided written consent, and the Institutional Review Board of the 
National Institute of Environmental Health Sciences approved this study.   
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Exposure Monitoring Questionnaire 
We collected demographic, socioeconomic, occupational, lifestyle, and health 
information during the GuLF STUDY enrollment and home visit interviews. CBS 
participants also answered questions about potential contributors to blood styrene 
levels, including residential building characteristics, self-reported proximity to industrial 
operations and waste sites (i.e., participants were asked to indicate whether they lived 
within a half mile of each of the following: major highways, a boatyard, docks, an oil 
refinery, a petroleum storage or transfer facility, a gas station, a factory, a power plant, a 
hazardous waste or Superfund site, and a landfill), personal chemical exposures, 
perceived air quality, drinking and bathing water source, smoking and tobacco use, and 
hobbies and activities, including exposure opportunities in the past 24 hours (e.g. 
refueling vehicles or lawn equipment), using an adapted version of the Centers for 
Disease Control and Prevention (CDC) NHANES 2007-2008 questionnaire [171] and 
US Environmental Protection Agency Detroit Exposure and Aerosol Research Study 
(DEARS) survey [173].  
 
National Emissions Inventory 
Point sources of styrene emissions were identified using the 2011 National 
Emissions Inventory Version 2 (NEI), the United States Environmental Protection 
Agency’s (EPA’s) latest comprehensive database of annual criteria, precursor, and 
hazardous air pollutant emissions [17]. State, local, and tribal air agencies report 
emissions sources, which are then augmented with information from the Toxics Release 
Inventory, the Acid Rain Program, and EPA’s regulatory air toxics data.  
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We abstracted all records of reported styrene emissions from the 2011 NEI point 
source database and mapped participants’ home geocodes onto the locations of the 
NEI point sources to calculate the distance between each participant’s residence and 
proximal point sources. We assigned exposure to point sources of styrene emissions 
based on number of sources, linear distance to point source locations, and volume of 
emissions at one-half, one, two, five, and ten mile buffers surrounding participants’ 
homes. 
 
National Air Toxics Assessment 
The EPA’s 2011 National-scale Air Toxics Assessment (NATA) evaluates 180 air 
toxics across the United States using emissions inventories, dispersion modeling, 
photochemical modeling, exposure modeling, and toxicity analyses [16, 174]. NATA 
uses dispersion modeling to generate annual average ambient air toxic concentrations 
for each U.S. census tract. The model predicts annual average census tract 
concentrations for each major source type (point, nonpoint, mobile), which are then 
summed to a total concentration value for all source types combined. Styrene 
concentrations in NATA 2011 arise from all three major source types. 
We employed NATA styrene estimates as indicators of typical, long-term 
environmental exposure by mapping each participant’s geocoded home location to a 
2010 U.S. census tract, and applying the annual average total and source-partitioned 
concentrations for that census tract to the participant.  
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Blood collection and blood VOC measurements 
Glass blood collection tubes containing potassium oxalate and sodium fluoride 
anticoagulant were used to collect 10 mL of blood for styrene measurement. Blood 
samples were collected using tubes and stoppers that had been pre-treated by the CDC 
laboratory to remove VOC residues to minimize pre-collection contamination [175, 176]. 
Samples were stored in a 4°C refrigerator prior to being shipped overnight on cold 
packs in biweekly batches to the Centers for Disease Control and Prevention in Atlanta, 
Georgia for analysis of VOCs. This laboratory conducts all NHANES VOC analyses. 
Analysis of styrene followed the standard CDC procedures for NHANES samples, using 
equilibrium headspace solid-phase micro-extraction with benchtop gas 
chromatography/mass spectrometry [168, 170], allowing direct comparisons between 
measurements in CBS and NHANES. 3 mL of blood was required per analysis. 
We measured 2,5-dimethylfuran (2,5-DMF), a VOC used as a smoking biomarker 
with comparable sensitivity and specificity to serum cotinine (a well-validated nicotine 
biomarker) [177]. Blood 2,5-DMF concentration of 0.014 ng/mL has been established as 
a threshold for distinguishing between current daily smokers (≥ 0.014 ng/mL) and 
nonsmokers (< 0.014 ng/mL) [177, 178], with the latter comprising infrequent smokers 
whose blood styrene levels have returned to that of nonsmokers. Unless otherwise 
specified, we use this definition to identify smokers and nonsmokers throughout all 
analyses. 
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Statistical Analysis 
We compared the distributions of blood styrene levels measured in CBS 
participants (n=935) to those observed in NHANES participants ages 21 and older who 
had blood styrene measured during the 2005-2006 and 2007-2008 NHANES cycles 
(N=3,958). All comparisons between NHANES and CBS were stratified by the 2,5-DMF 
threshold for smoking status (0.014 ng/mL). For comparisons to NHANES, we imputed 
blood styrene concentrations below the limit of detection (LOD) as the LOD divided by 
the square root of two [179], as is done in NHANES. For all other statistical analyses, 
we used all measured blood styrene values, including the actual values below the LOD 
[180].  
We also calculated the smoking-specific age- and sex-standardized prevalence 
ratio of CBS participants with blood styrene levels above the NHANES 95th percentile 
standardized to the CBS sample. We presented this standardization approach without 
applying NHANES sampling weights, but also conducted parallel analyses using 
NHANES sampling weights to verify that the weighting approach didn’t influence results. 
Styrene concentrations were approximately log-normally distributed, so we used natural 
logarithmically-transformed concentrations in continuous analyses. 
For regression analyses, we further restricted to participants who completed the 
exposure monitoring questionnaire (n=810) and had complete covariate information for 
demographic factors, potential predictors, and ambient exposure metrics (n=667). We 
selected predictors a priori based on previous literature [59, 181-186], with residential 
building characteristics, lifestyle and behaviors, recreational and occupational activities, 
and relevant recent exposures as candidate predictors. We additionally considered 
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ambient styrene predictors, including NATA total and source-partitioned (point, 
nonpoint, and mobile) concentrations as well as NEI point source emissions of styrene. 
Metrics of emissions included binary indicators (presence or absence of sources), 
number of sources, and distance- and volume-weighted intensity of sources 
surrounding participants’ homes. We used analysis of variance and t-tests to prioritize 
candidates based on the strength and statistical significance of their unadjusted 
relationship with blood styrene levels. 
We implemented a predictive modeling approach using least squares regression 
aimed at maximizing the model adjusted R2, and retained covariates with p-values < 
0.10. We chose this approach because many sources of styrene exposure were rare in 
this population. We maintained a statistical significance threshold of α=0.05, and report 
the change in log-styrene concentration (β coefficient) attributed to each predictor, and 
its associated 95% confidence interval and p-value.  
We also used multivariable regression to estimate prevalence ratios and 
corresponding 95% confidence intervals (PR, 95% CI) for a blood styrene measurement 
exceeding the smoking-specific NHANES 95th percentile. Due to model convergence 
problems for the log-binomial model, all analyses were completed using a modified log-
binomial approach with a Poisson distribution [187]. The same predictive modeling 
approach described for the analysis of continuous styrene was used to specify the 
modified Poisson model.  
Due to concerns about varying data reporting and quality of NATA estimates 
between states, we evaluated agreement between NATA modeled ambient styrene 
concentrations and observed styrene concentrations from EPA Ambient Monitoring 
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Archive (AMA) monitors in the study region. We compared annual average monitored 
concentrations to corresponding census tract NATA estimates for each state. Lacking 
sufficient sample size to conduct individual state regression analyses, we conducted 
sensitivity analyses excluding one state at a time to evaluate the influence of state 
reporting differences on the association between NATA exposure data and elevated 
blood styrene levels. 
To more efficiently examine ambient predictors of elevated blood styrene (i.e., 
NATA and NEI exposures), we identified a subgroup with no tobacco smoke-related 
styrene exposure by restricting to participants with blood 2,5-DMF < 0.014 ng/mL and 
removing an additional 97 individuals who reported any active or passive tobacco 
smoke exposure in the past 24 hours (n=300). We further restricted to participants living 
in states where NATA best reflected observed AMA concentrations (n=224), and 
removed individuals with spring and summer blood draws to account for seasonal 
differences in ambient styrene, resulting in a sample of 195 participants. We then used 
the same modified Poisson model to estimate associations between ambient exposures 
and blood styrene exceeding the NHANES 95th percentile in this subgroup. 
All statistical analyses were conducted in SAS 9.4 (Cary, NC, USA) and spatial 
analyses were completed in Esri ArcGIS Desktop 10.3 (Redlands, CA, USA). 
 
C. Results 
Blood styrene levels for these CBS participants (n=935) were two to three times 
higher than those reported in NHANES (n=3,958) (Table 3) for both smokers and 
nonsmokers, but considerably lower than levels typically observed among 
occupationally exposed populations. Among nonsmokers, detection rates were 
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considerably higher in CBS (61.9%) than NHANES (23.7%). Among smokers, rates 
were more comparable between study populations (CBS, 99.2%; NHANES, 96.1%). 
The distribution of blood styrene in CBS is right-skewed, regardless of smoking status. 
Nonsmokers in CBS were almost six times as likely to have elevated blood styrene 
(blood measurement above the NHANES 95th percentile), and smokers in CBS were 
more than four times as likely to have elevated blood styrene, as their NHANES 
counterparts (Figure 4). The apparent second peak in the blood styrene distributions 
above the NHANES 95th percentile for both smokers and non-smokers in CBS suggests 
that an elevated styrene measurement may indicate membership in a subgroup with a 
higher mean exposure distribution. 
Overall, two-thirds of CBS participants included in predictor models (n=667) are 
younger than 50, three-fourths are male, half are white, and three-fourths are 
overweight or obese (Table 4). Most participated in oil spill cleanup work (85.8%), and 
over half are unemployed. Approximately 40% of modeled CBS participants had blood 
2,5-dimethylfuran levels characteristic of smoking. Smokers tended to be younger, less 
educated, more likely to be nonwhite, and have lower body mass index. They were also 
more likely than nonsmokers to report lower income and unemployment. 
 We identified several predictors of blood styrene levels (Figure 5), though the 
overall model adjusted R2 was 0.19. Continuous log-transformed blood 2,5-
dimethylfuran level was a strong predictor of increasing blood styrene level (β, 0.42 log 
ng/mL; 95% CI: 0.34, 0.51), demonstrating the importance of smoking as a styrene 
exposure source (Table 5). Living in a home painted in the past six months (n=82; β, -
0.46 log ng/mL; 95% CI: -0.75, -0.17) was associated with lower styrene levels, while 
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concrete/cinderblock (n=169; β, 0.37; 95% CI: 0.11, 0.64) and wood (n=265; β, 0.35; 
95% CI: 0.13, 0.57), home exteriors predicted higher blood styrene levels. Other 
significant predictors of increasing styrene included boating in the Gulf in the past 24 
hours (n=10; β, 1.10; 95% CI: 0.31, 1.89), spending at least three hours in motor 
vehicles in the past 24 hours (n=122; β, 0.34; 95% CI: 0.09, 0.59), living in a mobile 
home, RV, or boat (n=99; β, 0.35; 95% CI: 0.07, 0.63), and reporting recreational fishing 
(n=330; β, 0.20; 95% CI: 0.0002, 0.39). Being employed (n=374; β= 0.19; 95% CI: -
0.01, 0.38) was a positive predictor of blood styrene, of borderline significance. Blood 
draws in fall or winter (n=597; β, -0.41; 95% CI: -0.73, -0.10) were associated with lower 
blood styrene levels, compared to spring and summer blood draws. Ambient nonpoint 
styrene concentrations were weakly and non-significantly predictive of increasing blood 
styrene levels, with the strongest association in the second quartile. State of residence 
was non-significantly associated with blood styrene levels, with Florida residents 
(n=165) having the highest blood styrene levels (β, 0.27; 95% CI: -0.07, 0.61). 
Predictors of elevated blood styrene in the overall sample were similar in magnitude and 
direction to the observed predictors of continuous blood styrene (Figure 6). 
 Predictors of elevated blood styrene (above the NHANES 95th percentile) among 
participants unexposed to tobacco smoke (active or passive), with fall or winter blood 
draw, and not living in Alabama included ambient nonpoint styrene concentration and 
Florida residence (Figure 7). This subgroup was identified to more efficiently assess 
ambient, as opposed to personal, predictors of styrene. We excluded Alabama based 
on results of a sensitivity analysis examining associations between NATA estimated 
concentrations and AMA observed concentrations by state (Appendix 2). Using the 
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limited data available, we determined that Alabama demonstrated appreciably less 
agreement with observed concentrations than the four remaining states. In this 
subgroup analysis, we observed a weak increasing exposure-response relationship 
across quartiles of ambient nonpoint styrene concentration, where participants in the 
highest exposure group were twice as likely to have elevated blood styrene as those in 
the lowest group (PR, 2.1; 95% CI: 1.0, 4.4). Florida residents were twice as likely to 
have elevated blood styrene as their counterparts from Mississippi (PR, 2.0; 95% CI: 
1.1, 3.7). Exposure to point source emissions of styrene was not associated with 
elevated blood styrene levels for any of the exposure metrics or spatial scales we 
examined. 
 
D. Discussion 
We conducted this study to characterize blood styrene levels among Gulf coast 
residents and identify determinants of styrene exposure. Blood styrene levels among 
CBS participants were substantially elevated compared to NHANES, particularly in the 
upper tail of the distribution. These levels, while higher than NHANES, are orders of 
magnitude lower than occupational exposure levels. Participants living in Florida had 
the highest blood styrene levels. Personal, as well as environmental factors, predicted 
blood styrene levels in the overall CBS sample. In a subgroup identified to facilitate 
examination of environmental factors, ambient styrene from nonpoint sources was 
associated with elevated blood styrene with a suggestive exposure-response 
relationship. However, proximity to industrial styrene emissions from point sources was 
not related to blood styrene. 
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Although several different environmental, behavioral, and social factors have 
been identified as determinants of styrene exposure, these factors typically explain less 
than 25% of the variance in measured styrene exposure [52, 59]. In our study, smoking, 
spending time in boats or vehicles in the past 24 hours, recreational fishing, being 
employed, and living in mobile housing were positively associated with blood styrene 
levels. Living in a home painted in the past six months and fall/winter blood draws were 
inversely associated with blood styrene levels. 
We observed a highly significant, precise, positive association between the 
biomarker for smoking (2,5-dimethylfuran) and blood styrene. Previous studies indicate 
that smokers have blood styrene levels approximately fourfold higher than those of 
nonsmokers [1, 51, 59-65]. Although cigarettes are considered the dominant source of 
styrene exposure among smokers, environmental tobacco smoke contributes only about 
8% of nonsmokers’ exposure [20].   
Spending at least three hours in a vehicle or any time in a boat in the Gulf of 
Mexico in the past 24 hours were both associated with increasing styrene levels. 
Likewise, recreational fishing was a predictor of styrene exposure. These predictors 
likely confer increased styrene exposure from combustion engine emissions, an 
established source of outdoor styrene exposure [20, 52, 75, 87]. 
The association between employment and increasing blood styrene suggests 
that sources outside the home could be driving higher exposures in non-smokers [75]. 
We conducted a preliminary analysis of reported occupation, industry, and main job 
activities to ascertain styrene-related occupational exposure opportunities. We 
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determined that such opportunities were too rare in our population (<0.1%) to account 
directly for the association between employment status and blood styrene.  
Participants who reported living in mobile housing had higher blood styrene 
levels. This association may reflect housing materials with more off-gassing than other 
types of residences, or lower air exchange rates resulting in higher indoor styrene levels 
[86]. Mobile housing is likely to be smaller than apartments, townhouses, and detached 
homes, with fewer rooms and windows. Previously, smaller house size and lower 
number of windows have been associated with increased styrene exposure [75].  
  Blood styrene levels are fairly consistent within season, though monitoring 
suggests significantly lower styrene levels in the spring compared to all other seasons 
[56]. We observed lower styrene levels in fall and winter compared to spring and 
summer, however the seasonal distribution of blood collection (90% in fall or winter) 
precluded seasonally-stratified analyses and further exploration into this relationship. 
Previous research suggests that individuals living near styrene manufacturing or 
processing facilities may experience increased exposure from point source emissions, 
totaling 47.3 million pounds annually in the U.S. [1]. Residential proximity to styrene 
emitting industrial facilities has been shown to confer up to 15 ppb of annual average 
styrene exposure [26] with elevated concentrations detected up to 10 kilometers away 
[55]. In our analyses, however, styrene levels varied independently of residential 
proximity to point source emissions, with no relationship to volume, intensity, distance, 
or type of emission source at a range of buffers from 0.5 miles to 10 miles. Similarly, 
NATA estimated concentrations attributable to point sources were not associated with 
blood styrene levels. Our measures of exposure to point source emissions may be 
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insufficient to capture episodic exposure scenarios, as both data sources rely on annual 
reporting. These measures fail to reflect seasonality or temporal variability that may 
influence prediction of a single blood draw. Because national-scale ambient styrene 
monitoring is limited, with poor spatial and temporal coverage, we were unable to 
evaluate monitored styrene concentrations in association with contemporaneous blood 
styrene levels. 
We evaluated total NATA concentrations, as well as source-partitioned values for 
each major source type. Total, point, and mobile concentrations were not associated 
with styrene levels in the full study population. However, when we looked in the 
subgroup identified to better examine environmental sources of elevated blood styrene, 
NATA nonpoint styrene concentration showed a positive exposure response 
relationship. This association only emerged among nonsmokers with no reported 
environmental tobacco smoke exposure, who had fall/winter blood draws, and did not 
live in Alabama. We selected this group to reduce other major sources of styrene 
variability and measurement error so that we could better assess the relationship 
between ambient and blood styrene. Improving the signal to noise ratio in this way did 
allow us to detect an association that was not apparent in the main analysis. 
Nonpoint sources are smaller sources or sources related to residential activity 
(residential wood combustion, consumer and commercial solvent usage, etc.), which 
are inventoried at the county level, and subsequently allocated to census tracts. These 
types of styrene exposure sources may demonstrate more temporal consistency within 
seasons than point source emissions, and therefore be more relevant predictors of spot 
blood styrene levels than sources which vary episodically. Reporting for nonpoint 
74 
 
sources may also be more reliable than other major source types, so that modeled 
concentrations are a more accurate representation of nonpoint exposures than other 
source types. 
The primary strength of our study is the examination of both indoor and outdoor 
predictors of internal burden of blood styrene in a population with elevated blood 
styrene levels. While other studies have typically prioritized either indoor or outdoor 
styrene sources, our study includes detailed indoor exposure information, as well as two 
different assessments of outdoor styrene levels and sources.   
We also used an established biomarker of internal styrene body burden, with a 
detailed, previously validated questionnaire capturing the relevant timing for the blood 
measurement [173]. This recall period, 24 hours, was sufficiently short to minimize the 
risk of recall bias and matched the styrene elimination half-life of approximately 13 
hours. We ascertained smoking using a validated biomarker, and supplemented with 
self-reported information on environmental tobacco smoke in sensitivity analyses. Blood 
styrene and 2,5-dimethylfuran levels in both CBS and NHANES were analyzed in the 
same laboratory, using the same methods, which permit quantification of general 
population exposure levels [168]. Geocoding participants’ residential locations allowed 
for a variety of flexible spatial analyses incorporating distance decay with point source 
emissions. Finally, our study was carried out in an understudied population that has 
been frequently exposed to multiple natural and man-made disasters, and lives in a 
region with enhanced industrial styrene exposure opportunity. 
Repeated biomarker measurements may provide a more reliable estimate of 
usual exposure than the single blood specimen obtained in our study, particularly 
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because of the rapid elimination of styrene from the body. Given the half-life of styrene 
in blood, blood levels reflect only exposures experienced within the past 12-24 hours.  
Occupational data were reported at enrollment and potentially not reflective of the 24-
hour exposure window preceding the blood draw. Despite this limitation, it is unlikely 
that occupational styrene exposure is influencing blood styrene levels in this study 
population because styrene-related occupations tend to be highly specific and were 
reported rarely among CBS participants. Candidate occupations we considered 
included: working in a fiberglass reinforced plastic or cultured marble factory, fiberglass 
boat building or repair, manufacturing styrene resin, polymer, rubber, or styrene-
butadiene rubber tires, manufacturing fiberglass wind turbines, and relining sewer lines 
with styrene-based resins pipe. 
Reporting to the NEI database is voluntary and designed for regulatory purposes. 
As such, the quality of the data and availability of information for our intended 
investigation may not be ideal. These data are limited to annual aggregate values, and 
lack any temporal specificity. Similarly, the NATA estimates are annual averages 
derived from voluntarily reported inputs, the protocols for which vary between states. 
Although imperfect, in the absence of sufficient monitoring data, these data sources 
provide the best available outdoor exposure information for a study of our scope and 
purpose. 
The modestly elevated blood styrene levels among CBS participants created a 
unique opportunity to assess a range of environmental styrene exposures. Although we 
were only able to account for approximately 20% of the variability in styrene exposure, 
we identified several personal predictors of blood styrene, which were largely consistent 
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with what has been published previously. Despite intense styrene-related industrial 
activity across the study region, we did not observe any relationship between proximity 
to point source styrene emissions and blood styrene. Rather, our results suggest that, at 
least among individuals without appreciable tobacco smoke exposure, exposure from 
nonpoint sources may be an important predictor of blood styrene levels. Future 
research in this area would benefit from repeated measures of blood styrene, as well as 
temporally specified environmental styrene sources, whether through monitoring or 
improved modeling. 
 
E. Conclusions 
The slightly elevated blood styrene levels among CBS participants created a 
unique opportunity to assess a range of environmental styrene exposures. Although we 
were only able to account for approximately 20% of the variability in styrene exposure, 
we identified several personal predictors of blood styrene, which were largely consistent 
with what has been published previously. Despite intense styrene-related industrial 
activity across the study region, we did not observe any relationship between proximity 
to point source styrene emissions and blood styrene in any analyses. Rather, exposure 
from nonpoint sources emerged as a potential predictor of blood styrene in a subgroup 
analysis. Future research in this area should incorporate repeated measures of blood 
styrene, as well as temporally specified environmental styrene sources, whether 
through monitoring or improved modeling. 
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F. Tables and Figures 
Table 3. Blood styrene levels in the CBS (n=935) and NHANES (2005-2008) (n=3,958). 
  Nonsmokers1 Smokers2 
  CBS NHANES CBS NHANES 
N 551 3,137 384 821 
Percent detect 61.9 23.7 99.2 96.1 
Mean 0.26 0.03 0.34 0.11 
Geometric mean 0.07 0.03 0.15 0.07 
25th percentile < LOD < LOD 0.07 0.06 
Median 0.04 < LOD 0.12 0.09 
75th percentile 0.08 < LOD 0.28 0.13 
95th percentile 1.67 0.06 1.62 0.23 
Maximum 4.81 4.10 4.58 0.78 
Blood styrene concentration measured in ng/mL. Limit of detection (LOD) = 0.03 ng/mL. 
Values below the LOD are imputed as LOD / √2 = 0.02 ng/mL. 
1 Nonsmokers defined as having blood 2,5-dimethylfuran > 0.014 ng/mL. 
2 Smokers defined as having blood 2,5-dimethylfuran concentration ≥ 0.014 ng/mL.  
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Figure 4. Prevalence ratio of blood styrene concentrations exceeding the smoking-
specific NHANES 95th percentile in the CBS compared to NHANES (n=935). 
 
Solid line indicates BTEX study; black shading indicates BTEX study 95th percentile. 
Dashed line indicates NHANES; grey shading indicates NHANES 95th percentile. 
NHANES 95th percentile: nonsmokers, 0.06 ng/mL; smokers, 0.23 ng/mL. 
PR, prevalence ratio (95% confidence interval). 
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Table 4. Characteristics of participants with blood styrene measurements in the CBS 
(n=667). 
 Overall 
(n=667) 
Smokers1 
(n=270) 
Nonsmokers1 
(n=397) 
 N % N % N % 
Age (years)       
< 30 123 18.4 59 21.9 64 16.1 
30 - 50 325 48.7 138 51.1 187 47.1 
> 50 219 32.8 73 27.0 146 36.8 
Body Mass Index 
(kg/m2)       
< 25 159 23.8 89 33.0 70 17.6 
25 - 30 200 30.0 75 27.8 125 31.5 
> 30 308 46.2 106 39.3 202 50.9 
Education       
< High school grad. 128 19.2 66 24.4 62 15.6 
High school grad. 249 37.3 109 40.4 140 35.3 
> High school grad. 290 43.5 95 35.2 195 49.1 
Race       
Black 277 41.5 133 49.3 144 36.3 
White 336 50.4 118 43.7 218 54.9 
Other 54 8.1 19 7.0 35 8.9 
Sex       
Female 164 24.6 57 21.1 107 27.0 
Male 503 75.4 213 78.9 290 73.0 
Timing of blood draw       
Fall/Winter 597 89.5 244 90.4 353 88.9 
Spring/summer 70 10.5 26 9.6 44 11.1 
Work status       
Employed 374 43.9 116 43.0 258 65.0 
Unemployed 293 56.1 154 57.0 139 35.0 
Oil spill clean-up work       
≥ 1 day 572 85.8 242 89.6 330 83.1 
None 95 14.2 28 10.4 67 16.9 
Annual income       
< $20,000 275 41.2 140 51.9 135 34.0 
$ 20,000 - $50,000 230 34.5 93 34.4 137 34.5 
> $50,000 162 24.3 37 13.7 125 31.5 
1 Smokers defined as having blood 2,5-dimethylfuran concentration ≥ 0.014 ng/mL; 
nonsmokers, blood 2,5-dimethylfuran > 0.014 ng/mL. 
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Figure 5. Predictors of blood styrene levels (n=667). 
 
Blood 2,5-DMF (log), log transformed blood 2,5-dimethylfuran concentration. 
NATA nonpoint, National Air Toxics Assessment 2011 annual average census tract 
ambient styrene concentration attributable to nonpoint sources. Q1, First quartile; Q2, 
Second quartile; Q3, Third quartile; Q4, Fourth quartile. 
State, participant’s state of residence. 
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Table 5. Predictors of blood styrene levels (n=667). 
Predictor N β (95% CI) p-value 
Blood 2,5-DMF (log)   0.42 (0.34, 0.51) <.0001 
Painted home in past 6 months 82 -0.46 (-0.75, -0.17) 0.002 
Home exterior       
Concrete/cinderblock 169 0.37 (0.11, 0.64) 0.006 
Wood 265 0.35 (0.13, 0.57) 0.002 
Other 233     
Boating in Gulf in past 24 hours 10 1.10 (0.31, 1.89) 0.006 
At least 3 hours in motor vehicles in 
past 24 hours 122 0.34 (0.09, 0.59) 0.008 
Season of blood draw       
Fall/winter 597 -0.41 (-0.73, -0.10) 0.01 
Spring/summer 70 Ref   
Home type       
Apartment/townhouse 170 0.08 (-0.15, 0.31) 0.49 
Mobile home/RV/boat/other 99 0.35 (0.07, 0.63) 0.02 
Detached home 398 Ref   
Recreational fishing 330 0.20 (0.0002, 0.39) 0.05 
Employed 374 0.19 (-0.01, 0.38) 0.06 
Ambient nonpoint styrene, quartiles       
1st quartile  160 Ref  
2nd quartile  157 0.24 (-0.04, 0.51) 0.09 
3rd quartile  164 0.09 (-0.21, 0.39) 0.55 
4th quartile  186 0.05 (-0.28, 0.37) 0.78 
State       
Florida 165 0.27 (-0.07, 0.61) 0.12 
Louisiana 175 -0.05 (-0.36, 0.26) 0.74 
Alabama 197 -0.07 (-0.35, 0.21) 0.64 
Mississippi 130 Ref    
2,5-DMF (log), log transformed blood 2,5-dimethylfuran concentration. 
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Figure 6. Predictors of blood styrene measurement above the NHANES 95th percentile 
(n=667). 
 
NHANES 95th percentile is smoking-specific: smokers, 0.23 ng/mL; nonsmokers, 0.06 
ng/mL. 
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Figure 7. Predictors of blood styrene measurement exceeding the NHANES 95th 
percentile among participants unexposed to tobacco smoke* with fall/winter blood 
draws, not living in Alabama (n=195). 
 
*Unexposed to tobacco smoker: jointly defined as having blood 2,5-dimethylfuran < 
0.014 ng/mL and reporting no active or passive smoke exposure in the 24 hours 
preceding blood collection. 
NATA nonpoint, National Air Toxics Assessment 2011 annual average census tract 
ambient styrene concentration attributable to nonpoint sources. 
Q1, First quartile; Q2, Second quartile; Q3; Third quartile; Q4, Fourth quartile. 
Point sources, National Emissions Inventory 2011 point source emitters of styrene 
within 1 mile of participant’s geocoded home location. 
Florida, Louisiana, Mississippi, participant’s state of residence. 
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CHAPTER V: STYRENE EXPOSURE AND NEUROLOGIC SYMPTOMS (SPECIFIC 
AIM 3) 
 
A. Introduction 
Styrene (CAS # 100-42-5, chemical formula C8H8) is an industrial hydrocarbon 
used in the production of plastics, fiberglass laminates, rubber, and resins found in 
consumer products and commercial and residential building materials. Manufactured 
styrene products include insulation, fiberglass boats, automotive parts, car tires, 
Styrofoam, and plastic drinking glasses [1]. Styrene is an established neurotoxicant at 
occupational levels [1, 5, 6], but has not been studied at environmental levels 
experienced by the general population. Epidemiologic studies to date have focused on 
highly exposed workers, whose average blood concentrations are 25 times higher than 
those of the general population [7-14]. 
Non-occupational exposure to styrene in the general population occurs primarily 
through inhalation of tobacco smoke, off-gassing of building materials, and vehicle and 
industrial emissions [2, 3]. Inhalation of airborne styrene accounts for over 90% of such 
exposures [6, 74], and is the main route of exposure resulting in health effects due to 
styrene toxicity [24]. Among smokers, cigarettes are considered the dominant source of 
styrene exposure, and smoking is the single most important individual predictor of 
human exposure to styrene [1, 20, 51, 59, 60, 64, 84, 85]. Styrene is released into the 
air from automobile exhaust, cigarette smoke, and photocopiers and printers, and 
industries using or manufacturing styrene. Styrene is commonly detected in urban air, 
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near industrial sites and landfills, and in high traffic areas, although typically at levels 
substantially lower than in occupational settings. Rural and suburban air generally 
contains lower concentrations of styrene than urban air [22]. 
  In humans, approximately 70% of inhaled styrene is absorbed [6]. Styrene is 
distributed throughout the body, with the highest concentration generally found in 
adipose tissue [1]. Because the half-life of styrene in blood is approximately 13 hours 
[5], blood styrene measurements reflect recent exposure. 
  Though styrene’s genotoxic properties have been well characterized and it is 
classified as possibly carcinogenic to humans by the International Agency for Research 
on Cancer (IARC) [6], the Agency for Toxic Substances and Disease Registry (ATSDR) 
has identified the central nervous system as the primary target for styrene toxicity, with 
less marked effects in the peripheral nervous system [2, 99]. Like many other volatile 
organic compounds, styrene monomer is a central nervous system depressant with 
anesthesia-like properties [6, 100]. Acute solvent-induced neurotoxicity, including that 
caused by styrene, is characterized by symptoms of acute intoxication, commonly 
described as a feeling of drunkenness. Long term exposures at levels found in 
occupational settings have been associated with chronic adverse neurotoxic effects. 
Occupational studies demonstrate styrene-induced neurotoxicity, from both acute 
and chronic inhaled exposure among highly-exposed workers. Symptoms include 
feeling “drunk” and tiredness [41], impaired vision [99, 102], vestibular dysfunction [12], 
headaches [103], delayed reaction time [104, 105], impaired attention and memory [9], 
hearing deficits [106], diminished nerve conduction velocity [9, 107-110], and abnormal 
EEG results [110, 111]. Similar effects have been observed at lower occupational 
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exposure levels, ranging from 10-30 ppm, in most [10, 99, 103-105, 114, 117-119], 
though not all [13, 120], studies.  
The human health effects of chronic styrene exposure at typical environmental 
levels among the general population remain largely unknown [20]. We set out to assess 
the associations between two metrics of styrene exposure - estimated ambient 
concentrations and measured blood levels - and self-reported neurologic symptoms. 
Quantifying the association between environmental styrene exposure and highly 
sensitive, but non-specific, neurologic symptoms may lend insight into early 
manifestations of environmentally induced neurotoxicity due to chronic exposures at 
levels insufficient to cause clinically apparent toxicity. 
 
B. Methods 
Study Design and Participants 
 We used data from the Gulf Long-term Follow-up Study (GuLF STUDY), a 
prospective cohort of adults (ages 21 and older) who participated in oil spill response 
activities and others who received safety training, but were not hired, following the 
Deepwater Horizon disaster. A detailed description of this study is available elsewhere 
[167]. Of the 25,848 English- or Spanish-speaking GuLF STUDY participants living in 
the Gulf region (Alabama, Florida, Louisiana, Mississippi, and Texas) at enrollment, 
24,903 reported addresses that were successfully geocoded to a 2010 U.S. Census 
tract. From this sample of participants with known residential locations, we excluded 
participants with any missing neurologic symptom information (n=304), missing 
demographic characteristics (n=573), and missing covariate information (n=201), 
leaving 23,825 eligible participants. Because autonomic and peripheral neuropathy are 
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known complications of diabetes [188], we further restricted the study sample to 
participants with no self-reported physician diagnosis of diabetes (exclude 1,825 
diabetics and 38 with missing diagnosis information), resulting in a final analytic sample 
of 21,962. 
Approximately 2-3 years after the oil spill (May 2012-July 2013), a subset of 
GuLF STUDY participants (N=1,055) living in the Gulf region were enrolled in the 
Chemical Biomonitoring Study (CBS) (Werder EJ, in press). CBS participants provided 
an extra blood sample for measuring styrene and other compounds and completed a 
questionnaire about usual and recent exposures.  
 Ultimately, 994 participants provided blood samples sufficient for quantification of 
styrene levels. Of those, we excluded 20 participants missing neurologic symptom 
information, nine with incomplete demographic characteristics, and four individuals 
missing other covariate information, leaving 961 eligible participants. We then excluded 
known diabetics (n=86 of the 1,825 diabetics from the parent study) or those missing 
diagnosis information (n=1), for a final analytic sample of 874. 
Participants provided written consent, and the Institutional Review Board of the 
National Institute of Environmental Health Sciences approved this study.   
 
National Air Toxics Assessment 
The United States Environmental Protection Agency (EPA) 2011 National-scale 
Air Toxics Assessment (NATA) [189] evaluates 180 air toxics across the United States 
using emissions inventories, dispersion modeling, photochemical modeling, exposure 
modeling, and toxicity analyses. NATA generates annual average ambient air toxic 
concentrations (µg/m3) for each U.S. census tract. We employed NATA styrene 
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estimates as indicators of typical, long-term environmental exposure by mapping each 
participant’s geocoded home location to a corresponding 2010 U.S. census tract. 
Geocodes were based on self-reported home address at enrollment. The 2011 NATA 
annual average ambient styrene concentration corresponding to an individual’s home 
census tract was applied as the estimate of ambient styrene exposure for each cohort 
member residing in the Gulf region. 
 
Blood styrene measurement 
Blood collection tubes containing potassium oxalate and sodium fluoride 
anticoagulant were used to collect 10 mL of blood for styrene measurement. Tubes and 
stoppers were pre-treated by the Centers for Disease Control and Prevention (CDC) 
laboratory to remove VOCs residues to minimize pre-collection contamination [175, 
176]. Samples were stored in a 4°C refrigerator prior to being shipped overnight on cold 
packs in biweekly batches to the Division of Laboratory Sciences, National Center for 
Environmental Health, CDC in Atlanta, Georgia, for analysis of VOCs. Analysis of 
styrene followed standard CDC procedures, using equilibrium headspace solid-phase 
micro-extraction with benchtop gas chromatography/mass spectrometry [168, 170].  
 
Neurologic symptoms 
Health information, including questions about neurologic symptoms, was 
collected at enrollment via Computer Assisted Telephone Interview (CATI) during the 
baseline interview. All participants were asked to report how often they experienced 
dizziness, lightheadedness, vision impairment, numbness, tingling, stumbling while 
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walking, headaches, and fatigue during the preceding 30 days. Three additional 
episodic outcomes, i.e., seizures, vomiting, and insomnia, were added to the 
questionnaire after data collection was underway. These latter outcomes were not 
combined with other symptoms for evaluation of “any” neurologic symptom or symptom 
clusters because their enumeration in the study population is incomplete (i.e., those 
people who completed the enrollment interview prior to the inclusion of questions about 
seizures, vomiting, and insomnia did not have the opportunity to report them). We did, 
however, analyze these additional symptoms individually among the subgroup of 
participants who had the opportunity to report them. 
Frequency of most symptoms was reported as: all of the time, most of the time, 
sometimes, rarely, or never. Symptoms were classified as a binary indicator of the 
‘presence’ (all or most of the time) or ‘absence’ (sometimes, rarely, or never) of 
occurrence. Seizures, vomiting and insomnia were reported as: every day, several 
times a week, once a week, rarely, or never. We applied a lower threshold for the 
reporting of episodic symptoms because the relative frequency of their occurrence is 
expected to be lower, as compared with potentially ongoing symptoms. Accordingly, the 
presence of vomiting included responses of once a week or more, and the presence of 
seizures included reporting a seizure at any point during the 30 days (rarely, once a 
week, several times a week, every day). 
 
Statistical analysis 
 We used multivariate log-binomial regression to estimate prevalence ratios and 
corresponding 95% confidence intervals (PR, 95% CI) for the cross-sectional 
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associations between modeled and measured styrene exposure and neurologic 
symptom prevalence. We evaluated associations between (i) ambient styrene exposure 
(µg/m3) and neurologic symptoms among all eligible study participants residing in the 
Gulf region (N=21,962), and (ii) blood styrene concentration (ng/mL) and neurologic 
symptoms among CBS participants (n=874). We also examined the distributions of 
NATA ambient concentrations and log-transformed blood styrene levels to determine 
relevant rank-based exposure metrics. 
We analyzed symptom clusters as primary outcomes. Based on results of a 
latent class analysis of symptom correlations among all reported symptoms (data not 
shown), we identified two neurologic clusters (i.e., CNS and PNS). The CNS cluster 
included dizziness, headache, nausea, sweating, and palpitations. The PNS cluster 
included tingling and numbness in the extremities, blurred vision, and stumbling while 
walking. For the main analyses, we separately examined associations between styrene 
exposure and the presence of any neurologic symptom, any CNS symptom, more than 
one CNS symptom, any PNS symptom, and more than one PNS symptom. We included 
sweating and palpitations in our identification of CNS symptoms, based on results of the 
latent class analysis. We did not, however analyze these symptoms as individual 
neurologic outcomes in any other analyses because of their non-specific nature and 
lack of precedent in neurotoxicity literature. We further completed sensitivity analyses 
excluding sweating and palpitations from the CNS symptom cluster. In secondary 
analyses, we examined associations between styrene exposure and each individual 
neurological symptom in a separate model.  
91 
 
All models were adjusted for sex (male, female), age (<30, 30-45, >45), season 
(spring, summer, fall, winter), race (white, black, other), employment status (currently 
working, not working), alcohol drinking (current, former/never), and self-reported 
smoking (current, former/never). Models assessing associations with blood styrene 
were additionally adjusted for the duration of time (days) between enrollment (symptom 
ascertainment) and the date of blood styrene collection. The median lag between 
enrollment and blood styrene collection was 100 days. For statistical analyses, we used 
all measured blood styrene values, including the actual values below the LOD [180]. 
Covariates were selected based on directed acyclic graph analysis [190] of the 
theoretical relationship between styrene exposure and neurologic symptoms. Covariate 
information was obtained during the enrollment interview. 
 We conducted several sensitivity analyses, examining the impact of depression, 
co-exposures, socioeconomic status, and amount of overall symptom reporting (i.e., 
number of symptoms reported) on observed associations. Depression was defined 
based on self-reported physician diagnosis at enrollment, and we conducted stratified 
analyses comparing associations between participants who did and did not report 
depression. For co-exposure analyses, we additionally adjusted for benzene and 
toluene, in separate models. Ambient benzene and toluene estimates were abstracted 
from NATA 2011, and blood benzene and toluene levels were measured on the same 
panel as styrene. In ambient analyses, we additionally adjusted for ambient particulate 
matter (PM 2.5). Annual census tract estimates of PM 2.5 were obtained from the EPA 
fused Downscaler Model 2011 output [191]. To address socioeconomic status, we 
adjusted for income, education, and self-reported concerns over affording housing and 
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food. Participants were asked about frequency of 18 symptoms in addition to those 
included here as indicative of potential neurological effects. We tried several 
approaches to account for symptom over-reporting, including making exclusions for 
different thresholds of number of symptoms reported, adjusting for total number of 
symptoms reported, excluding participants who reported excessive recent hair loss, 
which is not believed to be related to any of the exposures under investigation, and 
restricting analyses to participants reporting only neurologic symptoms. We also 
completed analyses specifying different exposure contrasts for both ambient and blood 
styrene exposure, as well as evaluating the impact of adjusting for diabetes instead of 
excluding participants reporting a diabetes diagnosis. We also repeated all main 
analyses for clusters and individual symptoms restricting to the subgroup of participants 
who had the opportunity to report on the three symptoms (seizures, vomiting, and 
insomnia) that were added later. 
All statistical analyses were conducted in SAS 9.4 (Cary, NC, USA). 
 
C. Results 
This cohort is predominantly male (80.6%), younger than 45 (58.8%), and 
overweight (40.4%) or obese (31.5%) (Table 6). Approximately one-third of participants 
are current smokers, and 75.6% completed at least one day of oil spill response or 
cleanup work. Participants who provided blood specimens for CBS were less likely to be 
employed (52.9% vs. 62.7%) and more likely to have worked on oil spill response 
(84.9% vs. 75.6%), compared to the full cohort of Gulf State residents. The CBS also 
has a higher proportion of nonwhite participants than the overall sample (49.8% 
compared to 37.6%), and fewer college graduates (12.0% compared to 18.5%). Among 
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the population eligible for the ambient styrene analyses, as well as the CBS, the 
distribution of demographic characteristics is similar between participants who were 
excluded due to incomplete covariate information and participants who were included in 
the respective modeled samples. 
Based on the distribution of ambient styrene concentrations among Gulf region 
participants (Figure 8), we modeled neurologic symptoms in relation to quartiles of 
ambient exposure. The distribution features a prominent right skew, with the top quartile 
ranging from 0.03 to 1.70 µg/m3 styrene. The referent exposure group (first quartile) 
experienced ambient styrene levels up to 0.01 µg/m3 styrene. When comparing airborne 
styrene concentrations in the Gulf region to the entire U.S., the exposure distributions 
are very similar with some slight variability in the top 5% of census tracts (data not 
shown). The distribution of blood styrene concentration has a less pronounced right 
skew (Figure 1) and the sample size is relatively small.  We elected to dichotomize 
blood concentrations at the median value, 0.067 ng/mL styrene.  
Increasing ambient styrene concentration was modestly associated with the 
presence of any neurologic symptom, though the association was only significant for the 
fourth quartile of exposure (PR, 1.07; 95% CI: 1.02, 1.12) (Figure 9). For any CNS 
symptom, multiple CNS symptoms, any PNS symptom, and multiple PNS symptoms, 
the top quartile of exposure was positively and significantly associated with reporting 
neurologic symptoms. The strongest association we observed among the cluster 
analyses was a 20% increase in prevalence of multiple CNS symptoms among those in 
the top quartile of ambient styrene concentration (PR, 1.20; 95% CI: 1.09, 1.32). We 
observed significant linear trends (p-value < 0.05) between styrene exposure quartiles 
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and each of the symptom clusters, though trends were most apparent for any CNS 
symptom, multiple CNS symptoms, and multiple PNS symptoms (Table 7). 
In analyses of blood styrene above the median concentration and neurologic 
symptom clusters, we observed small to modest, nonsignificant positive associations for 
multiple CNS, any PNS, and multiple PNS symptoms (Figure 10, Table 8). The 
strongest association was a 40% increase in prevalence of multiple PNS symptoms, 
which was of borderline significance (PR, 1.40; 95% CI: 1.00, 1.97). 
The prevalence of individual neurologic symptoms ranged from 1.8% for seizures 
to 16.1% for fatigue, with 30.8% of participants reporting at least one of the original 
neurologic symptoms (Table 7). Among those participants who were also asked about 
the additional symptoms added later (n=16,536), the prevalence of any original 
neurologic symptom (excluding vomiting, seizure, and insomnia) was 33.0% (and 38.0% 
including vomiting, seizure, and insomnia). The highest quartile of ambient exposure 
was positively and significantly associated with each individual neurologic symptom. 
Many of the associations with individual symptoms demonstrated an increasing 
exposure-response relationship across quartiles of exposure, and linear trends were 
significant (p < 0.05) for all symptoms except fatigue and nausea (Figure 11).  
Among CBS participants, seizure was the least common symptom (2.8%) and 
fatigue was the most prevalent (24.7%). Although associations between blood styrene 
and symptom clusters were generally modest, we did observe noteworthy, albeit 
nonsignificant, positive associations for the individual symptoms of dizziness (PR, 1.36; 
95% CI: 0.91, 2.04) and nausea (PR, 1.53; 95% CI: 0.93, 2.53), and a significant 
association for stumbling (PR, 2.14; 95% CI: 1.03, 4.44) (Table 8). 
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Our findings were robust to exclusions and adjustments made in sensitivity 
analyses. Neither excluding participants who reported a total number of symptoms 
exceeding a range of thresholds (e.g. the 95th percentile, or 12 symptoms), nor 
adjusting for total number of symptoms reported, had an appreciable impact on 
observed associations between ambient styrene and neurologic outcomes. Restricting 
the duration of time between enrollment and blood draw to below the median (100 days) 
attenuated some associations between blood styrene and CNS symptoms slightly, but 
did not meaningfully change associations. Results were generally similar in analyses 
using other exposure contrasts for both airborne and blood styrene exposures (e.g. 
tertiles, quintiles, 90th percentile, etc.), although risk estimates became more unstable 
as exposure groups became smaller. Excluding sweating and palpitations from the CNS 
symptom cluster did not meaningfully change results, though most associations were 
slightly stronger using this reduced CNS symptom cluster. 
Correlation coefficients between ambient concentrations of styrene and each of 
benzene, toluene, and PM 2.5 were 0.69, 0.76, and 0.43, respectively. Associations 
between styrene and neurologic symptom clusters were stronger in models adjusted for 
ambient benzene or toluene (Figure 12). Adjusting for PM 2.5 had little effect, yielding 
estimates that were virtually identical to our primary results. For multiple CNS or PNS 
symptoms, adjustment for co-exposures left associations essentially unchanged (data 
not shown). 
To evaluate the effect of depression on symptom reporting, we estimated 
associations separately for participants who reported a diagnosis of depression 
(n=3,069, 14%) and those who did not (n=18,805, 86%). Associations among 
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participants without depression, representing the majority of the sample, were similar to 
overall results (Figure 13). 
When we repeated analyses for clusters, as well as individual symptoms, among 
the subgroup of participants who completed the interview after questions about 
seizures, insomnia, and vomiting were added, results were virtually identical to originally 
reported associations. Indeed, because the order in which participants were enrolled in 
the study was largely random, we have no reason to suspect that individuals who 
responded before the additional symptoms were included would be meaningfully 
different from those who responded after their inclusion. 
 
D. Discussion 
To our knowledge, this study was the first to assess subclinical neurotoxicity of 
styrene exposure at environmental levels relevant to the general population. We 
observed consistent, positive relationships between increasing ambient styrene 
exposure and neurologic symptoms. Associations were consistently statistically 
significant among the highest exposure groups and a monotonic exposure-response 
was evident for many outcomes. Although associations between blood styrene and 
neurologic symptom clusters were generally not apparent, we did observe suggestive 
effects for the peripheral nervous system cluster and some individual symptoms 
(dizziness, nausea, and stumbling).  
Among the analyses of ambient exposure and symptom clusters, we observed 
slightly stronger associations with an unambiguous dose response and significant linear 
trends for the central nervous system cluster. These findings are supported by ASTDR’s 
97 
 
report identifying the central nervous system as the primary target of styrene toxicity [1], 
as well as increased mortality from diseases of the central nervous system, especially 
epilepsy, associated with styrene exposure in a cohort study of reinforced-plastics 
industry workers [121].  
When examining individual neurologic symptoms, we observed the strongest 
associations for ambient styrene with reported seizures, blurred vision, stumbling, 
dizziness, and insomnia. Symptoms with the strongest evidence for styrene-induced 
neurotoxicity at occupational levels include blurred or distorted vision [102, 149, 192-
195], dizziness or lightheadedness [13, 103, 117], headaches [41, 103, 119], and 
fatigue [41, 103, 117, 119]. Less consistent associations have been reported for 
vestibular impairment [119], tingling and numbness [11, 103, 105], seizures [105, 196], 
and insomnia [197]. Despite much lower ambient exposure levels in our study than 
those present in occupational settings, our results are generally consistent with these 
findings.  
Blood styrene levels among CBS participants were two to three times higher than 
those measured in the National Health and Nutrition Examination Survey, for smokers 
and nonsmokers alike. We observed suggestive associations of blood styrene 
concentration in relation to dizziness, nausea, stumbling, and having multiple peripheral 
nervous system symptoms. These effect estimates were larger in magnitude, but some 
lacked precision due to the sample size and frequency of symptom reporting.  
Having two or more peripheral nervous system symptoms was associated with 
both ambient and blood concentrations of styrene. Dizziness, nausea, and stumbling 
also demonstrated some consistency between elevated ambient and biomarker 
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exposures. Differences in associations between exposure types may be attributable to 
the relevant temporal window each exposure type captures. Measured blood styrene 
generally reflects the previous 24 hours, whereas NATA estimates are annual averages 
thought to reflect longer term exposure. Blood samples were drawn, on average 100 
days after symptom information was collected. Thus, exposure misclassification is 
especially likely to have limited our ability to detect significant associations.  
Our study is the first to investigate whether neurologic effects observed among 
highly exposed occupational populations are also observed among individuals with 
styrene exposure more typical of the general population. Recent environmental studies 
evaluating effects of simultaneous exposure to multiple hazardous air pollutants (HAPs) 
have documented associations between environmental styrene and other neurologic 
outcomes. When evaluating modeled ambient exposure estimates for a variety of HAPs, 
styrene was associated with increased risk of autism spectrum disorder [122, 123] and 
amyotrophic lateral sclerosis [124]. These results implicate low-level, chronic styrene 
exposure as a possible public health problem. However, a cross-sectional analysis of 
blood VOCs and neurobehavioral testing found a general lack of significant adverse 
effects, with the exception that a mixture of BTEX and styrene was modestly associated 
with slower reaction time [125].  
Studies in humans and experimental in vitro and in vivo animal models have 
attempted to determine the mode of action for styrene neurotoxicity, with a 
dopaminergic mechanism gaining traction [71], but explanations remain speculative. 
Several studies suggest that styrene exposure alters dopamine metabolism, marked by 
decreased dopamine levels and increased dopamine receptors in rodents and humans 
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[126-128]. The styrene metabolites phenylglyoxylic acid and mandelic acid were shown 
to deplete dopamine in neurologic tissues [129]. This mechanism is corroborated in 
blood samples of styrene-exposed plastics workers for whom prolactin levels are 
elevated, as prolactin release is chronically inhibited by dopamine [198]. Consistent with 
disturbance of the dopaminergic functions of the brain, styrene exposure potentiates a 
dose-dependent decrease in brain dopamine in male rats [128]. Styrene also caused 
cell loss and dopamine depletion in retinas isolated from female rats [132], which 
supports the established association between occupational styrene exposure and 
impaired vision [133]. 
Our study has several strengths, including a large sample size, a well-
characterized, diverse, understudied population, multiple sensitive measures of 
neurotoxicity, complementary metrics of exposure, and findings that were robust to 
multiple sensitivity analyses.  
Neurologic symptoms can reveal subtle impairments in neurologic function 
before the occurrence of clinically apparent disease. While less severe, these 
symptoms may be more sensitive to lower exposure levels, longer lasting, more 
prevalent in the general population, and possibly persist after exposure recedes. Self-
reported symptoms, despite being a subjective endpoint, can provide highly sensitive 
measures of neurologic and toxicant-associated neurotoxicity [199]. Thus, symptom 
assessment is an appropriate measure to capture the potentially subtle, widespread 
neurotoxic effects of the observed environmental exposure levels.  
We assessed two metrics of styrene exposure, one reflecting long-term 
environmental exposure and one reflecting short-term internal burden. Modeling 
100 
 
exposure this way helps address the trade-offs between possible confounding bias for 
blood styrene, and potential measurement error of NATA ambient styrene estimates 
[200]. Associations were not entirely consistent between blood and ambient styrene 
measures, which may be due to limitations of both biomarkers and proxy exposure 
measures, or the temporal windows they reflect. NATA estimates have been 
successfully used as measures of human air pollution exposure in epidemiologic studies 
of cancer [201-203], asthma [204], birth defects [205], autism spectrum disorder [122, 
123, 206], and neurodegenerative diseases [124]. We used NATA styrene estimates as 
indicators of typical, long-term environmental exposure, and blood styrene 
measurements to capture internal burden resulting from recent exposures. Blood 
styrene is a validated biomarker specific to styrene exposure [74] and it has been used 
extensively in occupational research [6], as well as in general population monitoring [1].  
Limitations of our study include the use of an annual average ambient 
concentration, single blood draw for styrene measurement, and lack of detailed 
occupational exposure information. Due to the cross-sectional study design, we cannot 
confirm temporality between styrene exposure and the onset of neurologic symptoms. It 
is, however, unlikely that the symptoms assessed would lead to the observed ambient 
or blood styrene concentrations we observed. More relevant to the cross-sectional 
design limitation is our inability to distinguish between transient effects due to acute 
exposures and persistent neurologic effects of long-term styrene exposure. 
Routine monitoring of ambient styrene in the U.S. does not provide sufficient 
temporal or spatial coverage to support exposure interpolation methods [143, 145, 155].  
NATA remains the only spatially-referenced exposure data source with sufficient 
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geographic coverage for the Gulf state region. Although the assumptions inherent to an 
annual average estimate of air pollution potentially limit interpretation for acute exposure 
scenarios, NATA data are a valid estimation of usual exposure levels. If styrene-
associated neurologic effects are the result of long-term exposure, this type of exposure 
metric may be better suited to capturing the associations of interest. Long-term ambient 
styrene trends indicate that year-to-year regional variation in concentration is not 
substantial, suggesting that lifetime average estimates are appropriate assessments of 
exposure [20]. Stable blood styrene levels in independent U.S. population samples, 
measured cross-sectionally, over a 20-year period corroborate these findings [60, 66, 
74].  
Although we obtained only a single blood measurement from each individual, the 
sample size is large for such a biomarker-based study. At occupational exposure levels, 
biomarkers consistently predict exposure classification according to job title and 
occupational styrene-related activities [7, 10, 38-47]. In general, these biomarkers 
correlate well with indoor air styrene levels, but the relationship does not necessarily 
persist for outdoor air styrene concentrations. Indeed, we observed limited concordance 
between measured blood styrene and NATA estimated concentrations (Werder EJ, 
submitted). In occupational studies, the correlation between styrene in blood and indoor 
air ranges from 0.62 to 0.94 [14, 46, 72]. In a study of low occupational styrene levels 
measured in air, blood, and urine, the best correlations with ambient levels were 
observed for blood styrene [45].  
Lacking detailed information on styrene-specific occupational exposure 
opportunities, we assessed reported industry, occupation, and activity information for 
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participant’s recent and longest-held jobs. We searched for any potentially styrene-
related work experience, with the intention of adjusting for work or excluding these 
individuals from analyses. Ultimately, occupational styrene exposure opportunities were 
so rare in our study population (0.1%), that we concluded that occupational exposures 
were not appreciably influencing results.  
Our results provide strong evidence for an association between ambient styrene 
exposure and neurologic symptoms, suggesting that styrene may be neurotoxic at 
exposure levels relevant to the general population. These findings were consistent and 
robust across a wide range of sensitivity analyses. The relationship between blood 
styrene exposure and neurologic symptoms was equivocal, but suggestive of an 
association for certain endpoints. Due to the cross-sectional nature of our study, the 
temporality of exposure and outcome is uncertain. While short-term acute intoxication is 
reversible, ceasing when styrene is cleared from the body, more concerning for overall 
health are the potential chronic, subtle but demonstrative, and irreversible effects that 
persist after styrene is cleared from the body [101]. If, however, environmental styrene 
exposure is geographically pervasive and temporally persistent, then transient effects 
will emulate chronic effects. Timing of environmental styrene exposure and duration of 
neurotoxic effects may be an important area of future public health research.  
 
E. Conclusions 
Our results provide compelling evidence for an association between ambient 
styrene exposure and neurologic symptoms, suggesting that styrene’s neurotoxic 
properties may persist at exposure levels relevant to the general population. These 
findings were consistent and robust to exhaustive sensitivity analyses. The relationship 
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between blood styrene exposure and neurologic symptoms was equivocal, but 
suggestive of an association for certain endpoints. Due to the cross-sectional nature of 
our study, we can’t evaluate the relevant timing of exposure and outcome. While short-
term acute intoxication is reversible, ceasing when styrene is cleared from the body, 
more concerning for overall health are the potential chronic, subtle but demonstrative, 
and irreversible effects that persist after styrene is cleared from the body [101]. Timing 
of environmental styrene exposure and duration of neurotoxic effects may be an 
important area of future public health research. 
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F. Tables and Figures  
Table 6. Demographic characteristics of participants living in the Gulf States (N=21,962) 
and those participating in the Chemical Biomonitoring Study (CBS, N=874). 
    Gulf States (n=21,962) CBS (n=874) 
Characteristic   N % N % 
Sex Female 4,259 19.4 220 25.2 
 Male 17,703 80.6 654 74.8 
Age, years < 30 4,685 21.3 194 22.2 
 30 - 45 8,241 37.5 343 39.2 
 < 45 9,036 41.1 337 38.6 
Season of 
enrollment 
Spring 6,104 27.8 174 19.9 
Summer 5,329 24.3 198 22.7 
Fall 4,968 22.6 185 21.2 
Winter 5,561 25.3 317 36.3 
Race White 13,723 62.5 439 50.2 
 Black 6,051 27.6 368 42.1 
 Other 2,188 10.0 67 7.7 
Work status Employed 13,780 62.7 462 52.9 
 Unemployed 8,182 37.3 412 47.1 
Current drinker Yes 16,441 74.9 598 68.4 
 No 5,521 25.1 276 31.6 
Current smoker Yes 7,514 34.2 261 29.9 
  No 14,448 65.8 613 70.1 
Oil spill response 
work1 
≥ 1 day 16,599 75.6 742 84.9 
None 5,363 24.4 132 15.1 
Education < High school 4,072 18.5 179 20.5 
 High school graduate 7,285 33.2 340 38.9 
 Some college 6,554 29.8 250 28.6 
 ≥ College graduate 4,051 18.5 105 12.0 
Body Mass Index, 
kg/m2 
  
≤ Normal (< 25) 6,173 28.1 249 28.5 
Overweight (25 - < 30) 8,877 40.4 333 38.1 
Obese (≥ 30) 6,912 31.5 292 33.4 
1Participants reported working on Deepwater Horizon oil spill cleanup for at least one day in 
2010-2011. 
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Figure 8. Probability density of styrene exposure in air (N=21,962) and blood (N=874). 
 
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 2011 
modeled estimates of annual average concentrations (µg/m3) at the census tract level. 
Blood styrene exposure concentrations (ng/mL) are measured from a single blood draw 
obtained in the participant’s home. 
Values at the top of reference lines indicate exposure concentrations; labels at the 
bottom of reference lines indicate locations in the exposure distribution: P25, 25th 
percentile; P50, 50th percentile; P75, 75th percentile; P90, 90th percentile; P95, 95th 
percentile; Max, maximum value. 
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Figure 9. Association between ambient styrene concentration and neurologic symptom clusters (N=21,962). 
 
Ambient styrene exposure quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of 
annual average concentrations at the census tract level; referent exposure group is the lowest quartile (not 
shown on figure). 
Q2, second quartile of exposure; Q3, third quartile; Q4 fourth (highest) quartile. 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking status at enrollment, 
and smoking status at enrollment.  
Central Nervous System (CNS) symptoms include: dizziness, headache, nausea, sweating, and palpitations. 
Peripheral Nervous System (PNS) symptoms include: tingling/numbness, blurred vision, and stumbling. 
Asterisks (*) indicate p-value for linear trend < 0.05. 
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Figure 10. Association between blood styrene concentration and neurologic symptom clusters (N=874). 
  
Blood styrene exposure concentrations are measured from a single blood draw obtained in the participant’s 
home, and exposure is classified as a measurement above or below the median value (0.067 ng/mL). 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking status at enrollment, 
smoking status at enrollment, and duration (days) between enrollment and blood draw. 
Central Nervous System (CNS) symptoms include: dizziness, headache, nausea, sweating, and palpitations. 
Peripheral Nervous System (PNS) symptoms include: tingling/numbness, blurred vision, and stumbling.
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Table 7. Association between ambient styrene concentration and individual neurologic 
symptoms (N=21,962). 
Outcome Prevalence, N (%) Exposure PR (95% CI) p-trend 
Any neurologic symptom 6,759 (30.8) 
Q2 1.04 (0.99,1.10) 
0.03 Q3 1.02 (0.97,1.07) 
Q4 1.07 (1.02,1.12) 
Any CNS symptom1 4,960 (22.6) 
Q2 1.02 (0.96,1.09) 
0.0001 Q3 1.06 (1.00,1.13) 
Q4 1.12 (1.05,1.19) 
≥ 2 CNS symptoms 2,037 (9.3) 
Q2 1.06 (0.95,1.18) 
0.0001 Q3 1.12 (1.02,1.24) 
Q4 1.20 (1.09,1.32) 
Dizziness 1,468 (6.7) 
Q2 0.98 (0.86,1.12) 
0.00001 Q3 1.09 (0.97,1.24) 
Q4 1.26 (1.12,1.40) 
Nausea 1,046 (4.8) 
Q2 1.01 (0.87,1.17) 
0.10 Q3 0.91 (0.79,1.06) 
Q4 1.16 (1.02,1.32) 
Headache 3,121 (14.2) 
Q2 1.06 (0.97,1.15) 
0.001 Q3 1.10 (1.02,1.19) 
Q4 1.13 (1.05,1.22) 
Any PNS symptom2 4,014 (18.3) 
Q2 1.05 (0.97,1.13) 
0.01 Q3 1.01 (0.94,1.09) 
Q4 1.11 (1.04,1.19) 
≥ 2 PNS symptoms 2,429 (11.1) 
Q2 1.04 (0.95,1.15) 
0.01 Q3 1.07 (0.98,1.18) 
Q4 1.12 (1.02,1.23) 
Tingling/Numbness 3,146 (14.3) 
Q2 1.05 (0.96,1.14) 
0.01 Q3 1.04 (0.96,1.14) 
Q4 1.12 (1.03,1.21) 
Stumble 739 (3.4) 
Q2 1.12 (0.93,1.34) 
0.008 Q3 1.11 (0.93,1.32) 
Q4 1.27 (1.07,1.50) 
Blurred vision 1,656 (7.5) 
Q2 1.10 (0.97,1.25) 
<.0001 Q3 1.12 (1.00,1.27) 
Q4 1.36 (1.21,1.52) 
Fatigue 3,529 (16.1) 
Q2 1.08 (0.99,1.16) 
0.08 Q3 1.02 (0.94,1.10) 
Q4 1.10 (1.02,1.18) 
Insomnia3 1,552 (13.8) 
Q2 1.18 (1.04,1.34) 
0.002 Q3 1.18 (1.04,1.34) 
Q4 1.23 (1.08,1.39) 
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Outcome Prevalence, N (%) Exposure PR (95% CI) p-trend 
Vomit3 1,363 (9.3) 
Q2 1.13 (0.99,1.30) 
0.01 Q3 1.15 (1.01,1.31) 
Q4 1.17 (1.03,1.33) 
Seizure3 263 (1.8) 
Q2 1.12 (0.80,1.55) 
0.005 Q3 1.17 (0.85,1.60) 
Q4 1.51 (1.12,2.02) 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking 
status at enrollment, and smoking status at enrollment. 
Prevalence indicates total prevalence in the study sample (all exposure levels).  
Ambient styrene exposure quartiles are based on National Air Toxics Assessment 
(NATA) 2011 estimates of annual average concentrations at the census tract level; 
referent exposure group is the lowest quartile (not shown in table). Q2, second quartile 
of exposure; Q3, third quartile; Q4 fourth (highest) quartile. 
1Central Nervous System (CNS) symptoms: dizziness, headache, nausea, sweating, 
palpitations. 
2Peripheral Nervous System (PNS) symptoms: tingling/numbness, blurred vision, and 
stumbling. 
3Sample sizes vary for insomnia (n=11,236), vomiting (n=14,591), and seizure 
(n=14,591) because they were added to the interview after data collection was 
underway, and they are therefore ineligible for inclusion in symptom groupings (Any 
neurologic/CNS/PNS). 
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Figure 11. Association between ambient styrene concentration and individual neurologic symptoms (N=21,962). 
 
Ambient styrene exposure quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of annual 
average concentrations at the census tract level; referent exposure group is the lowest quartile (not shown on figure). 
Q2, second quartile of exposure; Q3, third quartile; Q4 fourth (highest) quartile. 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking status at enrollment, and smoking 
status at enrollment.  
Central Nervous System (CNS) symptoms include: dizziness, headache, nausea, sweating, and palpitations. 
Peripheral Nervous System (PNS) symptoms include: tingling/numbness, blurred vision, and stumbling. 
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Table 8. Association between blood styrene concentration and individual neurologic 
symptoms (N=874). 
Outcome Prevalence, N (%) PR (95% CI) 
Any neurologic symptom 434 (49.7) 1.04 (0.89,1.21) 
Any CNS symptom1 274 (31.4) 0.97 (0.80,1.17) 
≥ 2 CNS symptoms 128 (14.7) 1.11 (0.80,1.54) 
Dizziness 90 (10.3) 1.36 (0.91,2.04) 
Nausea 80 (9.2) 1.53 (0.93,2.53) 
Headache 186 (21.3) 1.01 (0.78,1.31) 
Any PNS symptom2 240 (27.5) 1.14 (0.90,1.43) 
≥ 2 PNS symptoms 152 (17.4) 1.40 (1.00,1.97) 
Tingling/numbness 190 (21.7) 1.07 (0.81,1.40) 
Stumbling 45 (5.2) 2.14 (1.03,4.44) 
Blurred vision 105 (12.0) 0.99 (0.68,1.42) 
Fatigue 216 (24.7) 0.94 (0.73,1.20) 
Insomnia3 130 (16.7) 1.11 (0.79,1.54) 
Vomiting3 112 (13.1) 1.03 (0.73,1.45) 
Seizure3,4 24 (2.8) ― 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking 
status at enrollment, smoking status at enrollment, and duration (days) between 
enrollment and blood draw. 
Blood styrene exposure is classified as above the median concentration (0.067 ng/mL) 
compared to all measurements below the median concentration. 
1Central Nervous System (CNS) symptoms include: dizziness, headache, nausea, 
sweating, and palpitations. 
2Peripheral Nervous System (PNS) symptoms include: tingling/numbness, blurred 
vision, and stumbling. 
Prevalence indicates total prevalence in the study sample (both exposed and 
unexposed).  
3Sample sizes vary for insomnia (n=780), vomiting (n=857), and seizure (n=857) 
because they were added to the interview after data collection was underway, and they 
are therefore ineligible for inclusion in symptom groupings (Any neurologic/CNS/PNS).  
4No effect estimate presented for seizure due to lack of model convergence. 
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Figure 12. Association between ambient styrene concentration and neurologic symptom clusters adjusted for co-
exposures (N=21,962). 
 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking status at enrollment, smoking 
status at enrollment, and total ambient coexposure concentration (separate models for each coexposure). 
Ambient styrene exposure quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of annual 
average concentrations at the census tract level; referent exposure group is the lowest quartile (not shown on figure). 
Central Nervous System (CNS) symptoms include: dizziness, headache, nausea, sweating, palpitations. 
Peripheral Nervous System (PNS) symptoms include: tingling/numbness, blurred vision, stumbling. 
Benzene and Toluene coexposures are NATA 2011 annual average census tract estimates of the total concentration. 
Particulate matter with a diameter less than 2.5 micrometers (PM 2.5) coexposures are annual averages of US EPA 
Fused Downscaler Model daily census tract estimates.  
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Figure 13. Association between ambient styrene concentration and neurologic symptom clusters stratified by self-reported 
physician diagnosis of depression at enrollment (N=21,8741). 
 
Models adjusted for sex, age, season, race, employment status at enrollment, drinking status at enrollment, and smoking 
status at enrollment. 
Central Nervous System (CNS) symptoms include: dizziness, headache, nausea, sweating, palpitations. 
Peripheral Nervous System (PNS) symptoms include: tingling/numbness, blurred vision, stumbling. 
Ambient styrene exposure quartiles are based on National Air Toxics Assessment (NATA) 2011 estimates of annual 
average concentrations at the census tract level; referent exposure group is the lowest quartile (not shown on figure). 
Depression was ascertained via self-report: participants reported whether they had ever received a diagnosis of 
depression from a doctor. 
1Excludes 88 participants missing information on self-reported depression diagnosis at enrollment. 
 114 
 
CHAPTER VI: STYRENE EXPOSURE AND PERIPHERAL NEUROLOGIC FUNCTION 
(SPECIFIC AIM 3) 
 
A. Introduction 
Styrene is a hydrocarbon used in plastics, fiberglass, rubber, and resins. It is 
used to manufacture products such as insulation, fiberglass boats, automotive parts, car 
tires, Styrofoam, and plastic drinking glasses [1]. After the disposal of styrene-based 
products, styrene is released primarily into air, though smaller amounts are detected in 
soil and water [18]. Ambient styrene, a volatile organic compound, breaks down in the 
atmosphere within 1 to 2 days [1]. 
The general population is exposed to styrene primarily through inhalation of 
tobacco smoke, off-gassing of building materials, and vehicle and industrial emissions 
[2, 3]. The principal route of styrene exposure is through inhalation of contaminated air 
[1]. Typically, indoor air contains higher styrene levels than outdoor air [51] due to 
emissions from building materials, consumer products, and tobacco smoke [24].  
Emissions from industrial activities and motor vehicle exhaust are the primary 
sources of styrene in outdoor air. The Gulf States are home to over half of all U.S. 
styrene production [1, 4], as well as many industrial and manufacturing facilities that use 
and emit styrene in the production of plastics, rubber, and fiberglass. This geographic 
clustering of industries potentially exposes Gulf residents to disproportionately high 
environmental styrene emissions from petrochemical, manufacturing, and coastal 
fishing and boating operations [21]. 
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The half-life of styrene in blood is approximately 13 hours [5], so blood styrene 
levels reflect recent exposure. Approximately 40% of the U.S. adult population has 
measurable levels of styrene in their blood [24, 62].  
Styrene is an established neurotoxicant at occupational exposure levels. Acute 
exposure causes depression of the central nervous system (CNS) with anesthesia-like 
properties at high exposure levels [1, 5, 6, 100]. Epidemiologic studies to date have 
focused on highly exposed workers, whose average blood levels were 25 times higher 
than those of the general population [7-14]. Occupational studies demonstrate styrene-
induced neurotoxicity, evident as central (CNS) and peripheral nervous system (PNS) 
effects, from both acute and chronic inhaled exposure among highly-exposed workers. 
Acute effects include feeling “drunk” and tiredness [41], whereas impaired vision [99, 
102], vestibular dysfunction [12], headaches [103], delayed reaction time [104, 105], 
impaired attention and memory [9], diminished hearing [106] and nerve conduction 
velocity [9, 107-110], and abnormal electroencephalogram results [110, 111] are likely 
persistent, chronic effects. These effects have been observed at lower occupational 
exposure levels in many [10, 99, 103-105, 114, 117-119], but not all [13, 120], studies.  
Low-level, chronic styrene exposure may impact neurologic function at 
environmental levels relevant to the general population [20]. We investigated 
associations between environmental styrene exposure, assessed as both blood and air 
concentrations, and peripheral neurologic function.  
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B. Methods 
Study Design and Participants 
The Gulf Long-term Follow-up Study (GuLF STUDY) is a prospective cohort of 
adults (ages 21 and older) who participated in oil spill response activities and others 
who received safety training, but were not hired, following the Deepwater Horizon 
disaster [167]. Participants enrolled in the GuLF STUDY between March 2011 and 
March 2013.  
A convenience sample of GuLF STUDY participants (N=1,055) living in the Gulf 
region enrolled in a Chemical Biomonitoring Study (CBS) between May 2012-July 2013. 
Participation in CBS involved providing an extra blood sample for measuring styrene 
and other compounds and completing a questionnaire about usual and recent 
exposures. Because styrene is rapidly cleared from the body and blood measurements 
were obtained two to three years after the oil spill, these levels represent usual, ongoing 
exposures (i.e., they are not due to oil spill cleanup work).  
Another subset of GuLF STUDY participants (N=3,403) residing within 
approximately 60 miles of study clinics in New Orleans, Louisiana and Mobile, Alabama 
were recruited for a follow-up clinical examination between August 2014 and July 2016. 
Participation involved completing a clinical examination in one of two clinical settings 
(one in New Orleans, LA and one in Mobile, AL). Examinations included anthropometric 
measurements, biological sample collection, standardized computer-assisted 
neurocognitive testing, peripheral neurologic function evaluations, pulmonary function 
testing, and interviews on mental health and other factors.  
 117 
 
Of the 3,403 participants who completed the follow-up clinical exam, 3,329 
reported addresses at enrollment that were successfully geocoded to a 2010 U.S. 
Census tract. From this sample of participants with known residential locations, we 
excluded anyone with missing outcome information for all five neurologic function tests 
(n=8), missing demographic information (n=37), or missing covariate information (n=22). 
Of the remaining 3,262 participants with complete exposure, outcome, and covariate 
information, we restricted analyses to participants with no self-reported physician 
diagnosis of diabetes (i.e., we excluded 302 diabetics and 3 participants missing 
diagnosis information)  because peripheral neuropathy is a known complication of 
diabetes [188]. This resulted in a final analytic sample of 2,956. 
 A total of 348 CBS participants with blood samples sufficient for quantification of 
styrene concentration also participated in the follow-up clinical examination. Of those, 
we excluded five participants missing all peripheral neurologic function information. The 
remaining 343 participants had complete exposure, outcome, demographic, and 
covariate information. We then excluded known diabetics (n=33), for a final analytic 
sample of 310. 
Participants provided written consent and the Institutional Review Board of the National 
Institute of Environmental Health Sciences approved this study. 
 
National Air Toxics Assessment 
The United States Environmental Protection Agency (EPA) 2011 National-scale 
Air Toxics Assessment (NATA) [189] estimates annual average ambient air toxic 
concentrations for each U.S. census tract. NATA evaluates 180 air toxics across the 
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United States using emissions inventories, dispersion, photochemical, and exposure 
modeling, and toxicity analyses. We used NATA styrene estimates to indicate typical, 
long-term environmental exposure by geocoding self-reported home addresses at 
enrollment, mapping each participant’s location, and matching them to a corresponding 
2010 U.S. census tract. The 2011 NATA annual average ambient styrene concentration 
corresponding to an individual’s home census tract was applied as the estimate of usual 
ambient styrene exposure. 
 
Blood styrene measurement 
We collected 10 mL of blood for styrene measurement using tubes containing 
potassium oxalate and sodium fluoride anticoagulant; tubes and stoppers were pre-
treated by the Centers for Disease Control and Prevention (CDC) laboratory to remove 
VOCs to minimize pre-collection contamination [175, 176]. Samples were stored at 4°C 
until being shipped overnight on cold packs in biweekly batches to the Division of 
Laboratory Sciences, National Center for Environmental Health, CDC in Atlanta, 
Georgia for analysis of VOCs. Styrene was analyzed using equilibrium headspace solid-
phase micro-extraction with benchtop gas chromatography/mass spectrometry following 
standard CDC procedures [168, 170].  
 
Peripheral neurologic function testing 
The neurologic function testing battery, which was used in an earlier study of 
chronic, low-level neurotoxicants [148], included tests of visual acuity, visual contrast 
sensitivity, handgrip strength, vibrotactile threshold, standing steadiness, and single leg 
stance. These tests evaluate neurologic functions corresponding to neurotoxic effects 
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that have been demonstrated in association with occupational solvent exposure [149, 
150].   
Visual Acuity, an indicator of visual sharpness or clarity, was assessed using a 
standard vision testing instrument, the Optec 1000 (Optec, Inc. U.S.A). Results from this 
test were used to determine eligibility for analyses of visual contrast sensitivity.  
Visual contrast sensitivity was evaluated with the Optec 1000 Functional 
Assessment of Contrast Sensitivity test. Circular stimuli consisting of alternating light 
and dark bars were presented. Nine stimuli of decreasing contrast were presented at 
each of 5 spatial frequencies (1.5, 3, 6, 12, and 18 cycles per degree). The weakest 
contrast correctly identified was recorded for each spatial frequency. Participants with 
visual acuity scores of 20/50 or worse were excluded from visual contrast sensitivity 
analyses. 
Standing steadiness was evaluated with the Advanced Mechanical Technology, 
Inc. (AMTI, Inc., USA) force platform. Participants were instructed to stand on the 
platform without moving. Standing steadiness was measured twice with participant eyes 
open and twice with participant eyes closed. The force platform and associated software 
capture and store the forces applied to the platform by the participant’s feet during each 
trial. The force signals are processed and plotted as a time series of locations (path) of 
the participant’s center of pressure. The mean sway speeds in millimeters/second 
obtained during the two eyes open and the two eyes closed trials were used for 
statistical analysis of standing steadiness. 
Single leg stance was evaluated by asking the participant to stand on one leg 
and maintain upright balance for 30 seconds [207]. If the participant was unable to 
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maintain their upright balance for the entire 30 second test interval, then the procedure 
was repeated up to two additional times. Inability to maintain single leg balance was 
defined as a need for steadying by the examiner to prevent falling or participant inability 
to comply with instructions to stand on only one leg for the entire 30 second test interval 
(i.e., the participant placed the other foot on the ground to prevent falling). Examiners 
indicated whether, and on which attempt, the participant was able to maintain his/her 
balance for the entire 30 second test interval. We modeled the outcome for single leg 
stance as inability to maintain upright balance for 30 seconds. 
Vibrotactile sensory acuity was evaluated using a portable Vibratron II 
electromechanical vibrometer at a frequency of 120 Hz (Physitemp, Inc., USA). 
Examiners manually controlled the delivered vibration amplitude, obtaining five vibration 
threshold values (three descending and two ascending values) for each great toe. After 
discarding the first value, the final vibrotactile threshold for each toe was the median 
obtained from the remaining four values, which was converted to log microns of peak to 
peak amplitude displacement for statistical analysis. 
Handgrip strength was assessed with a baseline digital hydraulic hand 
dynamometer that records the maximum force exerted by the participant’s whole-hand 
grip. Participants performed three grip strength measures for each hand. We used the 
bilateral mean of all six tests, measured in pounds, as the summary metric in statistical 
analyses.  
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Statistical analysis 
We used multivariate linear regression to estimate continuous differences in 
peripheral neurologic function per unit change in the exposure metrics. For ease of 
interpretation, higher values indicate better performance for all continuous outcomes 
(mean contrast sensitivity score, vibrotactile threshold, handgrip strength, and postural 
sway speed). To achieve this internal consistency, we multiplied the raw values for 
vibrotactile threshold and postural sway speed by negative one. For tests of contrast 
sensitivity, we compared styrene-exposed to unexposed participants and evaluated 
differences in adjusted mean scores (adjustment covariates reported below) between 
exposure groups at each spatial frequency. We used log binomial regression to 
estimate prevalence ratios and corresponding 95% confidence intervals (PR, 95% CI) 
for single leg stance, the only dichotomous outcome. PRs above one indicate poorer 
test performance (i.e., inability to maintain balance for the full 30 seconds) and PRs 
below one indicate better test performance.  
We analyzed each exposure type (i.e., NATA-estimated ambient styrene 
concentration and measured blood styrene concentration) separately using identical 
statistical methods for both. For associations with ambient styrene (N=2,956), exposure 
was categorized in quartiles, with the lowest quartile designated as the referent group. 
For analyses of measured blood styrene (n=310), exposure was dichotomized at the 
90th percentile of the distribution, defining the top 10% of blood measurements as 
exposed and the remaining 90% as ‘unexposed’. For all tests except visual contrast 
sensitivity, we additionally modeled blood styrene as the top quartile (exposed) 
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compared to the three lower quartiles (‘unexposed’). We used all measured blood 
styrene values, including the actual values below the limit of detection [180].   
All models were adjusted for gender (female vs male), age (continuous years), 
race (white, black, other), education (less than high school/equivalent, high 
school/general equivalency diploma, some college/two-year degree, four-year college 
graduate or more), employment status (working vs not working), alcohol consumption 
(current vs former/never), and smoking status (current vs former/never). Covariate 
information was obtained during the enrollment interview, and adjustment covariates 
were selected based on directed acyclic graph analysis [190] of the theoretical 
relationship between styrene exposure and peripheral neurologic function. For analyses 
of vibrotactile threshold and handgrip strength, we additionally adjusted for height. For 
visual contrast sensitivity, we restricted analyses to participants with better than 20/50 
visual acuity and additionally adjusted for use of vision correction (i.e., wearing glasses 
or corrective lenses).  
We examined a range of ambient and blood exposure contrasts in sensitivity 
analyses. Such additional ambient exposure assessments included dividing the top 
quartile of exposure at different values to assess variability at the upper end of the 
distribution, removing the third quartile and creating a referent group of values below the 
median to draw a sharper contrast between exposed and unexposed participants, and 
other combinations designed to maximize exposure contrasts. For blood styrene 
analyses, we used a similar approach, although the smaller sample size and statistical 
power limited analyses to dichotomous comparisons. Specifically, we evaluated the top 
10%, top 15%, and highest quartile compared to participants below the median. We 
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also evaluated examiner and site effects by adjusting for examiner, and separately 
adjusting for and stratifying by clinic. Owing to concerns about overwhelming population 
variance in the handgrip strength tests, we also examined the influence of weight and 
gender on these associations.  
Because eligibility criteria required that participants completed at least one 
peripheral neurologic function test from the full battery (but not all such tests), analytic 
sample sizes vary between tests.  
All statistical analyses were conducted in SAS 9.4 (Cary, NC, USA). 
 
C. Results 
Participants in the ambient analysis and CBS were largely similar with respect to 
demographic characteristics (Table 9). Approximately 70% of participants completed 
their examinations at the Alabama testing site, less than half attended college, three-
fourths were male, and about half were younger than age 45 years. Half of all 
participants were white and about 40% were black. Among CBS participants, 85% 
completed all five peripheral neurologic function tests, compared to 81% of those in 
ambient analyses. Participants who were excluded due to incomplete covariate 
information are similar to participants included in the analytic sample with respect to the 
demographic characteristics reported in Table 9. We provide descriptive statistics on 
neurologic function in this population, presented as mean outcomes by exposure status 
and demographic group, in Tables 10 and 11, respectively.  
 For ambient exposure analyses, we modeled associations for each quartile of 
styrene exposure compared to the lowest quartile (≤ 0.01 µg/m3). Styrene 
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concentrations in the highest quartile ranged from 0.03 to 0.27 µg/m3, with most 
measurements below 0.05 µg/m3 (Figure 14). For analyses of blood styrene, we 
prioritized a binary exposure divided at the 90th percentile, 0.83 ng/mL. The maximum 
observed concentration was 3.03 ng/mL, with most participants having blood levels 
below 1.36 ng/mL. CBS participants have measured blood styrene levels 2-3 times 
higher than those measured in the National Health and Nutrition Examination Survey 
[172], but an order of magnitude below typical occupational blood styrene levels. The 
blood exposure distribution demonstrated a pronounced right skew.  
 For tests of contrast sensitivity, we compared the highest quartile of ambient 
styrene to the lower two quartiles (n=1,692). Low exposure group participants 
performed better than those with high exposure at each spatial frequency, with 
significant (p < 0.05) differences at 1.5, 3, and 12 cycles/degree (Figure 15). Results 
were virtually unchanged when we included the third quartile of ambient styrene in the 
referent group. We observed similar results for blood styrene above or below the 90th 
percentile (n=231), though the smaller sample size reduced precision and the only 
statistically significant difference was observed at 12 cycles/degree. Results were 
similar in sensitivity analyses unadjusted for vision correction, as well as those 
excluding participants with vision correction. These curves demonstrate a subtle, but 
consistent, decrement in visual contrast sensitivity associated with styrene exposure 
across spatial frequencies.  
Increasing ambient styrene concentration was associated with reduced 
vibrotactile sensitivity (n=2,888) (Figure 16). We observed an exposure-response 
relationship (p=0.003), with a significant effect in the highest exposure group (β=-0.13 
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log microns; 95% CI: -0.23, -0.03) (Table 12). For blood styrene (n=307), we observed a 
non-significant, but suggestive, association between the highest quartile of exposure 
and reduced vibrotactile sensitivity (Figure 16, Table 12). When comparing, the top 10% 
to the lower 90% of blood styrene concentrations, this association was stronger (β=-
0.39 log microns; 95% CI: -0.72, -0.05). For comparison, we found that aging ten years 
yielded a change in vibrotactile threshold of -0.49 log microns, compared to -0.39 log 
microns associated with a blood styrene measurement above the 90th percentile and -
0.13 log microns for the highest quartile of ambient styrene. 
Ambient styrene exposure (n=2,855) was associated with decreased standing 
steadiness, with statistically significantly worse stability at each quartile of exposure 
(Figure 17). The linear trend across quartiles of exposure was significant when 
participants’ eyes were closed (p=0.02), as well as open (p < 0.0001). The highest 
quartile of exposure was associated with a difference in sway speed of 4.5 mm/s for 
both tests (eyes closed and open). For comparison, a ten-year difference in age was 
associated with differences in sway speed of 7.4 and 4.2 mm/s for eyes closed and 
open, respectively. Put alternatively, exposure-related effects were equivalent to 0.13 
and 0.24 standard deviations of mean sway speed for eyes closed and open, 
respectively.  In contrast, we did not observe effects in blood styrene exposure analyses 
(n=299). 
Styrene exposure was also positively associated with impairments in single leg 
stance (Figure 18). Participants in the highest quartile of ambient styrene exposure 
were 40% more likely to experience balance loss during the test compared to those in 
the lowest quartile (PR, 1.42; 95% CI: 1.17, 1.71) and those with blood measurements 
 126 
 
above the 90th percentile were twice as likely to lose their balance compared to all 
others (PR, 2.07; 95% CI: 1.18, 3.61). A sensitivity analysis comparing participants 
unable to maintain balance to those who maintained balance on the first attempt yielded 
similar, albeit slightly attenuated, results as the main analysis. 
Unexpectedly, handgrip strength improved with increasing ambient styrene 
exposure (n=2,930), demonstrating a significant linear trend (p < 0.0001). Higher 
exposure groups (i.e., the third and fourth quartile) were associated with increases of 
approximately six pounds of force (Figure 19). We did not observe associations 
between blood styrene exposure and handgrip strength (n=310). 
Assessing other exposure contrasts revealed very slight changes in associations, 
with some subtle attenuation and loss in precision for ambient styrene exposure 
analyses. Overall, results were robust to a variety of exposure definitions and 
associations observed in the main analyses persisted. Exposure-related differences in 
neurologic function were less apparent and relatively imprecise for analyses of blood 
styrene and modeling exposure using different blood styrene cutpoints did not influence 
these results meaningfully. 
Adjustment for clinical examiner did not meaningfully change results, nor did 
adjustment for clinical site. We did not stratify analyses by clinic because the 
imbalanced geographic distribution of participation resulted in imprecise effect estimates 
among participants attending the Louisiana clinic. Handgrip strength results were robust 
to adjustment for weight and BMI, as well as the exclusion of female participants. We 
observed no changes in associations for handgrip strength in sensitivity analyses. 
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D. Discussion 
Our study of styrene-induced neurotoxicity investigated environmental exposure 
levels in association with five measures of peripheral neurologic function. We observed 
styrene-associated impairment in visual, sensory, and postural function, though we did 
not detect evidence of voluntary motor system effects. Differences in neurologic 
performance were generally more consistent in relation to ambient styrene exposure, 
but we also observed associations with measured blood styrene concentration. 
When comparing mean visual contrast sensitivity scores between exposure 
groups across spatial frequencies, we observed modest effects, some of which 
achieved statistical significance. Overall, however, a consistent pattern emerged, 
revealing decrements in visual contrast sensitivity associated with higher ambient and 
blood styrene concentration. Some investigations of occupational styrene exposure 
among fiberglass plastic workers have also reported diminished contrast sensitivity 
[149, 208], although others found no exposure-related effects [209, 210]. Occupational 
exposure to organic solvents, generally, has been shown to affect visual contrast 
sensitivity [211], but the occupational styrene literature has emphasized loss of color 
vision specifically [102, 192, 193, 208, 212]. 
Cutaneous vibrotactile threshold testing assesses the integrity of the entire 
somatosensory pathway, including the peripheral sensory nerves. Cutaneous vibratory 
stimuli are carried on large, heavily myelinated, sensory nerve fibers, which are believed 
to be more susceptible to both systemic and focal insult than small myelinated and 
unmyelinated fibers. Furthermore, longer nerve fibers such as those innervating the toe 
are more susceptible than shorter fibers innervating other anatomical sites. Many 
occupational and environmental hazards, including some organic solvents, are known to 
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affect these fibers. We observed impairments in vibrotactile threshold associated with 
blood styrene concentration, as well as a significant monotonic exposure-response 
trend across increasing quartiles of ambient styrene exposure. For both exposure types, 
significant effects were observed among participants in the highest exposure groups 
(i.e., top 10% in blood styrene, top quartile in ambient styrene). For comparison, the 
observed decrement in vibrotactile threshold associated with a ten-year age difference 
was greater than styrene-associated decrements, although the magnitude was 
comparable between a decade of aging and the highest blood styrene exposure. 
Although this specific endpoint has not been widely evaluated in the styrene literature, 
one study of workers exposed to both styrene and toluene found exposure-related 
adverse changes in somatosensory evoked potentials [109] and another study of 
painters documented similar effects [213]. Cutaneous vibrotactile threshold is an 
established, sensitive, and well validated test, which has been used to assess 
peripheral neurologic function in a variety of settings [214]. As such, our results are 
compelling evidence of styrene-associated decreases in somatosensory function. 
Handgrip strength provides information about the functional integrity of the 
voluntary motor system from the motor cortex to peripheral skeletal muscles. Sub 
chronic styrene exposure induced impaired motor function in rats [129, 131], but we are 
not aware of such effects in humans. We observed a paradoxical association between 
ambient styrene exposure and grip strength, with increased styrene concentration 
associated with increased grip strength, although we observed no associations between 
blood styrene concentration and grip strength. We attribute these paradoxical findings, 
in part, to high population variance of this measure. Detecting associations in the 
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presence of such variance would require a strong exposure effect on the nerves being 
tested. Because longer nerves are typically more susceptible to adverse effects of toxic 
exposures than shorter nerves, effects in the expected direction may have been 
observed had we been able to measure motor strength of the lower extremities. 
Unfortunately, such testing was not feasible in the current study. Tests of great toe 
vibrotactile threshold and standing stability do assess the longest peripheral nerves and 
are likely more sensitive to subtle adverse effects.  We attempted to account for some 
grip strength variance by adjusting for body mass index and physical activity, as well as 
by excluding women, however results were unchanged in these analyses. Another 
possible explanation for the paradoxical association is residual confounding by 
socioeconomic status. In our study, ambient exposure was estimated geographically, 
and potentially covaries with socioeconomic status. Indeed, a recent analysis of NATA 
2011 data reported that census tracts with greater proportions of nonwhite and low 
income populations are exposed to higher concentrations of ambient air toxics than their 
wealthier, less diverse counterparts [215]. In addition to potentially experiencing higher 
exposures, people living in communities characterized by lower socioeconomic status 
may also be more likely to engage in labor-intensive jobs or activities, and therefore be 
stronger as a consequence of occupational physical conditioning. As such, associations 
between ambient styrene and handgrip strength may be confounded by social factors, 
or simply reflect muscular training effects, as opposed to effects on motor control 
systems.  
Tests of balance assess the integrated function of several components of the 
nervous system, including the vestibular apparatus, cerebellum, and proprioceptive 
 130 
 
system [216]. Loss of functional integrity of any of these systems secondary to toxic 
exposure may affect postural stability. In the current study, we observed significant 
associations between all quartiles of ambient styrene exposure and decreased standing 
steadiness (i.e., increased sway), with a monotonic exposure response. We did not, 
however, detect any associations between postural sway and blood styrene 
concentration. Results for ambient styrene and inability to maintain single leg stance 
were similar to those observed for postural sway. We also observed an association 
between inability to maintain single leg balance and the top 10% of blood styrene 
exposure. Combined, these results suggest a potential impairment of the motor control 
system necessary to balance due to environmental styrene exposure. These findings 
are supported by a study of reinforced plastic boat builders, which also reported 
impaired postural stability in association with styrene exposure [12]. 
Although the occupational styrene literature has focused on central nervous 
system toxicity [1], the peripheral nervous system may be another critical target for 
styrene’s neurotoxic effects, particularly at environmental levels. The peripheral nervous 
system is composed of multiple nerve fiber populations, including long, large diameter, 
heavily myelinated neurons with limited tolerance to physiological and toxicological 
insult. Therefore, portions of the peripheral nervous system may be more vulnerable to 
small perturbations, resulting in impaired peripheral nerve performance earlier, and at 
lower exposure levels, than other neurologic tissues.  
A dopaminergic mechanism for styrene neurotoxicity remains the leading 
mechanistic hypothesis, although it is speculative [71]. Studies suggest that styrene 
exposure decreases dopamine levels and increases dopamine receptors in rodents and 
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humans [126-128]. In blood samples of styrene-exposed plastics workers, prolactin 
levels were elevated, indicating reduced prolactin inhibition by dopamine [198]. 
Consistent with disturbance of the dopaminergic functions of the brain, styrene 
exposure potentiates a dose-dependent decrease in brain dopamine in male rats [128], 
as well as cell loss and dopamine depletion in retinas isolated from female rats [132]. 
This finding supports the established association between occupational styrene 
exposure and impaired vision [133]. 
An important strength of the present study was the use of well-validated, 
quantitative measures of peripheral neurologic function which may detect toxicologic 
effects earlier in disease progression than clinical assessments [216, 217]. We used a 
broad test battery, assessing multiple domains of neurologic function in a clinical 
research setting. Further, we collected these quantitative measures of neurologic health 
outcome from among over 3,000 participants, providing sufficient statistical power to 
detect small differences in neurologic function relevant to the observed exposure range. 
Our study also investigated an understudied, diverse population, for whom we had 
detailed covariate, exposure, and outcome information. 
Associations were not entirely consistent between blood and ambient exposure 
metrics, which may be attributable to the unique limitations of biomarkers and proxy 
exposures, or the temporal windows they reflect. Biomarkers of exposure potentially 
introduce confounding bias, whereas ambient proxy estimates may be subject to 
measurement error and exposure misclassification [200]. Our study attempted to 
address this tradeoff by assessing both types of exposure metrics. We used NATA 
estimates to represent typical, long-term environmental exposure, and blood styrene 
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measurements to capture internal exposure burdens resulting from recent exposures. 
NATA estimates have previously been used as indicators of air pollution exposure in 
epidemiologic studies of autism spectrum disorder [122, 123, 206] and 
neurodegenerative diseases [124]. Blood styrene is a validated biomarker specific to 
styrene exposure [74] and it has been used extensively in occupational research [6], as 
well as in general population monitoring [1].  
In the Relationships of Indoor, Outdoor, and Personal Air (RIOPA) study, blood 
styrene demonstrated stronger correlation with indoor than outdoor air concentrations, 
but outdoor sources explained more variability in levels than did indoor sources [61, 75]. 
Indeed, we observed a lack of concordance between measured blood styrene and 
NATA estimated annual average concentrations. At low occupational styrene levels 
measured in air, blood, and urine, blood demonstrated the highest correlations with 
ambient exposures [45].  
Our study was potentially limited by the cross-sectional design, and subsequent 
inability to establish temporality between styrene exposure and peripheral neurologic 
effects. Although results are unlikely to have been substantially biased by the limitations 
of cross-sectional study design, we were not able to discern between transient and 
persistent neurologic effects of styrene exposure. Additionally, we obtained only a single 
blood measurement for each individual, whereas repeated measures would potentially 
improve estimation of usual exposure. Blood styrene concentrations were obtained two 
to four years prior to neurologic testing, and may introduce exposure misclassification 
depending on the relevant timing of exposure. 
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Covariate information was obtained at enrollment or the time of the blood draw, 
and may not be reflective of immediate confounding exposures near the time of the 
peripheral neurologic testing. As such, the degree to which potential confounders 
changed between exposure and outcome ascertainment may have introduced residual 
confounding. 
Using an annual average ambient concentration limits interpretation. However, 
as routine monitoring of ambient styrene in the U.S. doesn’t provide sufficient temporal 
or spatial coverage to support exposure interpolation methods [143, 145, 155], NATA 
remains the only spatially-referenced exposure data source with sufficient geographic 
coverage for our study region. Although the assumptions inherent to an annual average 
estimate of air pollution potentially limit interpretation, NATA data are a valid estimation 
of usual exposure levels experienced by Gulf region residents. Long-term blood and 
ambient styrene trends indicate that year-to-year regional variation in concentration is 
generally not substantial, suggesting that an annual average estimate is an appropriate 
assessment of exposure [20, 60, 66, 74]. If long-term styrene exposure exerts chronic 
neurologic effects, NATA estimates may be a more relevant exposure metric than 
measures with more precise temporal windows.  
Although styrene-associated impairment of peripheral neurologic function was 
not universally apparent across all exposure and outcome measures, in aggregate, our 
results are suggestive of peripheral neurotoxic effect of styrene. Particularly compelling 
are associations demonstrated with the standing steadiness and vibrotactile threshold 
tests, which are well-established and validated measures of peripheral neurologic 
performance with known standard covariates [217-219]. Testing peripheral neurologic 
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function in this way may allow for early detection of subclinical neurotoxicity among 
groups exposed at levels relevant to the general population. Furthermore, large fiber 
function abnormality may be an early indicator of peripheral neurologic disease. Future 
research is needed to confirm these findings and to determine whether styrene-induced 
neurotoxicity derived from environmental exposures persists over time, and how it may 
relate to future risk of clinically-apparent neurologic disease. 
 
E. Conclusions 
Though styrene-associated impairment of peripheral neurologic function was not 
universally apparent across all exposure and outcome measures, our results taken 
together indicate a possible peripheral neurotoxic effect of styrene. Particularly 
compelling are associations demonstrated in the standing steadiness and vibrotactile 
threshold tests, which are regarded to be gold standard assessments, featuring well 
established operating characteristics, low noise, and known standard covariates [217-
219]. Testing large fiber function in this way may allow for early detection of subclinical 
neurotoxicity at exposure levels relevant to the general population. Furthermore, large 
fiber function abnormality is a possible early indicator of peripheral neurological disease. 
Future research is needed to determine whether styrene-induced neurotoxicity derived 
from environmental exposures persists over time, and how it may relate to neurological 
disease. 
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F. Tables and Figures  
Table 9. Demographic characteristics of participants living in the Gulf States (N=2,956) 
and those participating in the Chemical Biomonitoring Study (CBS, N=310). 
    Ambient (n=2,956) CBS (n=310) 
Characteristic   N % N % 
Sex Female 689 23.3 77 24.8 
 Male 2,267 76.7 233 75.2 
Age, years < 30 463 15.7 59 19.0 
 30 - 45 1,022 34.6 110 35.5 
 < 45 1,471 49.8 141 45.5 
Race White 1,520 51.4 156 50.3 
 Black 1,180 39.9 131 42.3 
 Other 256 8.7 23 7.4 
Work status Employed 1,559 52.7 165 53.2 
 Unemployed 1,397 47.3 145 46.8 
Current drinker Yes 2,132 72.1 215 69.4 
 No 824 27.9 95 30.7 
Current smoker Yes 1,009 34.1 79 25.5 
  No 1,947 65.9 231 74.5 
Oil spill response 
work ≥ 1 day 2,518 85.2 275 88.7 
 None 438 14.8 35 11.3 
Education < High school 625 21.1 66 21.3 
 High school graduate 1,037 35.1 116 37.4 
 Some college 873 29.5 92 29.7 
 ≥ College graduate 421 14.2 36 11.6 
Body Mass Index, 
kg/m2 ≤ Normal (< 25) 782 25.7 87 28.1 
 Overweight (25 - < 30) 1,131 38.3 121 39.0 
  Obese (≥ 30) 1,043 35.3 102 32.9 
Clinic Louisiana 904 30.6 87 28.1 
 Alabama 2,052 69.4 223 71.9 
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Table 10. Mean outcomes by exposure status among modeled population. 
    Ambient (n=2,956) Blood (n=310) 
Test Units Exposure N Mean Std Dev Exposure  N Mean Std Dev 
Grip strength pounds Q1 724 100.73 35.27 Lower 90 278 104.02 37.64 
  Q2 738 101.75 35.90 Top 10 32 100.32 38.17 
  Q3 745 108.65 40.03     
    Q4 723 108.76 39.13         
Vibrotactile threshold log microns Q1 707 1.85 1.21 Lower 90 275 1.71 1.19 
  Q2 727 1.78 1.16 Top 10 32 1.82 1.06 
  Q3 738 1.78 1.17     
    Q4 716 1.69 1.17         
Standing steadiness mm/s Q1 704 61.44 28.41 Lower 90 268 59.99 33.38 
Closed eyes  Q2 721 63.09 40.32 Top 10 31 52.86 19.20 
  Q3 731 61.48 36.37     
    Q4 699 57.52 27.60         
Standing steadiness mm/s Q1 704 39.15 13.58 Lower 90 268 37.99 14.73 
Closed eyes  Q2 721 40.54 25.15 Top 10 31 37.76 12.19 
  Q3 731 39.72 15.55     
    Q4 699 38.50 19.39         
Contrast sensitivity score Q1 672 5.03 1.03 Lower 90 263 5.02 1.02 
  Q2 685 5.14 1.07 Top 10 30 4.65 1.07 
  Q3 697 5.04 1.06     
    Q4 673 4.95 1.04         
N, number; Std Dev, standard deviation of mean. 
 
  
 137 
 
137 
Table 11. Mean outcomes in eligible participant demographic subgroups. 
    Grip strength 
Vibrotactile 
threshold 
Standing 
steadiness: 
closed 
Standing 
steadiness:   
open 
Contrast 
sensitivity 
    pounds log microns mm/s mm/s score 
Overall 
(n=3,262) 
N 3234 3175 3143 3143 2987 
Mean 103.96 1.84 62.27 40.33 5.01 
Std Dev 37.55 1.20 36.49 20.10 1.06 
Non-diabetics 
(n=2,956) 
N 2930 2888 2855 2855 2727 
Mean 104.98 1.78 60.91 39.49 5.04 
Std Dev 37.81 1.18 33.73 18.96 1.05 
Smokers 
(n=1,093) 
N 1082 1067 1051 1051 983 
Mean 103.51 1.79 63.78 41.26 5.01 
Std Dev 35.84 1.15 41.06 23.11 1.04 
Nonsmokers 
(n=2,169) 
N 2152 2108 2092 2092 2004 
Mean 104.18 1.86 61.51 39.87 5.02 
Std Dev 38.39 1.22 33.95 18.39 1.07 
Men (n=2,506) N 2483 2434 2414 2414 2313 
Mean 113.15 1.95 65.48 41.67 5.09 
Std Dev 35.59 1.23 39.09 20.52 1.07 
Women (n=756) N 751 741 729 729 674 
Mean 73.55 1.49 51.65 35.91 4.76 
Std Dev 26.09 1.01 23.14 17.96 1.00 
N, number; Std Dev, standard deviation of mean. 
  
 138 
 
Figure 14. Probability density of styrene exposure in air (N=2,956) and blood (N=310). 
 
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 2011 
modeled estimates of annual average concentrations (µg/m3) at the census tract level. 
Blood styrene exposure concentrations (ng/mL) are measured from a single blood draw 
obtained in the participant’s home. 
Values at the top of reference lines indicate exposure concentrations; labels at the 
bottom of reference lines indicate locations in the exposure distribution: P25, 25th 
percentile; P50, 50th percentile; P75, 75th percentile; P90, 90th percentile; P95, 95th 
percentile; Max, maximum value. 
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Figure 15. Ambient (n=1,392) and blood (n=231) styrene concentrations and visual contrast sensitivity performance. 
 
Symbol markers and labels indicate mean score at each spatial frequency; error bars indicate 95% confidence intervals 
associated with mean scores. 
Models adjusted for vision correction (eyeglasses, corrective lenses), gender, age, race, enrollment employment status, 
enrollment drinking status, and enrollment smoking status. Excluded participants with 20/50 or worse visual acuity. 
Asterisks indicate p-value for difference in means < 0.05. 
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 2011 modeled estimates of annual 
average census tract concentrations (µg/m3). Q4, fourth quartile; Q1-Q2, first and second quartile (below median). 
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Blood styrene exposure concentrations (ng/mL) are measured from a single blood draw obtained in the participant’s 
home. High exposure, blood styrene measurements above the 90th percentile of the distribution; Low exposure, blood 
styrene measurements up to the 90th percentile of the distribution. 
 141 
 
Figure 16. Ambient (n=2,888) and blood (n=307) styrene concentrations and differences 
in vibrotactile threshold. 
 
Symbol markers and labels indicate change in vibrotactile threshold multiplied by -1 (log 
microns) associated with each exposure metric; negative values reflect neurologic 
deficits; positive values reflect neurologic improvement; diamond, age (decade); empty 
circles, blood styrene exposures; filled circles, ambient styrene quartiles; error bars 
indicate 95% confidence intervals associated with effect estimates. 
Models adjusted for gender, age, height, race, enrollment employment status, 
enrollment drinking status, and enrollment smoking status.  
Asterisks indicate p-value for linear trend < 0.05. 
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 2011 
modeled estimates of annual average concentrations (µg/m3) at the census tract level. 
Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.  
Blood styrene exposure concentrations (ng/mL) are measured from a single blood draw 
obtained in the participant’s home. Top 10%, blood styrene measurements above the 
90th percentile of the distribution; Lower 90%, blood styrene measurements up to the 
90th percentile of the distribution. 
 
 
  
Ambient (n=2,888) * Blood (n=307) 
 142 
 
Figure 17. Ambient (n=2,855) and blood (n=299) styrene concentrations and differences 
in standing steadiness. 
 
Symbol markers and labels indicate change in sway speed multiplied by -1 (mm/s) 
associated with each exposure metric; negative values reflect neurologic deficits; 
positive values reflect neurologic improvement; error bars indicate 95% confidence 
intervals associated with effect estimates. 
Models adjusted for gender, age, race, enrollment employment status, enrollment 
drinking status, and enrollment smoking status.  
Asterisks indicate p-value for linear trend < 0.05. 
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 2011 
modeled estimates of annual average census tract concentrations (µg/m3). Q1, first 
quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.  
Blood styrene exposure concentrations (ng/mL) are measured from a single blood draw 
obtained in the participant’s home. Top 10%, blood styrene measurements above the 
90th percentile of the distribution; Lower 90%, blood styrene measurements up to the 
90th percentile. 
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Figure 18. Ambient (n=2,271) and blood (n=237) styrene concentrations and 
inability to maintain single leg stance. 
 
Prevalence ratio, inability to maintain balance for 30 seconds on any of three 
attempts compared to ability to maintain balance for 30 seconds on first attempt. 
Values above 1 indicate problems with balance; values below 1 indicate ability to 
balance for 30 seconds. 
Error bars indicate 95% confidence intervals associated with prevalence ratios. 
Models adjusted for gender, age, race, enrollment employment status, enrollment 
drinking status, and enrollment smoking status.  
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 
2011 modeled estimates of annual average concentrations (µg/m3) at the census 
tract level. Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth 
quartile.  
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Blood styrene exposure concentrations (ng/mL) are measured from a single 
blood draw obtained in the participant’s home. Top 10%, blood styrene 
measurements above the 90th percentile of the distribution; Lower 90%, blood 
styrene measurements up to the 90th percentile. 
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Figure 19. Ambient (n=2,930) and blood (n=310) styrene concentrations and 
differences in handgrip strength. 
 
Symbol markers and labels indicate change in mean force (pounds) associated 
with each exposure metric; circles, ambient styrene quartiles; square, blood 
styrene highest quartile; diamond, blood styrene 90th percentile; error bars 
indicate 95% confidence intervals associated with effect estimates. 
Models adjusted for gender, age, height, race, enrollment employment status, 
enrollment drinking status, and enrollment smoking status.  
Asterisk indicate p-value for linear trend < 0.05. 
Ambient styrene exposure is based on National Air Toxics Assessment (NATA) 
2011 modeled estimates of annual average concentrations (µg/m3) at the census 
tract level. Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth 
quartile.  
Blood styrene exposure concentrations (ng/mL) are measured from a single 
blood draw obtained in the participant’s home. Top 10%, blood styrene 
measurements above the 90th percentile of the distribution; Lower 90%, blood 
styrene measurements up to the 90th percentile of the distribution. 
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Table 12. Associations between ambient (N=2,956) and blood (N=310) styrene concentrations and peripheral nerve 
function. 
Peripheral neurologic  
function test 
  Ambient   Blood 
N Exposure Effect (95% CI) p-trend N Exposure Effect (95% CI) p-value 
Vibrotactile threshold1 2,888 Q1 Ref 
0.003 
307 Q1-Q3 Ref ― 
β, Change in log microns 
 Q2 0.02 (-0.07, 0.12)  Q4 -0.17 (-0.41, 0.06) 0.14 
 Q3 -0.07 (-0.16, 0.03)  Low 90% Ref ― 
    Q4 -0.12 (-0.22, -0.01)   Top 10% -0.37 (-0.71, -0.04) 0.03 
Grip strength 2,956 Q1 Ref 
<0.0001 
310 Q1-Q3 Ref ― 
β, Change in force 
(pounds) 
 Q2 -0.11 (-3.45, 3.23)  Q4 -3.04 (-11.52, 5.44) 0.48 
 Q3 6.13 (2.76, 9.49)  Low 90% Ref ― 
  Q4 6.27 (2.67, 9.87)   Top 10% -1.86 (-14.04, 10.31) 0.76 
Standing steadiness,  2,855 Q1 Ref 
0.02 
299 Q1-Q3 Ref ― 
eyes closed1  Q2 -3.72 (-7.01, -0.43)  Q4 -1.54 (-9.27, 6.19) 0.70 
β, Change in sway speed 
(mm/s) 
 Q3 -4.31 (-7.62, -1.00)  Low 90% Ref ― 
  Q4 -4.65 (-8.20, -1.10)   Top 10% -2.46 (-8.71, 13.64) 0.66 
Standing steadiness,  2,855 Q1 Ref 
<0.0001 
299 Q1-Q3 Ref ― 
eyes open1  Q2 -2.68 (-4.53, -0.83)  Q4 -1.36 (-4.73, 2.01) 0.43 
β, Change in sway speed 
(mm/s) 
 Q3 -3.22 (-5.08, -1.36)  Low 90% Ref ― 
  Q4 -4.53 (-6.52, -2.54)   Top 10% -2.09 (-6.97, 2.78) 0.40 
Single leg stance,  2,821 Q1 Ref 
0.001 
295 Q1-Q3 Ref ― 
never vs ever2  Q2 1.33 (1.11, 1.59)  Q4 0.82 (0.47, 1.42) 0.48 
PR, Failure to stand for 30 
seconds 
 Q3 1.26 (1.04, 1.52)  Low 90% Ref ― 
  Q4 1.40 (1.16, 1.70)   Top 10% 2.05 (1.20, 3.53) 0.01 
Single leg stance,  2,271 Q1 Ref 
0.002 
237 Q1-Q3 Ref ― 
never vs 1st attempt3  Q2 1.19 (1.00, 1.41)  Q4 1.07 (0.65, 1.76) 0.79 
PR, Failure to stand for 30 
seconds 
 Q3 1.19 (1.00, 1.442)  Low 90% Ref ― 
  Q4 1.33 (1.11, 1.59)   Top 10% 1.82 (1.07, 3.08) 0.03 
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  N Range Effect (95% CI) p-value N Range Effect (95% CI) p-value 
Contrast sensitivity4 2,956 1.5 0.15 (0.04, 0.25) 0.01 231 1.5 0.12 (-0.29, 0.52) 0.56 
Difference, mean contrast 
score 
  
 3 0.14 (0.03, 0.25) 0.01  3 0.30 (-0.14, 0.75) 0.18 
 6 0.05 (-0.11, 0.21) 0.53  6 0.34 (-0.26, 0.95) 0.27 
 12 0.18 (0.01, 0.35) 0.04  12 0.79 (0.08, 1.50) 0.03 
  18 0.10 (-0.06, 0.26) 0.23   18 0.58 (-0.05, 1.22) 0.07 
1Reported values for these tests are raw values multiplied by -1, so that negative numbers indicate diminished neurologic 
function and positive numbers indicate improved neurologic function for all continuous outcomes. 
2Single leg stance prevalence ratio = inability to maintain balance for 30 seconds on any of three attempts / ability to 
maintain balance for 30 seconds on any of three attempts. Values above 1 indicate diminished balance, values below 1 
indicate improved balance. 
3Single leg stance prevalence ratio = inability to maintain balance for 30 seconds on any of three attempts / ability to 
maintain balance for 30 seconds on first attempt. Values above 1 indicate diminished balance, values below 1 indicate 
improved balance. 
4For contrast sensitivity: ambient exposure contrast is Q4 vs Q1-Q2; blood exposure contrast is Top 10% vs Lower 90%; 
restricted to participants with normal visual acuity (better than 20/50). 
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CHAPTER VII: CONCLUSIONS 
A. Summary of results 
Styrene is an established neurotoxicant, though epidemiologic research to date 
has focused on occupational exposure levels and emphasized central nervous system 
effects. In this dissertation, we evaluated sources of environmental styrene exposure in 
Gulf coast residents, and examined associations of such exposure levels with 
neurologic effects. We included in our assessment of neurologic effects a detailed 
assessment of peripheral neurologic function. 
 For Specific Aims 1 and 2, we evaluated personal, environmental, and spatial 
predictors as determinants of blood styrene levels in a population of Gulf coast 
residents with apparently elevated environmental styrene exposure. Blood styrene 
levels in this population were two to three times higher than those observed in 
NHANES, for smokers and nonsmokers, with marked differences at the upper end of 
the distribution. Indeed, nonsmokers from our study sample were 5.9 (95% CI: 5.0, 6.8) 
times as likely as NHANES participants to have blood styrene levels exceeding the 
NHANES 95th percentile. Smokers from the Gulf coast population were 4.3 (95% CI: 
3,5, 5.1) times as likely as their NHANES counterparts to have elevated levels. 
Our predictive model of determinants of styrene exposure captured only 20% of 
the variability in blood levels, and results were largely confirmatory with previous 
literature on VOC exposures. Smoking (β = 0.42 log ng/mL, 95% CI: 0.34, 0.51), 
vehicular emissions (β = 0.34, 95% CI: 0.09, 0.59), time spent on boats (β = 1.10, 95% 
CI: 0.31, 1.89), mobile housing (β = 0.35, 95% CI: 0.07, 0.63), and home exterior 
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materials (β = 0.37, 95% CI: 0.11, 0.64) were associated with increases in blood 
styrene. In primary analyses, neither ambient styrene concentrations nor proximity to 
point source emissions of styrene predicted blood styrene levels. In a subgroup defined 
to more efficiently examine environmental sources, however, we did observe 
associations between elevated blood styrene and ambient styrene due to nonpoint 
sources. The subgroup was defined as participants with fall/winter blood draws, no 
reported recent active or passive tobacco smoke exposure, and not living in Alabama. 
Participants in this subgroup with the highest quartile of ambient nonpoint styrene 
exposure were 2.1 (95% CI: 1.0, 4.4) times as likely as participants in the lowest 
exposure quartile to have blood styrene measurements exceeding the NHANES 95th 
percentile. As in the main analysis, proximity to point source styrene emissions was not 
an informative predictor in any subgroup analyses. 
For Specific Aim 3, we evaluated cross-sectional associations between styrene 
exposure and neurologic symptoms. We considered both ambient and blood styrene in 
relation to each symptom individually, as well as clustered outcomes defined by the 
presence of any neurologic, CNS, or PNS symptom. We found that participants with the 
highest quartile of ambient styrene exposure (0.03-1.70 µg/m3) had significantly 
increased prevalence of each symptom and cluster, when compared to participants in 
the lowest quartile of exposure (≤ 0.01 µg/m3). Furthermore, we observed significant 
exposure-response trends (p < 0.05) across quartiles of exposure for all outcomes 
except nausea and fatigue. The highest quartile of exposure was associated with a 7% 
increase (PR = 1.07, 95% CI: 1.02, 1.12) in reporting at least one neurologic symptom, 
a 20% increase (PR = 1.20, 95% CI: 1.09, 1.32) in reporting multiple CNS symptoms, 
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and a 12% increase (PR = 1.12, 95% CI: 1.02, 1.23) in reporting multiple PNS 
symptoms. While effect sizes are small (suggesting subtle neurotoxic effects) and 
exposure levels are low, the consistency across symptoms and the exposure-response 
relationships suggest that these associations are not due to chance alone. 
When evaluating blood styrene levels in relation to neurologic symptoms, 
relationships were less consistent. We did not observe increases in symptom clusters 
associated with blood styrene exposure above the median value (0.067 ng/mL), apart 
from a 40% increase among participants reporting multiple PNS symptoms (PR = 1.40, 
95% CI: 1.00, 1.97). Suggestive associations were apparent for dizziness (PR = 1.36, 
95% CI: 0.91, 2.04), nausea (PR = 1.53, 95% CI: 0.93, 2.53), and stumbling (PR = 2.14, 
95% CI: 1.03, 4.44). The remaining symptoms did not appear to be related to blood 
styrene exposure. While the overall relationship between exposure and outcome is less 
consistent for blood styrene than for ambient exposure, the magnitude of the 
associations was larger where we did detect exposure-related effects in blood. These 
results lacked precision, due at least in part to the smaller sample size (N=874), and 
may be subject to greater misclassification given the short half-life of the exposure 
measure and the fact that symptom data were reported before the blood draw 
As an extension of Specific Aim 3, we examined the effect of styrene exposure 
on peripheral neurologic function using a battery of objective neurologic tests. For 
primary analyses, we assessed associations between quartiles of ambient styrene 
exposure and five dimensions of neurologic function (visual contrast sensitivity, 
vibrotactile threshold, postural stability, single leg stance, and handgrip strength). 
Higher exposure was associated with impaired visual contrast sensitivity at all spatial 
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frequencies, though differences were subtle, and were only statistically significant at 1.5 
(mean difference = 0.15, 95% CI: 0.04, 0.25), 3 (mean difference = 0.14, 95% CI: 0.03, 
0.25), and 12 (mean difference = 0.18, 95% CI: 0.01, 0.35) cycles/degree. We observed 
a monotonic decrement in vibrotactile sensitivity with increasing ambient exposure (4th 
quartile, β = -0.12, 95% CI: -0.22, -0.01). All quartiles of ambient styrene exposure were 
associated with significant decreases in postural stability, with a statistically significant 
exposure-response relationship (eyes closed, p = 0.01; eyes open, p < 0.0001). We 
found similar evidence of vestibular dysfunction for single leg stance, with participants in 
the highest quartile demonstrating a 40% increase in inability to maintain balance (PR = 
1.4, 95% CI: 1.2, 1.7). We observed a statistically significant, but paradoxical, 
association of improving handgrip strength with increasing ambient styrene exposure. 
In secondary analyses for Specific Aim 3, we modeled associations between 
more extreme blood styrene exposure measures and the same five tests of peripheral 
neurologic function (n=310). We assessed exposure as the top 10% of blood levels 
(versus the lower 90%), as well as the top quartile (versus all other quartiles) of the 
distribution. Participants with blood styrene measures above the 90th percentile had 
slightly, but consistently, lower visual contrast sensitivity scores. The difference was 
significant at 12 cycles/degree only (mean difference = 0.79, 95% CI: 0.08, 1.50), but a 
similar pattern was evident at all spatial frequencies. Similarly, the top 10% of blood 
styrene exposure was associated with diminished performance on tests of vibrotactile 
threshold (β = -0.37 log microns, 95% CI: -0.71, -0.04) and single leg stance (PR = 2.1, 
95% CI: 1.2, 3.5). We did not detect any exposure-related associations for tests of 
postural stability or handgrip strength. Further, the highest quartile of blood styrene 
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levels was not associated with meaningful differences in peripheral neurologic function 
on any of the tests. 
Styrene exposure, both ambient concentrations and blood levels, was associated 
with self-reported PNS symptoms. Associations were stronger and more precise for 
participants reporting two or more PNS symptoms. This suggestion of a styrene-
associated peripheral neurologic effect was corroborated in analyses of objective 
peripheral neurologic function testing where we observed suggestive associations 
between styrene exposure and vision, sensory, and vestibular impairment. We compare 
associations between symptoms and corresponding neurologic function tests 
cautiously, as the analyses are not perfectly exchangeable. Not only is the timing 
between exposure and outcome ascertainment different between analyses, but the 
subjective and objective outcomes are imperfect analogues of each other. Therefore, 
we draw the following comparisons speculatively. 
Vision impairment was assessed two ways, as self-reported blurred vision and as 
visual contrast sensitivity score (Table 13). We observed associations between ambient 
styrene and both metrics, self-reported and objectively measured, vision impairment. 
Blood styrene exposure was associated with objectively measured vision impairment, 
but not with self-reported blurred vision. One explanation for the discrepancy in findings 
with blood styrene is that blurred vision might be expected to be an acute effect, 
whereas contrast sensitivity may be a more long-term measure. If this is the case, the 
timing of symptom ascertainment and the blood measurement would inhibit our ability to 
detect an association. Styrene causes cell loss and dopamine depletion in retinas 
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isolated from female rats [132], which supports our results and the established 
association between occupational styrene exposure and impaired vision [133].  
Vestibular impairment and balance problems were assessed subjectively via self-
reported stumbling while walking, as well as objectively via tests of postural stability and 
single leg stance. Styrene exposure was associated with increased subjective and 
objective measures of vestibular impairment for both exposure metrics, apart from the 
association between blood styrene and measured postural stability. A study of 
reinforced plastic boat builders also reported impaired postural stability in association 
with styrene exposure [12], though occupational results are less consistent for vestibular 
effects. 
Sensory impairment was assessed as self-reported numbness/tingling in the 
extremities, as well as measured vibrotactile threshold. Except for blood styrene and 
self-reported numbness/tingling, we observed associations between both styrene 
metrics and both measures of sensory impairment. Occupational studies of subjective 
sensory impairment, including tingling and numbness, have yielded conflicting results 
[11, 103, 105]. In studies with objectively measured outcomes, workers exposed to both 
styrene and toluene exhibited exposure-related changes in somatosensory evoked 
potentials [109] and painters experienced similar effects [213]. We conducted sensitivity 
analyses to address other common factors that could contribute to sensory impairment, 
such as nerve injury and diabetes. Results were unchanged when participants were 
excluded based on these characteristics, as well as when we adjusted for them. 
A dopaminergic mechanism [71] remains the prevailing hypothesis for styrene’s 
mode of neurotoxicity. Several studies suggest that styrene exposure alters dopamine 
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metabolism and receptors in rodents and humans [126-128]. This mechanism is 
demonstrated in blood samples of styrene-exposed plastics workers for whom prolactin 
levels are elevated, as prolactin release is chronically inhibited by dopamine [130], and 
in male rats where styrene exposure potentiates a dose-dependent decrease in brain 
dopamine [128]. 
Taken together, results from Specific Aim 3 offer compelling evidence of 
styrene’s potentially neurotoxic effects at environmental levels (Table 13). Consistent, 
albeit small, increases in neurologic symptoms among participants with higher ambient 
styrene exposure are supported by similar relationships of decreases in peripheral 
neurologic function. While these effect sizes are relatively small, they are of plausible 
magnitude given that the exposure levels reflect ambient, usual environmental levels 
across a large geographic region. Associations between blood styrene exposure and 
both indicators or neurologic effects (symptoms and peripheral neurologic function) 
were less consistent, but we did observe some suggestive effects for both sets of 
outcomes. Blood exposure analyses had smaller sample sizes, and were potentially 
underpowered to detect statistically significant differences of the magnitude we 
observed. While these findings are based on cross-sectional analyses, and we therefore 
cannot establish temporality or assess causality, they do provide suggestive evidence of 
styrene-associated neurologic effects at environmental exposure levels. 
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B. Strengths and limitations 
Strengths 
The GuLF STUDY is a large, well characterized cohort with rich exposure 
information and near complete residential geocoding. Although the present study is not 
focused on the DWH oil spill, this cohort presents a unique opportunity to investigate a 
novel exposure scenario in an understudied, diverse population.  
Blood styrene is a validated biomarker specific to styrene exposure [25]. It has 
been used extensively in occupational research [6], as well as in general population 
monitoring [1]. With approximately 1,000 independent measurements and 77% 
detection, analyses predicting blood styrene measurements were sufficiently well-
powered. Moreover, the laboratory provided all measured styrene values, including 
those below the limit of detection. We were able to use these values as the best 
estimates of the true styrene level, which is generally preferable to other approaches 
[180]. The distribution of observed levels supported evaluation of exposure-response 
relationships and allowed stratification by smoking status, an important predictor of 
styrene exposure in the general population. Furthermore, the blood styrene exposure 
range in this population consisted of somewhat elevated blood styrene levels with a 
broad range of exposures and high rate of detection. This distribution is ideally suited to 
a predictive analysis that assesses elevated exposure, but is relevant to usual 
environmental levels. 
Although each person provided only one specimen at a single time point, detailed 
questionnaire data were collected about relevant activities and determinants of VOC 
exposure occurring at the time of blood collection. Exposure questions were framed with 
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respect to the 24 hours and 7 days prior to blood collection, as well as over the longer 
term.  
Routine monitoring of ambient styrene across the U.S. does not provide sufficient 
temporal or spatial coverage to support kriging or other exposure interpolation methods 
[143, 145, 155] for prediction in Specific Aims 1 and 2. As a result, most GuLF STUDY 
participants live very far from monitors, negating any meaningful contribution of 
observed levels. Instead, we integrated two complementary data sources to quantify 
ambient styrene exposure. NATA generally performs well in comparison to monitored 
data, incorporates meteorology, uses sophisticated dispersion modeling, and includes 
all source types, but is limited by spatial resolution based on census tracts. Proximity 
measures for point sources, while limited in scope of underlying source possibilities, 
provide enhanced spatial resolution because they are based on geocodes. These 
measures implement finer dispersion ranges, and facilitate examination of the 
hypothesized importance of point sources. This method, combining NATA and NEI, has 
been used to identify HAP hot spots in urban and suburban communities [220]. 
In Specific Aim 3, we assessed effects associated with long-term ambient 
styrene and acute internal dose of styrene. Modeling exposure using both proxy and 
personal metrics helps address possible confounding bias introduced by the biomarker, 
and potential measurement error of NATA ambient styrene estimates [200]. NATA 
estimates have been applied as measures of human air pollution exposure in 
epidemiologic studies of cancer [201-203], asthma [204], birth defects [205], autism 
spectrum disorder [122, 123, 206], and neurodegenerative diseases [124]. NATA data 
remain the only valid, spatially-referenced estimation of usual exposure levels with 
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sufficient geographic coverage for the Gulf state region. Long-term ambient styrene 
trends indicate that year-to-year regional variation in concentration is not substantial, 
suggesting that annual average estimates are appropriate assessments of exposure 
[20]. Stable measured blood styrene levels in independent U.S. population samples, 
measured cross-sectionally, over a 20-year period corroborate these findings [25, 60, 
66]. Blood styrene is a validated biomarker specific to styrene exposure [25] and it has 
been used extensively in occupational research [6], as well as in general population 
monitoring [1].  
Although self-reported symptoms have been criticized for their subjective nature, 
they provide a highly sensitive measure of neurologic impairment equipped to detect 
subclinical, and perhaps early, indications of styrene-induced neurotoxicity [199]. The 
blood styrene levels observed in the GuLF STUDY are certainly elevated, but they are 
more similar to general population levels than to occupational levels. As such, these 
exposures are not expected to elicit severe, pronounced neurologic effects [148], so 
sensitive neurologic symptoms are well-suited to capture the potentially subtle, 
widespread neurotoxic effects for this exposure range.  
To address potential concern about symptom reporting subjectivity, we 
additionally employed objective measures of peripheral neurologic function ascertained 
in a clinical research setting using validated tests [216]. This additional assessment of 
neurologic impairment allowed us to investigate PNS effects, whereas the occupational 
literature has focused on CNS effects. Our approach using both subjective and 
objective outcome assessments also allowed us to evaluate patterns between the 
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subjective and objective measures, lending potential insight into the validity of symptom 
reporting in relation to environmental exposures. 
Limitations 
Although we had a large sample size for a biomarker study, we obtained only a 
single blood measurement from each individual. Repeated biomarker measurements 
may provide a more reliable estimate of usual exposure than the single blood specimen 
obtained in our study, particularly because of the rapid elimination of styrene from the 
body. Given the half-life of blood styrene, we are limited in our interpretation of the 
blood level relative to neurologic outcomes.  It should be noted that symptom 
ascertainment predated the blood draw, whereas peripheral neurologic function was 
tested after blood collection. Therefore, timing-related exposure misclassification may 
have led to underestimation of effects, unless all measured exposures truly reflect usual 
daily exposure. The observed similarity of findings across exposure metrics and 
outcomes, however, suggests that temporality issues did not entirely obscure 
associations. 
Lacking detailed information on styrene-specific occupational exposure 
opportunities, we assessed reported industry, occupation, and activity information for 
participant’s recent and longest-held jobs. Occupational data were reported at 
enrollment and potentially not reflective of the relevant 24-hour exposure window 
preceding the blood draw. Despite this limitation, it is unlikely that occupational styrene 
exposure is influencing blood styrene levels in this study population because styrene-
related occupations tend to be highly specific and reported rarely among CBS 
participants. We searched through self-reported industry/occupation information for any 
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potentially styrene-related work experience, with the intention of adjusting for work or 
excluding these individuals from analyses. Ultimately, occupational styrene exposure 
opportunities were so rare in our study population (0.1%), that we concluded that 
occupational exposures were not influencing results. 
Reporting to the NEI database is voluntary and designed for regulatory purposes. 
As such, the quality of the data and availability of information for our intended 
investigation may not be ideal. These data are limited to annual aggregate values, and 
lack any temporal specificity. Similarly, the NATA estimates are annual averages 
derived from voluntarily reported inputs, the protocols for which vary between states. 
Although imperfect, in the absence of sufficient monitoring data, these data sources 
provide the best available outdoor exposure information for a study of our scope and 
purpose. Although the assumptions inherent to an annual average estimate of air 
pollution potentially limit interpretation for acute exposure scenarios, NATA data are a 
valid estimation of usual exposure levels experienced in the Gulf region. 
Due to the cross-sectional nature of our study, we could not evaluate the relevant 
timing of exposure and outcome in Specific Aim 3. Associations examining neurologic 
symptoms are conceptually cross-sectional, though exposure assessment was 
completed after outcome ascertainment in sub-analyses examining associations 
between blood styrene levels and neurologic symptoms among CBS participants. Blood 
measurements were obtained within three months of enrollment for 47% of participants, 
and approximately 70% of all home visits were completed within six months of 
enrollment. Scheduling was not related to oil spill cleanup or other exposures, so the 
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interval duration between outcome and exposure assessment is expected to be 
randomly distributed. 
Because blood styrene measurements reflect recent exposure, assessing 
exposure after outcome ascertainment is a potential limitation. There is no biological 
basis to assume that impaired neurologic function would affect subsequent blood 
burden of styrene, so reverse causality seems unlikely. However, if the measured blood 
styrene reflects transient exposures encountered before or after outcome 
ascertainment, exposure misclassification would potentially bias associations between 
blood styrene and neurologic outcomes. We conducted sensitivity analyses restricted to 
participants who completed the home visit within three and six months of enrollment, 
and found that results were unchanged. This suggests that the temporal lag did not 
introduce exposure misclassification to bias associations.   
C. Public health significance 
Given that styrene use and generation are widespread, and inhalation of airborne 
styrene is the principal route of exposure, it is a critical public health priority to evaluate 
whether adverse health effects may result from chronic ambient exposure at levels 
relevant to the general population. Our research lent limited insight into the underlying 
sources responsible for styrene exposure in this population and region. This was the 
first study to examine the neurologic effects of styrene exposure of this magnitude. The 
combined findings from our analyses suggest that styrene is an important exposure for 
human health effects, and that more research is warranted to determine policy 
implications. 
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Our investigation into ambient styrene in relation to neurologic symptoms 
suggests that styrene’s neurotoxic properties may be apparent even at exposure levels 
relevant to the general population. The relationship between blood styrene exposure 
and neurologic symptoms was equivocal, but suggestive of an association for certain 
endpoints. People exhibiting the symptoms evaluated in our study may be at risk for 
more severe neurologic impairments or disease, as these outcomes may be early 
markers of more severe manifestations. Furthermore, the large fiber function 
abnormality we detected via objective neurologic testing is a possible early indicator of 
peripheral neurological disease.  
Future research is needed to determine whether styrene-induced neurotoxicity 
derived from environmental exposures persists over time, and how it may relate to 
neurological disease. In the presence of a ubiquitous exposure like air pollution, even 
subtle neurologic effects can have significant impacts on population-level health effects. 
Implementing policies and styrene exposure mitigation efforts could lead to widespread, 
incremental improvements in neurologic health at the population level.  
D. Directions for future research 
While occupational styrene levels have been characterized fairly extensively, 
environmental exposure levels and their underlying sources remain less clear. Most 
exposure assessment in the general population has been cross-sectional and 
monitoring is limited. To improve elucidation of determinants of styrene exposure, as 
well as typical environmental levels, valuable future research could assess exposure 
using repeated measures in varying media. 
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Based on the apparently bimodal distribution of blood styrene levels in the CBS 
cohort, we could potentially improve prediction of blood styrene exposure using finite 
mixtures modeling [221]. This approach offers a parametric alternative to an unknown 
distribution like the one we observed, potentially accounting for unobserved 
heterogeneity in our data [222]. Ideally, this would allow us to predict the likelihood of 
membership in different ranges of the exposure distribution, potentially revealing 
previously unrecognized determinants of elevated blood styrene levels. 
GuLF STUDY data collection and follow-up are ongoing, creating an opportunity 
to evaluate associations between styrene exposure and neurologic effects 
longitudinally. Our current research is limited to cross-sectional data, and establishing 
temporality through a prospective analytic design would strengthen results, and the 
interpretations of relationships between styrene exposure and neurologic effects.  
Because humans are commonly exposed to multiple correlated air pollutants 
simultaneously [223], it is important to build on observed associations with individual 
chemical exposures in isolation by evaluating exposure mixtures. Styrene is highly 
correlated with BTEX in air and blood, as these VOCs share many common 
environmental sources [1, 60, 84]. BTEX are also neuroactive [78-80, 224, 225]. We 
can extend the present analyses by considering BTEX and styrene exposure mixtures 
in air and blood using penalized regression or other statistical methods [226, 227], 
including weighted quantile sums, lasso, ridge, elastic net, or Bayesian kernel machine 
regression [228]. Implementing a mixtures-focused approach would potentially yield 
important benefits for the public health impact of this research [229], as well as further 
insight into environmental styrene neurotoxicity. 
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NATA data are currently the best available proxy measures for ambient styrene 
exposure across the Gulf region, though a lack of temporal specificity limits their utility. 
More sophisticated air quality modeling that incorporates temporal variability would 
improve environmental exposure assessment for both analyses: predicting blood 
styrene levels, as well as investigating the relationship between styrene exposure and 
neurologic effects, especially if some portion of the effects is transient. Further, 
enhanced or targeted monitoring of ambient styrene levels would potentially improve the 
validity of modeled environmental styrene concentrations [162, 230].  
Beyond the scope of this cohort, objective evaluation of neurologic impairment in 
occupational settings has largely been restricted to CNS effects, commonly measured 
through neurobehavioral and psychological testing. Applying our comprehensive battery 
of peripheral neurologic function testing to a new or existing occupational cohort would 
contribute meaningfully to the understanding of styrene-related PNS impairment, a 
relationship that remains unclear.
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Table 13. Summary of findings for ambient and blood styrene exposure in relation to neurologic effects. 
Peripheral 
Neurologic 
function  
Styrene exposure type  
Neurologic symptom 
Styrene exposure type 
Ambient Blood  Ambient Blood 
Contrast 
Sensitivity 
Association 
(Q4) 
Association 
(P90) 
 Blurred vision Association (Q3, Q4) Null 
Vibrotactile 
Threshold 
Association 
(Q4) 
Association 
(P90) 
 Tingling/Numbness Association (Q4) Null 
Single Leg 
Stance Association (All) 
Association 
(P90) 
 
Stumbling Association (Q4) 
Association 
(Median) 
Postural Stability Association (All) Null  
Positive denotes evidence of an association between styrene exposure and impaired neurologic function or increased risk 
of neurologic symptoms. Null denotes lack of evidence for an association between styrene exposure and neurologic 
effects. 
Q3, statistically significant for third quartile. 
Q4, statistically significant for fourth quartile. 
P90, statistically significant for exposure above the 90th percentile. 
All, statistically significant for all exposure quartiles. 
Median, statistically significant for exposure above the median value.  
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APPENDIX 1. DISTRIBUTION OF EPA MONITORS AND GULF STUDY 
PARTICIPANTS 
 
Table A1. Distribution of Gulf STUDY biomonitoring sub-study participants’ (N=1,055) 
distance to nearest styrene monitor  
 2011 monitors  
(N=44) 
2013 monitors  
(N=68) 
 Miles Kilometers Miles Kilometers 
Mean (SD) 114.4 (56.5) 184.2 (91.0) 134.5 (69.8) 216.5 (112.3) 
Minimum 1.7 2.7 0.3 0.5 
25th percentile 62.6 100.8 68.0 109.5 
Median 119.5 192.4 145.9 234.8 
75th percentile 170.1 273.7 186.6 300.3 
Maximum 213.3 343.2 259.9 418.2 
 
 
Table A2. Number of Gulf STUDY biomonitoring sub-study participants (N=1,055) with 
≥1 styrene monitor within a given radius (buffers drawn around participants) 
 
 
 
 
 
 
 
 
 
 
 
  
Radius 
(miles) 
All 2011 monitors  
(N=44) 
NATA 2011 paired monitors 
(N=15) 
All 2013 monitors  
(N=68) 
No. people No. people No. people 
1 0 0 2 
2 1 1 3 
5 9 6 9 
10 31 22 30 
20 62 44 56 
50 171 142 154 
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Figure A1. Blood measurements and monitors in the Gulf region 
 
 
  
167 
 
APPENDIX 2. EVALUATION OF NATIONAL AIR TOXICS ASSESSMENT BY STATE 
Owing to concerns about inter-state variability in NATA data quality and reporting, 
we examined agreement between NATA estimates and monitored concentrations in 
corresponding census tracts by state (Table A1). Treating the annual average of 
observed values at monitors as the true estimate of exposure at that location, NATA 
performance is best in Louisiana and Texas, followed by Mississippi and Florida. 
Alabama emerged as potentially problematic based on the large disparity with 
monitored data. Estimated concentrations in Alabama are furthest from monitored 
concentrations, with a marked difference from the other Gulf states. This analysis is 
very limited by the sparsity of monitoring coverage, but given the general lack of data 
availability, we felt that any additional information contributed to our evaluation. 
Based on the patterns observed in Table A1, we examined effects of differential 
reporting to NATA by state on associations between ambient and blood styrene levels. 
Given insufficient sample sizes in each individual state to support state-specific 
analyses, we instead conducted four parallel analyses eliminating one state each time 
(Figure A1). Results were fairly consistent across analyses, apart from the removal of 
Alabama. When participants from Alabama were excluded, we observed an association 
between nonpoint ambient exposure and elevated blood styrene.  
We hypothesized that NATA data may represent different underlying information 
in Alabama, as compared with the other Gulf states. We used this information to select 
a subpopulation in which we had higher confidence in NATA data, ultimately excluding 
participants from Alabama for sensitivity analyses that were focused on NATA estimates 
of exposure. 
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Table A3. Comparing NATA 2011 estimated annual concentrations and Ambient Monitoring Archive observed annual 
concentrations by Gulf state. 
State Number of monitors Average difference (µg/m
3) Average Ratio 
(Monitors – NATA) (Monitors / NATA) 
Alabama 3 0.67 27.3 
Florida 9 0.23 11.9 
Louisiana 4 0.07 1.7 
Mississippi* 2 0.08 4.4 
Texas 19 0.07 1.3 
* No monitoring data available in 2011; the only two active monitors from 2010 were used instead. 
 
Figure A2. Association between ambient styrene quartiles and elevated blood styrene (> NHANES 95th percentile), 
excluding one state at a time to assess variability in NATA.  
 
Adjusted for 2,5-dimethylfuran (log), state, season, and time in vehicles (≥3 hours). 
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